You are on page 1of 84

List of European Pharmacopoeia Reference Standards

Order
Reference Standard
Code
Y0001414 Human Hepatitis B immunoglobulin BRP

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
100 mg
1 55 IU/vial

Information

Monograph Leaflet

Storage

Extra
Price
charges
90
c

0722, 0338

Yes

-20C

0673

Yes

+5C

79

2439

Yes

+5C

79

Yes

+5C

79

+5C

79

Y0001484 Medroxyprogesterone acetate for peak identification

25 mg

Y0001523 Ursolic acid

25 mg

Y0001532 Norethisterone acetate for system suitability

2.585 mg

0850

Y0001562 Doxylamine hydrogen succinate

60 mg

1589

Y0001565 Recombinant Major Allergen rBet v 1

0.01025 mg 1

10.25 micrograms of rBet v 1

1063

Yes

-20C

90

Y0001566 Recombinant Major Allergen rPhl p 5a

0.00856 mg 1

8.56 micrograms of rPhl p 5a

1063

Yes

-20C

90

Y0001567 Docusate sodium

10 mg

Y0001570 Nitrofural impurity B

30 mg

Y0001571 Naloxone impurity D

25 mg

Y0001572 Atovaquone

270 mg

Y0001573 Atovaquone for system suitability

10 mg

New Y0001574 Mesalazine for system suitability

10 mg

Batch 1 is valid until 30 April 2014

Y0001575 Bupivacaine impurity F

70 mg

2,6-dimethylaniline

Y0001577 Isoprenaline impurity A

15 mg

1-(3,4-dihydroxyphenyl)-2-[(1-methylethyl)amino]ethanone

Y0001580 Rocuronium bromide

10 mg

Y0001585 Cellulose acetate butyrate

60 mg

Y0001591 Flutamide for system suitability

10 mg

Y0001592 Ivy leaf dry extract HRS

70 mg

Y0001594 Megestrol acetate impurity K

0.01 mg

150 mg

New Y0001595 Diacerein

94.0 % CHO

1418
94.8 % CHON; (5-nitrofuran-2-yl)methylene diacetate
99.3% CHClO

+5C

79

1135

Yes

+5C

79

0729

Yes

+5C

79

2192

Yes

+5C

79

2192

Yes

+5C

79

1699

Yes

+5C

79

0541

+5C

79

1332

+5C

79

1764

-20C

g(c)

79

+5C

79

1423

Yes

+5C

79

16% of CHO

2148

Yes

-20C

79

+5C

79

99.2% CHO

2409

Yes

+5C

79

94,4%

Y0001596 Diacerein impurity B

20 mg

2409

Yes

+5C

79

Y0001597 Diacerein impurity mixture

0.014 mg

2409

Yes

+5C

79

Y0001598 Dutasteride

150 mg

2641

Yes

+5C

79

Y0001599 Wedelolactone

15 mg

2564

Yes

-20C

79

Y0001603 Dutasteride for system suitability

10 mg

2641

Yes

+5C

79

Y0001604 Finasteride for peak identification

15 mg

Yes

+5C

79

Y0001605 Eucommia bark HRS

2100 mg

Yes

-20C

79

Y0001609 Norflurane - reference spectrum

1 mg

79

Y0001611 Esculetin

25 mg

99.9% CHO

2452

Yes

+5C

79

Y0001612 Esculin

25 mg

92,4% CHO

2452

Yes

+5C

79

Y0001615 Beta-sitosterol

72.5% CHO

2579

Yes

-20C

79

1592

Yes

+5C

79

+5C

79

2410

Yes

+5C

79

+5C

79

25 mg

New Y0001617 Ketotifen for peak identification

15 mg

New Y0001619 Ketotifen hydrogen fumarate

10 mg

New Y0001620 2,4-dichlorobenzyl alcohol

250 mg

New Y0001621 2,4-Dichlorobenzyl alcohol impurity A

25 mg

Council of Europe, all rights reserved 2013

2412

99,9% CHClO

2410
1

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
New Y0001622 2,4-Dichlorobenzyl alcohol impurity C

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
25 mg
1

Information

Monograph Leaflet

Storage

Extra
Price
charges
79
g

2410

+5C

0822

+5C

79

+5C

79

Y0001633 Ethylcellulose

100 mg

New Y0001642 Capecitabine

150 mg

New Y0001643 Capecitabine impurity A

5 mg

+5C

79

New Y0001644 Capecitabine impurity B

5 mg

2762

+5C

79

New Y0001645 Capecitabine impurity D

10 mg

2762

+5C

79

Y0001561 Abacavir sulfate

20 mg

2589

+5C

79

Y0001551 Abacavir for system suitability

10 mg

2589

Yes

+5C

79

Y0001552 Abacavir for peak identification

10 mg

2589

Yes

+5C

79

Y0000055 Acamprosate calcium - reference spectrum

n/a

79

Y0000116 Acamprosate impurity A

50 mg

3-aminopropane-1-sulphonic acid

1585

+5C

79

Y0000500 Acarbose

94.7 mg

94.7 mg CHNO

2089

+5C

79

Y0000354 Acarbose for identification

10 mg

2089

+5C

79

Y0000427 Acarbose for peak identification

20 mg

A0040000 Acebutolol hydrochloride

50 mg

Y0000359 Acebutolol impurity B

10 mg

-[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino]
acetamide (diacetolol)

Y0000127 Acebutolol impurity C

20 mg

Y0000128 Acebutolol impurity I

0.004 mg

Y0000056 Aceclofenac - reference spectrum

n/a

Y0001094 Aceclofenac for peak identification

10 mg

Y0000085 Aceclofenac impurity F

20 mg

benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate ; Batch 1 is
valid until 31 March 2014

1281

Y0000086 Aceclofenac impurity H

10 mg

[[[[[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetyl] oxy]acetyl]oxy]
acetic acid

Y0000810 Acemetacin

100 mg

Y0000811 Acemetacin impurity A

10 mg

Y0000842 Acemetacine impurity mixture

0.06 mg

A0070000 Acesulfame potassium

50 mg

A0070020 Acesulfame potassium impurity B

15 mg

A0100000 Acetazolamide

100 mg

Y0001084 Acetazolamide for system suitability

0.0068 mg

0454

Y0000002 Acetylcholine chloride

50 mg

1485,1971

A0150000 Acetylcysteine

50 mg

A0152000 Acetylcysteine impurity C

10 mg

88.5% CHNOS; N,N'-diacetyl-L-cystine

10 mg

N,-diacetyl-L-cysteine
2

A0153000 Acetylcysteine impurity D


Council of Europe, all rights reserved 2013

1585

2089

+5C

79

0871

+5C

79

0871

+5C

79

N-(3-acetyl-4-hydroxyphenyl)butanamide

0871

+5C

79

N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl]
butanamide

0871

+5C

79

79

+5C

79

+5C

79

1281

+5C

79

1686

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

Batch 1 is valid until 1 May 2013


propoxy]phenyl]

Yes

1281
1281

Yes

1686

4-chlorobenzoic acid

1686

Yes

1282
5-chloro-6-methyl-1,2,3-oxathiazin-4(3)-one 2,2-dioxide ; Batch 3 is valid
until 31 August 2013

1282

Yes

0454
Yes

0967
0967

Yes

+5C

79

-20C

79

+5C

79

+5C

79

79
0967
+5C
a
For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000565 -Acetyldigoxin

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
2
50 mg
1 98.6% CHO

Information

Monograph Leaflet
2168

Y0000642 -Acetyldigoxin for peak identification

10 mg

2168

A0200000 Acetylsalicylic acid

15 mg

0309

Y0001460 Acetylsalicylic acid for peak identification

10.26 mg

0309

A0208000 N-Acetyltryptophan

125 mg

1383

A0202000 N-Acetyltyrosine

200 mg

Y0001462 Acetylsulfadiazine

0.002 mg

Y0000693 Acholeplasma laidlawii BRP

1 ml

20607

A0220000 Aciclovir

75 mg

0968

Y0001271 Aciclovir for peak identification 1

0.303 mg

0968

Y0001269 Aciclovir for peak identification 2

0.004 mg

0968

Y0001264 Aciclovir for system suitability

10 mg

A0225000 Acitretin

100 mg

Y0001464 Actaea racemosa dry extract for system suitability HRS

1200 mg

Y0001543 Actaea racemosa for assay CRS

300 mg

Y0001463 Actaea racemosa HRS

1200 mg

Y0001121 Adapalene

100 mg

99.9% CHO

2445

Y0001120 Adapalene impurity C

6 mg

1-[2-(methyloxy)phenyl]tricyclo[3.3.1.1]decane

2445

Y0001119 Adapalene for peak identification

2.022 mg

2445

A0230000 Adenine

50 mg

A0230200 Adenosine

50 mg

Y0000110 Adipic acid

50 mg

Y0000882 Adrenaline

5 mg

A0300000 Adrenaline tartrate

Y0000740 Adrenaline impurity mixture


Y0000707 Adrenaline tartrate with impurity A
Y0000883 Adrenaline with impurity F
Y0000728 Agnus castus fruit standardised dry extract

Storage
+5C

Yes

Extra
Price
charges
79
f

+5C

79

+5C

79

+5C

79

+5C

79

1384

+5C

79

0294

+5C

79

-80C

120

+5C

79

Yes

+5C

79

Yes

+5C

79

Yes

Yes

+5C

79

1385

Yes

+5C

g(b)

79

2069

Yes

-20C

79

2069

Yes

+5C

79

2069

Yes

+5C

79

+5C

79

+5C

79

+5C

79

0800,1486

+5C

79

1486

+5C

79

1586

+5C

79

2303

+5C

79

100 mg

0254, 0285,
0732

+5C

79

0.005 mg

0254,2303

Yes

+5C

79

15 mg

0254

Yes

+5C

79

10 mg

2303

Yes

+5C

79

200 mg

2147

Yes

-20C

79

A0325000 Alanine

60 mg

0614,0752

+5C

79

A0325100 Albendazole

50 mg

1386

+5C

79

A0325200 Alcuronium chloride

50 mg

A0325450 Alfacalcidol

5 mg

Y0001601 Alfacalcidol for system suitability

2.5 mg

A0325451 Alfacalcidol - reference spectrum

n/a

A1225000 Alfadex

150 mg

Council of Europe, all rights reserved 2013

0968
99.7% CHO
74.7% CHNO; Monoammonium glycyrrhizate

0.13% CHO

Yes

1285

-20C

g(c)

79

1286

Yes

-20C

e(d)

300

1286

Yes

-20C

e(d)

79

1286

79

79

99.8% CHO ; Batch 7 is valid until 31 December 2012

89.7% [CH0]
3

1070,1487

+5C

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
A0325500 Alfentanil hydrochloride - reference spectrum

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
n/a
1

Information

Monograph Leaflet
1062

A0325800 Alfuzosin hydrochloride

10 mg

Y0001581 Alimemazine for system suitability

5 mg

Y0000832 Alfuzosin for system suitability

10 mg

1287

Y0001583 Alimemazine hemitartrate

15 mg

2650

A0349000 Allantoin

60 mg

A0350000 Allopurinol

100 mg

99.9% CHNO

0576

A0350010 Allopurinol impurity A

10 mg

5-amino-1H-pyrazole-4-carboxamide

A0350020 Allopurinol impurity B

10 mg

5-formylamino-1H-pyrazole-4-carboxamide ; Batch 2 is valid until 31


December 2012

A0350030 Allopurinol impurity C

10 mg

A0350040 Allopurinol impurity D

15 mg

G0400000 Glycerol (85 per cent) - reference spectrum

n/a

A0350050 Allopurinol impurity E

20 mg

A0351000 Allylstrychnine bromide

10 mg

H0215000 Hepatitis C Virus RNA for NAT testing BRP

40 mg

HCV-RNA content 500 IU per vial; For plasma pool testing by NAT

Y0000235 Almagate

25 mg

13.4% carbonic acid

Y0000255 Almagate - reference spectrum

n/a

2010

A0357000 Alprazolam - * psy

100 mg

1065

A0360000 Alprenolol hydrochloride

100 mg

Y0000054 Alprostadil

50 mg

99.4% CHO ; Batch 1 is valid until 31 January 2013

Y0000606 Altizide

150 mg

99.9% CHClNOS

Y0000843 Altizide impurity B

15 mg

3-[(2,2-dimethoxyethyl)sulphanyl]prop-1-ene

Y0000687 Alverine citrate

5 mg

0.125 mg

Batch 1 is valid until 31 December 2013

2156

N-(3-cyclohexylpropyl)-N-ethyl-3-phenylpropan-1-amine

New Y0000595 Alverine for peak identification

Storage

1287

Extra
Price
charges
79
l

+5C

79

Yes

+5C

79

Yes

+5C

79

+5C

79

+5C

79

+5C

79

0576

+5C

79

0576

+5C

79

5-(4H-1,2,4-triazol-4-yl)-1H-pyrazole-4-carboxamide ; Batch 2 is valid until 1


May 2013

0576

+5C

79

ethyl 5-amino-1H-pyrazole-4-carboxylate

0576

+5C

79

79

+5C

79

1288
Yes

0496,0497
0576

ethyl 5-(formylamino)-1H-pyrazole-4-carboxylate

1285
See leaflet,
20621

Yes

2010

-20C

g(c)

79

-20C

e(d)

242

+5C

79

79

79

+5C

0628,0876

+5C

79

1488

Yes

-20C

g(c)

79

0370,2185

Yes

+5C

79

+5C

79

2185
2156
Yes

+5C

79

-20C

79

Y0000607 Alverine impurity D

10 mg

2156

+5C

79

A0363000 Amantadine hydrochloride

100 mg

0463

+5C

79

A0363700 Ambroxol hydrochloride

125 mg

1489

+5C

79

A0900000 Amfetamine sulfate - reference spectrum

n/a

0368

79

A0365000 Amidotrizoic acid dihydrate

100 mg

0873

+5C

79

Y0001461 Amidotrizoic acid for system suitability

0.08 mg

0873

Yes

+5C

79

A0368000 Amikacin

200 mg

91.7 % CHNO ; Batch 2 is valid until 28 February 2013

1289,1290

Yes

+5C

79

Y0001467 Amikacin impurity I

20 mg

(2S)-4-amino-2-hydroxybutanoic acid

1290

+5C

79

A0365900 Amikacin sulfate

200 mg

The batch 3 is not suitable for use in the assay in monograph 1290:07/2012.
Amikacin CRS A0368000 is also needed. See leaflet.

1290

+5C

79

Council of Europe, all rights reserved 2013

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0001117 Amikacin for system suitability

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
2
10 mg
1 amikacin for system suitability CRS 1 is suitable for 01/2010:1289 and
01/2010:1290 only. Batch 2 is suitable for 07/2012:1289 and 07/2012:1290.

Monograph Leaflet
1289,1290

Yes

A0370000 Amiloride hydrochloride

100 mg

Y0000020 Amiloride impurity A

20 mg

Y0000173 4-Aminobenzoic acid

60 mg

A0420000 Aminocaproic acid

50 mg

A0460000 7-Aminodesacetoxycephalosporanic acid

20 mg

A0496000 Aminoglutethimide

125 mg

A0496005 Aminoglutethimide impurity A

20 mg

A0496020 Aminoglutethimide impurity D

10 mg

A0575000 Amiodarone hydrochloride

100 mg

Y0000129 Amiodarone impurity D

20 mg

Y0000130 Amiodarone impurity E

20 mg

A0590000 Amisulpride

10 mg

1490

Y0001534 Amisulpride for system suitability

1.0015 mg

1490

Y0000563 Amitriptyline hydrochloride

10 mg

Y0000049 Amlodipine besilate

150 mg

99.7% CHClNOS

1491

Yes

Y0001067 Amlodipine for peak identification

15 mg

Batch 1 is valid until 31 August 2013

1491

Y0001068 Amlodipine impurity A

15 mg

3-ethyl 5-methyl (4RS)-4-(2-chlorophenyl)-2-[[2-(1,3-dioxo-1,3-dihydro-2Hisoindol-2-yl)ethoxy]methyl]-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate ;


Batch 1 is valid until 1 June 2013

1491

Y0001069 Amlodipine impurity B

15 mg

3-ethyl 5-methyl (4RS)-4-(2-chlorophenyl)-6-methyl-2-[[2-[[2(methylcarbamoyl)benzoyl]amino]ethoxy]methyl]-1,4-dihydropyridine-3,5dicarboxylate ; Batch 1 is valid until 30 November 2013

Y0001070 Amlodipine impurity G

15 mg

dimethyl 4-(2-chlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5dicarboxylate ; Batch 1 is valid until 1 June 2013

Y0000302 Ammonio methacrylate copolymer(type A) - reference


spectrum

n/a

Y0000303 Ammonio methacrylate copolymer(type B) - reference


spectrum

n/a

A0650000 Amobarbital - * psy

A0700000 Amobarbital sodium - * psy


A0800000 Amoxicillin trihydrate

Y0001521 Amoxicillin trihydrate for performance verification


Council of Europe, all rights reserved 2013

Storage
+5C

Extra
Price
charges
79
a

0651

+5C

79

0651

+5C

79

1687

+5C

79

0874

+5C

79

0708,0813

+5C

79

1291

+5C

79

(3)-3-(3-aminophenyl)-3-ethylpiperidine-2,6-dione; (3-aminoglutethimide)

1291

+5C

79

3,3'-[diazenediyldi(4,1-phenylene)]bis(3-ethylpiperidine-2,6-dione);
(azoglutethimide)

1291

+5C

79

0803

+5C

g(b)

79

(2-butyl-benzofuran-3-yl)-(4-hydroxy-3,5-diiodophenyl)methanone

0803

+5C

79

(2-butylbenzofuran-3-yl)(4-hydroxyphenyl)methanone

0803

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

Yes

+5C

79

Yes

+5C

79

1491

+5C

79

1491

+5C

79

2081

79

2082

79

500 mg

0594

+5C

79

500 mg

0166

+5C

79

200 mg

86.2% CHNOS

0167,0168,0
260,
0577,0578,0
813,
1140,1653

+5C

79

5000 mg

Instructions

+5C

79

methyl-3,5-diamino-6-chloropyrazine-2-carboxylate ; Batch 2 is valid until 31


August 2013

Cefadroxyl impurity B

Yes

0464

Yes
5

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000005 Amphotericin B
Y0001014 Amphotericin B for peak identification

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
4
100 mg
1 Batch 4 is not suitable for microbiological assay (see leaflet).
2
10 mg
1 Batch 1 is valid until 1 June 2013

Monograph Leaflet
1292

Yes

-20C

1292

Yes

-20C

79

Yes

-20C

79

0167,0168,0
578,
1168,1169

Yes

+5C

79

+5C

79

+5C

79

100 mg

944 IU per mg

A1000000 Ampicillin (anhydrous)

220 mg

97.7% CHNOS ; Batch 4 is valid until 31 December 2013

A1100000 Ampicillin trihydrate

150 mg

Y0001522 Anastrozole

100 mg

100.0% CHN

2406

Y0001531 Anastrozole impurity E

10 mg

2,2'-[5-(hydroxymethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)

2406

Y0001386 Angelica dahuria root

160 mg

A1200000 Anhydrotetracycline hydrochloride

15 mg

93.3% CHNO

Y0001244 Amylmetacresol

285 mg

99.5% CHO

Y0001245 Amylmetacresol for peak identification

10 mg

Y0001466 Anhydrous Docetaxel

15 mg

A1210000 Antazoline hydrochloride

50 mg

A1220000 Alpha-apo-oxytetracycline

20 mg

Y0001465 Apomorphine hydrochloride hemihydrate

15 mg

Y0001471 Apomorphine impurity B (morphine sulfate) * - narc

40 mg

88.2% CHNOS,5HO; morphine sulfate

0136

Yes

A1230000 Beta-apo-oxytetracycline

20 mg

88,0% CHNO

0198

Yes

A1250000 Aprotinin solution BRP

0.5 ml

22.3 Ph. Eur. Units per ml

0579,0580

Y0001154 Aprotinin for system suitability

2.7 mg

0580

A1269000 L-Arabinitol

10 mg

Y0000806 Arbutin

100 mg

93.5% CHO

1054

Yes

A1270000 Arginine

50 mg

99.8% CHNO

0806,0930,1
654,
2114,2566

Yes

Y0000304 Arginine aspartate

20 mg

New A1271000 Arginine hydrochloride

60 mg

Batch 2 is valid until 30 April 2014

New Y0001649 Aripiprazole

170 mg

See leaflet

2617

New Y0001650 Aripiprazole impurity F

10 mg

7-[4-[4-(2,3-dichlorophenyl)-1-oxidopiperazin-1-yl]-3,4-dihydroquinolein-2
(1H)-one

2617

Y0001323 Aristolochia

140 mg

Y0001185 Aristolochic acid I

1 mg

Y0001175 Aristolocholic acid for system suitability

1 mg

Council of Europe, all rights reserved 2013

0168,0260,0
577,
0578,0808,2
211, 2212
Yes

+5C

79

2556

Yes

+5C

79

0210,0211,1
654

Yes

+5C

79

2405

Yes

+5C

79

2405

Yes

+5C

79

2593

+5C

79

0972

+5C

79

+5C

79

+5C

79

+5C

90

+5C

79

Yes

+5C

79

Yes

+5C

79

+5C

79

+5C

79

+5C

79

2096

+5C

79

0805,0885,0
998

+5C

79

+5C

79

+5C

79

0198

Yes

0136

1381

1.00 mg CHNO
6

Extra
Price
charges
79
c

20702

Y0001361 Amphotericin B for microbiological assay

Batch 4 is valid until 31 December 2013

Storage

Yes

20821

Yes

+5C

79

20821

Yes

+5C

79

20821

Yes

+5C

79

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000079 Articaine hydrochloride

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
2
100 mg
1

Information

Monograph Leaflet

Storage

1688

+5C

Extra
Price
charges
79
a

Y0000080 Articaine impurity A

15 mg

methyl3-[[2-(propylamino)acetyl]amino]-4-methylthiophene-2- carboxylate

1688

+5C

79

Y0000081 Articaine impurity E

10 mg

methyl 4-methyl-3-[[(2RS)-2-[(1-methylethyl)amino]propanoyl]amino]
thiophene-2-carboxylate

1688

+5C

79

A1300000 Ascorbic acid

100 mg

Vitamin C ; Batch 3 is valid until 31 December 2012

0253,0958,1
791

+5C

79

Y0001024 Ascorbic acid impurity C

20 mg

D-xylo-hex-2-ulosonic acid (D-sorbosonic acid)

0253,1791

+5C

79

Y0001170 Ascorbic acid impurity D

10 mg

methyl D-xylo-hex-2-ulosonate (methyl D-sorbosonate) ; Batch 1 is valid until


31 December 2012

0253,1791

+5C

79

Y0000800 Ascorbyl palmitate

10 mg

0807

+5C

79

Y0000305 Asparagine monohydrate

60 mg

2086

+5C

79

A1320000 Aspartame

40 mg

0973

+5C

79

A1321000 Aspartame impurity A

10 mg

0973

+5C

79

A1330000 Aspartic acid

50 mg

0750,0797

+5C

79

Y0001171 Astragaloside IV

40 mg

2435

-20C

79

A1340000 Atenolol

100 mg

0703

+5C

79

Y0001089 Atenolol for system suitability

5 mg

0703

Yes

+5C

79

Y0001587 Atomoxetine for impurity A identification

10 mg

N-methyl-3-phenoxy-3-phenylpropan-1-amine

2640

Yes

+5C

79

Y0001586 Atomoxetine hydrochloride

110 mg

99,9% CHClNO

2640

Yes

+5C

79

Y0001588 Atomoxetine impurity B

10 mg

(3S)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1amine

2640

+5C

79

Y0001589 Atomoxetine impurity D

5 mg

(3R)-N-methyl-3-(3-methylphenoxy)-3-phenylpropan-1amine

2640

+5C

79

Y0001327 Atorvastatin calcium trihydrate

150 mg

95.3% CHCaFNO ; Batch 1 is valid until 30 November 2013

2191

+5C

79

Y0001328 Atorvastatin impurity A

10 mg

desfluoroatorvastatin ; Batch 1 is valid until 31 January 2014

2191

+5C

79

Y0001329 Atorvastatin impurity B

10 mg

3-epi-atorvastatin ; Batch 1 is valid until 30 November 2013

2191

+5C

79

Y0001330 Atorvastatin impurity C

10 mg

fluoroatorvastatin

2191

+5C

79

Y0001331 Atorvastatin impurity D

10 mg

3-[(4-fluorophenyl)carbonyl]-2-(2-methylpropanoyl)-N,3-diphenyloxirane-2carboxamide ; Batch 1 is valid until 31 August 2013

2191

+5C

79

Y0001332 Atorvastatin impurity E

10 mg

ent-atorvastatin ; Batch 1 is valid until 28 February 2013

2191

+5C

79

Y0000424 Atracurium besilate

120 mg

98.5% CHNOS

1970

Yes

+5C

g(b)

79

Y0000105 Rutoside trihydrate

100 mg

87.6% CHO

1795,1874,2
184,
2427,2639

Yes

+5C

79

Y0000503 Atracurium for impurity F identification

5 mg

1970

Yes

+5C

g(b)

79

Y0000504 Atracurium for peak identification

5 mg

1970

Yes

+5C

g(b)

79

Y0000878 Atropine

30 mg

2056

+5C

79

Y0000845 Atropine for peak identification

0.25 mg

+5C

79

Council of Europe, all rights reserved 2013

2-(5-benzyl-3,6-dioxopiperazin-2-yl) acetic acid (diketopiperazine)


97.8% CHO

Batch 1 is valid until 31 January 2013


7

0068,2056

Yes

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000816 Atropine impurity B

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
1
10 mg
1 (1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl (2RS)-3-hydroxy-2-phenylpropanoate
(noratropine)

A1400000 Atropine sulfate

Y0000029 Azaperone
A1500000 Azathioprine

Monograph Leaflet

Storage

Extra
Price
charges
79
g

0068,2056

+5C

0068

+5C

79

20 mg

50 mg

1708

+5C

79

100 mg

0369

+5C

79

Y0001240 Azathioprine impurity A

10 mg

1-methyl-4-nitro-1H-imidazol-5-amine

0369

+5C

79

Y0001246 Azathioprine impurity G

5 mg

6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purin-2-amine
(thiamiprine)

0369

+5C

79

Y0000326 Azelastine hydrochloride

25 mg

1633

+5C

79

Y0000327 Azelastine impurity B

5 mg

1-benzoyl-2-[(4RS)-1-methylhexahydro-1H-azepin-4-yl]diazane

1633

+5C

79

Y0000328 Azelastine impurity D

5 mg

4-(4-chlorobenzyl)phthalazin-1(2H)-one

1633

+5C

79

Y0000329 Azelastine impurity E

5 mg

3-(4-chlorobenzilidene)isobenzofuran-1(3H)-one

1633

+5C

79

Y0000306 Azithromycin

200 mg

94.4% CHNO ; Batch 3 is valid until 31 December 2013

1649

Yes

+5C

79

Y0000637 Azithromycin for peak identification

15 mg

1649

Yes

+5C

79

Y0000641 Azithromycin for system suitability

0.05 mg

Batch 5 is valid until 31 October 2013

1649

Yes

+5C

79

Y0000307 Azithromycin impurity A

10 mg

6-demethylazithromycin

+5C

79

Y0000285 B19 virus DNA for NAT testing BRP

150 mg

B19 virus DNA content log 5.8 IU per ml for plasma pool testing by NAT

Yes

-20C

e(d)

242

B0070000 Bacampicillin hydrochloride

120 mg

92.9% CHClNOS

+5C

79

B0100000 Bacitracin zinc

150 mg

62.9 IU per mg

Yes

-20C

79

B0200000 Baclofen

50 mg

+5C

79

B0200050 Baclofen impurity A

50 mg

91.4% CHClNO; (4RS)-4-(4-chlorophenyl)pyrrolidin-2-one ; Batch 2 is


valid until 31 January 2013

0653

Yes

+5C

79

Y0001273 Baicalin

10 mg

88.5% CHO

2438

Yes

+5C

79

B0250000 Bambuterol hydrochloride

100 mg

1293

+5C

79

B0300000 Barbital - * psy

500 mg

0170

+5C

79

Y0001525 Basic butylated methacrylate copolymer

20 mg

1975

+5C

79

Y0000295 Basic butylated methacrylate copolymer -reference


spectrum

n/a

1975

79

B0305000 Beclometasone dipropionate anhydrous

150 mg

+5C

79

Y0000351 Beclometasone dipropionate monohydrate

10 mg

Y0000352 Beclometasone dipropionate for system suitability

15 mg

Y0000469 Beclometasone dipropionate for peak identification

10 mg

0.052 mg

110 mg

New Y0001073 Beclometasone dipropionate impurities F and N


Y0001607 Belamcanda chinensis rhizome HRS
Council of Europe, all rights reserved 2013

Batch 3 is valid until 31 August 2013

1649
See leaflet,
0557,
1527,1646
0808,0852
0465,0466,2
0702
0653

Yes

99.2% CHClO ; Batch 3 is valid until 1 June 2013

0654,1449,
1709

Yes

+5C

79

Batch 2 is valid until 28 February 2013

0654,1709

Yes

+5C

79

0654,1709

Yes

+5C

79

0654,1709

Yes

+5C

79

2561

Yes

+5C

79

1709

Batch 1 is valid until 30 April 2013

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0001025 Benazepril hydrochloride

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
160 mg
1 99.5 % CHClNO

Information

Monograph Leaflet
2388

Y0001038 Benazepril for system suitability

0.016 mg

Y0001026 Benazepril impurity A

10 mg

B0400000 Bendroflumethiazide

100 mg

Y0000564 Bendroflumethiazide impurity A

5 mg

B0470000 Benperidol

100 mg

B0477000 Benserazide hydrochloride

50 mg

B0477010 Benserazide impurity A

20 mg

Y0001071 Benserazide impurity C

10 mg

Y0001079 Benserazide for peak identification

10 mg

1173

Y0001064 Benzaldehyde

150 mg

Y0001060 Benzalkonium chloride for system suitability

20 mg

B0490000 Benzarone

10 mg

(2-ethylbenzofuran-3-yl)(4-hydroxyphenyl)methanone

1393

B0500000 Benzathine benzylpenicillin

200 mg

90.7% CHNOS
24.1% CHN (N,N'-dibenzylethylenediamine)

0373

Y0000775 Benzbromarone

10 mg

B0550000 Benzethonium chloride

100 mg

B0600000 Benzocaine

50 mg

Y0001470 Benzoic acid

Y0000647 Benzophenone

Y0000167 Benzyl alcohol

B0670000 Benzyl benzoate - reference spectrum


B0680000 S-Benzylmercaptoacetyltriglycin

+5C
+5C

79

+5C

79

0370

+5C

79

0370

+5C

79

1010,1172,1
254, 1708

+5C

79

1173

+5C

79

(2RS)-2-amino-3-hydroxypropanohydrazide

1173

+5C

79

(2RS)-2-amino-3-hydroxy-2'-[(1EZ)-(2,3,4-trihydroxybenzylidene)]
propanohydrazide

1173

+5C

79

Yes

+5C

79

0372,0371

Yes

+5C

79

0371,0372

Yes

+5C

79

+5C

79

+5C

79

1393

+5C

79

0974

+5C

79

0011,1088

+5C

79

30 mg

0934

+5C

79

40 mg

1784

+5C

79

50 mg

+5C

79

n/a

0705

79

10 mg

1372

+5C

79

B0700000 Benzylpenicillin potassium

100 mg

0113,0148,0
149

+5C

79

B0900000 Benzylpenicillin sodium

200 mg

99.4% CHNNaOS; Penicillin G sodium

Y0001149 Berberine chloride

20 mg

84.3% CHClNO

B0950000 Betadex

200 mg

88.4% [CHO]

Y0000391 Betahistine dihydrochloride

50 mg

B0990000 Betahistine mesilate

100 mg

B1000000 Betamethasone

75 mg

[(3R)-3-[[(1R)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2-oxo-2,3,4,5tetrahydro-1H-1-benzazepin-1-yl]acetic acid
4-amino-6-(trifluoromethyl)benzene-1,3-disulphonamide

0256,0371,0
372,1827

See leaflet

Yes

Extra
Price
charges
79
a

2388

Council of Europe, all rights reserved 2013

2388

Storage

Yes

Yes

0113,0114,0
148, 0149

Yes

+5C

79

1831,2500

Yes

+5C

79

1070,1487,1
804

+5C

79

1665

+5C

79

1071

+5C

79

0312,0354,0
388,
0561,0811

+5C

79

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
B1030000 Betamethasone acetate

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
2
100 mg
1

B1040000 Betamethasone dipropionate

150 mg

Y0001416 Betamethasone dipropionate for peak identification

10 mg

Y0001418 Betamethasone dipropionate for system suitability

10 mg

B1045000 Betamethasone sodium phosphate

B1054000 Betamethasone 17-valerate

B1055000 Betamethasone 21-valerate


Y0001027 Betamethasone valerate for system suitability

Information

Monograph Leaflet
0548,0975

Storage
+5C

Extra
Price
charges
79
g

0809

Yes

+5C

79

0809

Yes

+5C

79

0809

Yes

+5C

79

100 mg

0549,0810

+5C

79

100 mg

0322,0811

+5C

79

15 mg

0811

+5C

79

25 mg

0811

+5C

79

Y0001065 Betamethasone valerate impurity mixture

0.018 mg

Batch 1 is valid until 31 December 2012

0811

+5C

79

B1103000 Betaxolol hydrochloride

60 mg

Batch 1 is valid until 1 June 2013

1072

+5C

79

B1103100 Betaxolol impurity A

10 mg

(2RS)-1-(4-ethylphenoxy)-3-[(1-methylethyl)amino]propan-2-ol

1072

+5C

79

Y0001354 Betaxolol impurity C

5 mg

2-[[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]methyl]oxirane

1072

-20C

79

Y0001360 Betaxolol for peak identification

15 mg

1072

+5C

79

B1115000 Bezafibrate

100 mg

1394

+5C

79

Y0001444 Bicalutamide

100 mg

2196

Yes

+5C

79

Y0001448 Bicalutamide for system suitability

15 mg

2196

Yes

+5C

79

Y0001078 Bicisate labelling kit

24 mg

2123

+5C

79

B1110000 Bifonazole

100 mg

1395

+5C

79

Y0001421 Bifonazole for system suitability

10 mg

1395

Yes

+5C

79

Y0001059 Bilberry dry extract

250 mg

3.44% of cyanidin 3-O-glucoside chloride (CHClO)

2394

Yes

-20C

79

B1116000 Biotin

20 mg

Vitamin H

1073

+5C

79

B1120000 Biperiden hydrochloride

60 mg

1074

+5C

79

B1121000 Biperiden impurity A

20 mg

1074

+5C

79

B1140000 Bisacodyl

50 mg

0595

+5C

79

Y0000608 Bisacodyl for peak identification

10 mg

0595

+5C

79

Y0000694 Bisacodyl for system suitability

5 mg

0595

+5C

79

Y0000812 Bisoprolol fumarate

50 mg

1710

+5C

79

Y0000877 Bisoprolol for peak identification

1.007 mg

Bisoprolol for system suitability method A CRS has been renamed as


Bisoprolol for peak identification CRS.

1710

Yes

+5C

79

New Y0000813 Bisoprolol for system suitability

1.003 mg

Bisoprolol for system suitability method B CRS has been renamed as


Bisoprolol for system suitability CRS ; Batch 2 is valid until 30 April 2014

1710

Yes

+5C

79

New B1141000 Bleomycin sulfate

99.5% CHFO; Betamethasone dipropionate CRS 2 is suitable for


monograph 01/008:0809 only.

99.8% CHFNOS

(1RS)-1-[(1SR,2SR,4SR)-bicyclo[2.2.1]hept-5-en-2-yl]-1-phenyl- 3(piperidin-1-yl)propan-1-ol (endo form)

Yes

Yes

Yes

7 mg

See leaflet ; Batch 1 is valid until 30 April 2014

0976,20702

Yes

-20C

79

Y0000434 Boldine

30 mg

98.8% CHNO

1396, 1816

Yes

+5C

79

B1142000 Bordetella pertussis mouse antiserum BRP

0.5 mg

Anti-PT: 19.5 ELU/vial Anti-FHA: 69 ELU/vial


Anti-69k: 17 ELU/vial Anti-Fim 2/3: 28 ELU/vial

See leaflet,
20716

Yes

-20C

90

60 mg

B1143000 Bromazepam - * psy


Council of Europe, all rights reserved 2013

10

79
0778,0879
+5C
j
For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000645 Bromazepam for system suitability - * psy

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
10 mg
1

Information

Monograph Leaflet
0879

B1145000 Bromhexine hydrochloride

100 mg

Y0000200 Bromhexine impurity C

15 mg

B1150000 Bromocriptine mesilate

30 mg

Y0000677 Bromocriptine mesilate for system suitability

5 mg

0596

B1152000 Bromperidol

100 mg

0616,1178

B1152050 Bromperidol decanoate

60 mg

B1153000 Brompheniramine maleate

100 mg

Y0000468 Brotizolam - * psy

10 mg

Y0000470 Brotizolam impurity B

10 mg

B1155000 Brucella melitensis Rev. 1 strain BRP - * MOT (Biotox)

1 mg

B1157300 Budesonide

110 mg

Y0001148 Budesonide for system suitability

10 mg

B1156000 Bufexamac

100 mg

B1157400 Buflomedil hydrochloride

100 mg

Y0001529 Buflomedil for peak identification

0.45 mg

20 mg

B1158000 Bumetanide

150 mg

Y0000309 Bumetanide impurity A

5 mg

Y0000310 Bumetanide impurity B

5 mg

B1160000 Bupivacaine hydrochloride

100 mg

Y0000088 Bupivacaine impurity B

20 mg

(2RS)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide

Y0000089 Bupivacaine impurity E

20 mg

6-(butylamino)-N-(2,6-dimethylphenyl)hexanamide

Y0001108 Buprenorphine - * psy

10 mg

Y0001109 Buprenorphine hydrochloride - * psy

10 mg

1181

Y0001122 Buprenorphine for system suitability - * psy

10 mg

1180,1181

B1168000 Buserelin

2 mg

B1168020 D-His-Buserelin

0.5 mg

Y0000131 Buspirone hydrochloride

5 mg

Y0000471 Buspirone for system suitability

2 mg

B1170000 Busulfan

50 mg

Y0001487 Butyl methacrylate

100 mg

Y0001304 Butyl methanesulfonate

30 L

20537,2053
8, 20539

New B1157410 Buflomedil impurity B

Council of Europe, all rights reserved 2013

N-(2-aminobenzyl)-N-methylcyclohexanamine ; Batch 2 is valid until 1 June


2013

2-bromo-4-(2-chlorophenyl)-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]
diazepine (demethylbrotizolam)
99.7% CHO

Yes

Storage
+5C

Extra
Price
charges
79
j

0706

+5C

79

0706

+5C

79

0596

-20C

g(c)

79

-20C

g(c)

79

+5C

79

1397,1431

+5C

79

0977,1196

+5C

79

2197

+5C

79

2197

+5C

79

Yes

0793

Yes

+5C

e(b)

79

1075

Yes

+5C

79

1075

Yes

+5C

79

1179

+5C

79

1398

+5C

79

1398

+5C

79

1398

+5C

79

1076

+5C

79

3-nitro-4-phenoxy-5-sulphamoylbenzoic acid

1076

+5C

79

3-amino-4-phenoxy-5-sulphamoylbenzoic acid

1076

+5C

79

0541

+5C

79

0541

+5C

79

0541

+5C

79

1180

+5C

79

+5C

79

+5C

79

1077

-20C

79

1077

-20C

79

+5C

79

+5C

79

0542

+5C

79

1975

+5C

79

+5C

79

4-(pyrrolidin-1-yl)-1-(4-hydroxy-2,6-dimethoxyphenyl)butan-1-one ; Batch 2
is valid until 28 February 2014

2.00 mg per vial of CHNO

Yes

Yes

1711
Batch 1 is valid until 30 April 2014

11

1711

Yes

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
B1217000 Butyl parahydroxybenzoate
Y0001357 Butyl parahydroxybenzoate impurity E

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
2
100 mg
1 See leaflet
1
15 mg
1 2-methylpropyl 4-hydroxybenzoate (iso-butyl parahydroxybenzoate)

Monograph Leaflet
0881,1216

Yes

Storage
+5C

Extra
Price
charges
79
a

0881

+5C

79

0880

+5C

79

Plastic additive 07

0581,30103,
30105,3010
6, 30107

+5C

79

99.8% CHNO

1773

Yes

-20C

79

70 mg

See leaflet

0267,0268,1
504,2412

Yes

+5C

79

10 mg

Batch 2 is valid until 30 November 2013

0267, 0268

Yes

+5C

79

5 mg

95.3% CHO ; Batch 3 is valid until 28 February 2013

1295

Yes

-20C

e(d)

150

C0166001 Calcifediol - reference spectrum

n/a

1295

79

Y0000499 Calcipotriol (anhydrous) - reference spectrum

n/a

2011

79

Y0000473 Calcipotriol monohydrate

10 mg

79

Y0000474 Calcipotriol monohydrate - reference spectrum

n/a

79

C0200000 Calcitonin (salmon)

1 mg

Batch 8 is valid until 1 June 2013


Batch 9 is valid until 30 May 2013

0471

-20C

79

Y0000632 Calcitonin-Gly

1 ml

About 0.9 mg per ml

0471

-20C

79

C0200010 N-acetyl-cys1-calcitonin

0.1 mg

about 0.1mg N-acetyl-cys-1-calcitonin per vial

0471

-20C

79

C0225000 Calcitriol

10 mg

99.8% CHO

0883

-20C

e(d)

C0226000 Calcitriol - reference spectrum

n/a

C0249000 Calcium ascorbate - reference spectrum

n/a

130 mg

60 mg

100 mg

C0340000 Calcium levulinate dihydrate

250 mg

C0350000 Calcium oxalate monohydrate

500 mg

C0400000 Calcium pantothenate

60 mg

0470

C0405000 Camphor (racemic)

50 mg

Y0001388 Candesartan cilexetil

60 mg

Y0001387 Candesartan cilexetil for peak identification

10 mg

2375

Y0001389 Candesartan cilexetil for system suitability

10 mg

2573

C0410000 Canrenone

50 mg

C0426000 Caprylic acid

200 mg

B1212000 Butylhydroxyanisole

60 mg

Batch 3 is valid until 31 August 2013

B1215000 Butylhydroxytoluene

50 mg

Y0000472 Cabergoline

100 mg

C0100000 Caffeine

Y0000787 Caffeine for system suitability


C0166000 Calcifediol

New C0250000 Calcium folinate


C0299000 Calcium glucoheptonate
New C0300000 Calcium gluconate

Council of Europe, all rights reserved 2013

94.3% CHO ; Batch 1 is valid until 31 August 2013

2011,2284

Yes

+5C

2284
Yes

Yes

0883
1182
See leaflet ; Batch 5 is valid until 31 March 2014
Calcium digluconate ; Batch 1 is valid until 31 March 2014

Loss of 12.1% m/m (U= 0.2%, n=10, k=2.23)

12

0978,1606

Yes

1000

79

79

+5C

79

1399

+5C

79

0172,0658,0
979,1399,21
61,2162,216
4,2364

+5C

79

1296

+5C

79

+5C

79

+5C

79

0655,1600

+5C

79

2375

+5C

79

Yes

+5C

79

Yes

+5C

79

0688

+5C

79

1401,1471

+5C

79

20234

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Code
Y0000671 Capsaicin

Reference Standard

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
2
50 mg
1 98,7% CHNO ; (E)-N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8methylnon-6-enamide ; Batch 1 is valid until 1 April 2013

C0430000 Captopril

10 mg

Y0001182 Captopril for system suitability

20 mg

Y0001219 Captopril impurity B

10 mg

Y0001220 Captopril impurity C

10 mg

Y0001221 Captopril impurity D

Y0000435 Captopril impurity E

Y0001450 Captopril impurity J

Y0000113 Carbachol
C0450000 Carbamazepine

Monograph Leaflet
1859,2336,2
337, 2529

Yes

Storage
+5C

Extra
Price
charges
79
g

1079

+5C

79

Batch 1 is valid until 31 August 2013

1079

+5C

79

87.4% CHBrNO; (2S)1-[(2S)-3-bromo-2-methylpropanoyl]pyrrolidine-2carboxylic acid

1079

+5C

79

84.8% CHOS; (2RS)-2-methyl-3-sulphanylpropanoic acid

1079

Yes

+5C

79

10 mg

85.4% CHBrO; (2RS)-3-bromo-2-methylpropanoic acid

1079

Yes

+5C

79

10 mg

(2S)-1-isobutyryl-pyrrolidine-2-carboxylic acid

1079

+5C

79

10 mg

92.5% CHNOS; (2S)-1-[(2S)-3-(acetylsulfanyl)-2-methylpropanoyl]


pyrrolidine-2-carboxylic acid (acetylcaptopril)

1079

+5C

79

50 mg

+5C

79

200 mg

99.9% CHNO ; Batch 4 is valid until 31 October 2013

0543

+5C

79

Y0000033 Carbamazepine impurity A

10 mg

10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide (10,11dihydrocarbamazepine)

0543

+5C

79

C0451000 Carbasalate calcium - reference spectrum

n/a

1185

79

Y0001161 Carbasalate impurity B

5 mg

1185

+5C

79

C0455000 Carbenicillin sodium

50 mg

0956

+5C

79

C0460000 Carbidopa

50 mg

0755

+5C

79

C0465000 Carbimazole

120 mg

+5C

79

C0470000 Carbocisteine

60 mg

0885

+5C

79

C0499900 Carbon dioxide - reference spectrum

n/a

0375

79

C0550000 Carboplatin - reference spectrum

n/a

1081

79

Y0000475 Carboprost trometamol

40 mg

79

Y0000536 Carboprost trometamol - reference spectrum

n/a

79

Y0000035 Carisoprodol

50 mg

Y0000036 Carisoprodol impurity A

10 mg

Y0001214 Carmellose

10 mg

C0580004 Carmustine - reference spectrum

n/a

C0580010 Carmustine impurity A

20 mg

Y0000846 Carprofen

30 mg

Y0000884 Carprofen for system suitability

5 mg

Y0000192 Carteolol hydrochloride - reference spectrum

Y0000193 Carteolol for system suitability

Y0001427 Carvedilol

Y0000075 Carvedilol - reference spectrum

Council of Europe, all rights reserved 2013

Yes

1971

99.7% CHNOS

99.1% CHNO

0884

Yes

Yes

1712

-20C

1712
1689

+5C

79

1689

+5C

79

2360

+5C

79

79

1187

-20C

g(c)

79

2201

+5C

79

2201

+5C

79

n/a

1972

79

30 mg

1972

+5C

79

50 mg

1745

+5C

79

n/a

1745

79

(2RS)-2-(hydroxymethyl)-2-methylpentyl(1-methylethyl)carbamate

1187
1,3-bis(2-chloroethyl)urea

13

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000103 Carvedilol impurity C

Effective from 2013/11/12


Batch n Quantity Sale
Information
Monograph Leaflet
per vial Unit
2
15 mg
1 (2RS)-1-[benzyl[2-(2-methoxyphenoxy)ethyl]amino]-3-(9H- carbazol-4-yloxy)
1745
propan-2-ol

Y0001426 Carvedilol for system suitability

10 mg

1745

C0600000 Casein BRP

100000 mg

Batch 2 is valid until 31 December 2012

0350

C0630000 Cefaclor

450 mg

94.9% CHClNOS ; Batch 2 is valid until 30 November 2013

0986

New C0640000 Delta-3-Cefaclor

20 mg

Batch 3 is valid until 31 March 2014

C0650000 Cefadroxil

250 mg

93,8% CHNOS ; Batch 2 is valid until 1 July 2013

C0675000 Cefalexin monohydrate

150 mg

94.2% CHNOS

C0682000 Cefalotin sodium

100 mg

98.8% CHNNaOS

Y0000505 Cefalotin for impurity B identification

10 mg

C0682300 Cefamandole nafate

125 mg

99.0% CHNNaOS

1402

Y0000240 Cefapirin sodium

100 mg

98.5% CHNNaOS

1650

C0682400 Cefatrizine propylene glycol

150 mg

81.8% CHNOS

C0682410 Cefatrizine impurity A

60 mg

7-amino-(6R,7R)-3-[(2H-1,2,3-triazol-4-yl)sulfanyl]-methyl-8- oxo-5-thia-1azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (7-ACA triazole)

C0682800 Cefazolin

150 mg

99.6% CHNOS

0988

Y0000633 Cefepime dihydrochloride monohydrate

150 mg

95.2% CHClNOS

2126

15 mg

Batch 1 is valid until 28 February 2014

2126

Y0001336 Cefepime impurity E

10 mg

(6R,7R)-7-amino-3-[(1-methylpyrrolidinio)methyl]-8-oxo-5thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

2126

C0684000 Cefixime

200 mg

88.8% CHNOS

1188

C0684750 Cefoperazone dihydrate

100 mg

94.2% CHNOS

1404

C0684800 Cefoperazone sodium - reference spectrum

n/a

Y0000420 Cefotaxime acid

80 mg

C0685000 Cefotaxime sodium

30 mg

Y0000506 Cefotaxime for peak identification

10 mg

C0688000 Cefoxitin sodium

100 mg

Y0001496 Cefoxitin sodium for peak identification

15 mg

Y0001305 Cefpodoxime proxetil

70 mg

Y0001318 Cefpodoxime proxetil for impurity H identification

10 mg

Y0001306 Cefpodoxime proxetil for peak identification

10 mg

Y0001371 Cefprozil

120 mg

Y0001368 Cefprozil impurity mixture

10 mg

Y0001372 Cefprozil impurity A

20 mg

Y0001367 Cefprozil for peak identification

10 mg

New Y0000634 Cefepime dihydrochloride monohydrate for system


suitability

Council of Europe, all rights reserved 2013

Yes
Yes

0986

Storage
+5C
+5C

79

+5C

131

+5C

79

-20C

79

0260,0577,0
813,2342

Yes

+5C

79

0708,0814

Yes

+5C

79

0987

+5C

79

0987

+5C

79

+5C

79

+5C

79

1403

+5C

79

1403

+5C

79

+5C

79

+5C

79

+5C

79

-20C

g(c)

79

Yes

-20C

79

Yes

+5C

79

79

Yes

Yes
Yes

1404
94.3% CHNOS

Extra
Price
charges
79
g

0989

+5C

79

0708,0989

+5C

79

0989

Yes

+5C

79

0990

Yes

+5C

79

0990

Yes

+5C

79

2341

Yes

-20C

79

2341

Yes

-20C

79

2341

Yes

-20C

79

2342

Yes

+5C

79

2342

Yes

+5C

79

+5C

79

+5C

79

97.4% CHNNaOS
97.1% CHNOS

See leaflet CHNOS


(2R)-2-amino-2-(4-hydroxyphenyl)acetic acid
(p-hydroxyphenylglycine)

2342
2342

14

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Code
C0690000 Cefradine

Reference Standard

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
4
300 mg
1 93.9%

Information

Monograph Leaflet

Storage

0167,0168,0
578,
0708,0814

Yes

+5C

Extra
Price
charges
79
a

Y0000568 Cefradine for peak identification

15 mg

Must be used with Cefradine impurity mixture CRS Y0001174

0814

Yes

+5C

79

Y0001174 Cefradine impurity mixture

0.04 mg

Must be used with Cefradine for peak identification Y0000568

0814

Yes

+5C

79

C0690500 Ceftazidime

200 mg

85.3% CHNOS

Y0001111 Ceftazidime for peak identification

10 mg

C0691000 Ceftriaxone sodium

100 mg

C0692000 Ceftriaxone impurity A

10 mg

C0694990 Cefuroxime axetil

60 mg

97.3% CHNOS ; Batch 3 is valid until 31 December 2013

1300

C0695000 Cefuroxime sodium

150 mg

96.7% CHNNaOS

0988,0992

Y0001445 Celecoxib

200 mg

99.9% CHFNOS

2591

Y0001446 Celecoxib impurity A

10 mg

4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]
benzenesulfonamide

2591

Y0001447 Celecoxib impurity B

10 mg

4-[3-(4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]
benzenesulfonamide

Y0000311 Celiprolol hydrochloride

10 mg

Y0000312 Celiprolol impurity I

0.02 mg

Y0000239 Celiprolol for peak identification

20 mg

1632

Y0000784 Cellulose acetate

40 mg

Y0001054 Cellulose acetate phthalate

10 mg

C0700000 Cephaline hydrochloride

15 mg

C0980650 Cetirizine dihydrochloride

100 mg

C0980651 Cetirizine impurity A

10 mg

(RS)-1-[(4-chlorophenyl)phenylmethyl]piperazine ; Batch 4 is valid until 31


July 2013

Y0001197 Cetirizine for peak identification

1.01 mg

Replaces Cetirizine impurity mixture CRS

1084

C0984100 Cetostearyl isononanoate - reference spectrum

n/a

C0990000 Cetyl alcohol

300 mg

Y0000073 Cetyl palmitate 15

60 mg

Y0000074 Cetyl palmitate 95

50 mg

C1000000 Cetylpyridinium chloride

20 mg

C1050000 Chenodeoxycholic acid

125 mg

Y0000104 Chitosan hydrochloride

30 mg

Council of Europe, all rights reserved 2013

1405

Yes

+5C

79

1405, 2344

Yes

+5C

79

90.4% CHNNaOS

0991

Yes

+5C

79

E-isomer

0991

+5C

79

Yes

+5C

79

Yes

+5C

79

Yes

+5C

79

+5C

79

2591

+5C

79

1632

+5C

79

+5C

79

+5C

79

0887

+5C

79

0314

+5C

79

0080,0081,0
093,
0094,1530,1
875

+5C

79

1084

+5C

79

1084

+5C

79

Yes

+5C

79

79

Yes

+5C

79

1906

+5C

79

1906

+5C

79

0379

+5C

79

1189,1275

+5C

79

1774

+5C

79

1632

1-acetyl-1-(4-ethoxyphenyl)-3,3-diethylurea

Yes

1085
99.7% CHO ; Batch 1 is valid until 30 November 2013

Batch 2 is valid until 31 August 2013

15

0540,0702,0
801,
0802,0847,0
969, 1411

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Code
C1100000 Chlorambucil

Reference Standard

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
100 mg
1

Information

Monograph Leaflet
0137

Storage
+5C

Y0001298 Chlorambucil for system suitability

10 mg

0137

+5C

79

Y0001299 Chlorambucil with impurity G

10 mg

0137

+5C

79

C1200000 Chloramphenicol

500 mg

0071,0473,0
709

+5C

79

C1300000 Chloramphenicol dipalmitate

100 mg

0473

+5C

79

C1350000 Chloramphenicol disodium disuccinate

25 mg

0709

+5C

79

C1400000 Chloramphenicol palmitate isomer

100 mg

0473

+5C

79

C1425000 Chloramphenicol sodium succinate

1500 mg

0709

+5C

79

C1435000 Chlorcyclizine hydrochloride

100 mg

1086

+5C

79

C1450000 Chlordiazepoxide - * psy

50 mg

0656,1974

+5C

79

C1500000 Chlordiazepoxide hydrochloride - * psy

100 mg

Y0000476 Chlordiazepoxide impurity A

10 mg

C1510000 Chlorhexidine

50 mg

C1520000 Chlorhexidine diacetate

10 mg

C1540000 Chlorhexidine dihydrochloride

Y0001545 Chlorhexidine for system suitability

C1530000 Chlorhexidine for performance test


New Y0000569 Chlorogenic acid

Batch 1 is valid until 31 March 2014

0474

+5C

79

0474,0656

+5C

79

0658

+5C

79

0657

+5C

79

50 mg

0659

+5C

79

15 mg

0658

Yes

+5C

79

50 mg

0657,0658,0
659

Yes

+5C

79

25 mg

97% CHO ; (1S,3R,4R,5R)-3-[(3,4-Dihydroxycinnamoyl)oxy]-1,4,51821,1822,1


trihydroxycyclohexanecarboxylic acid ; Batch 1 is valid until 28 February 2014
823,
1824,1866,1
897, 2389
Clemastine fumarate impurity C
1190

Yes

+5C

79

C2223030 1-(4-Chlorophenyl)-1-phenylethanol

15 mg

C1650000 Chloroquine sulfate

200 mg

C1700000 Chlorothiazide

100 mg

C1800000 Chlorphenamine maleate

100 mg

New Y0000436 Chlorphenamine impurity A

0.01 mg

Y0000437 Chlorphenamine impurity C

10 mg

C1900000 Chlorpromazine hydrochloride

200 mg

Y0000507 Chlorpromazine impurity A

15 mg

Y0000479 Chlorpromazine impurity D

10 mg

Y0000508 Chlorpromazine impurity E

Y0001449 Chlorpromazine impurity F

Council of Europe, all rights reserved 2013

91.1% CHClNNaO

Yes

Extra
Price
charges
79
g

7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one 4-oxide

-20C

g(c)

79

0544,0545

+5C

79

0394

+5C

79

0386,0977,1
084, 1196

+5C

79

2-(4-chlorophenyl)-4-(dimethylamino)-2-[2-(dimethylamino)
ethyl]butanenitrile ; Batch 3 is valid until 31 March 2014

0386

+5C

79

(3RS)-3-(4-chlorophenyl)-N-methyl-3-(pyridin-2-yl)propan-1amine

0386

+5C

79

0475,20303

+5C

79

3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1amine S-oxide (chlorpromazine sulphoxide)

0475

+5C

79

3-(2-chloro-10H-phenothiazin-10-yl)-N-methypropan-1-amine
(demethylchlorpromazine)

0475

+5C

79

10 mg

2-chloro-10H-phenothiazine

0475

+5C

79

2 mg

3-(4-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine

0475

+5C

79

16

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
C1905000 Chlorpropamide

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
100 mg
1

Information

Monograph Leaflet
1087

C1905020 Chlorpropamide impurity B

50 mg

1,3-Dipropylurea

C1915000 Chlorprothixene hydrochloride

50 mg

2.0% E-isomer

C1950000 Chlortalidone

150 mg

Y0000779 Chlortalidone for peak identification

1.017 mg

C2000000 Chlortetracycline hydrochloride

100 mg

Y0001451 Chlortetracycline for system suitability

20 mg

C2100000 Cholecalciferol

480 mg

C2150000 Cholecalciferol for system suitability

1 mL

C2155000 Cholesterol

100 mg

C2158000 Cholic acid

60 mg

Y0000280 Chondroitin sulfate sodium

250 mg

Y0000593 Chondroitin sulfate sodium (marine)

100 mg

C2160000 Chymotrypsin BRP

100 mg

Y0001553 Ciclesonide

Y0001554 Ciclesonide containing impurity A

Y0001555 Ciclesonide impurity B

Storage
+5C

1087

Extra
Price
charges
79
a

+5C

79

0815,1365

Yes

+5C

79

99.7% CHClNOS ; Batch 2 is valid until 31 August 2013

0546

Yes

+5C

79

Batch 2 is valid until 30 November 2013

0546

Yes

+5C

79

92.4% of of CHClNO ; Batch 4 is valid until 31 December 2012

0173

Yes

+5C

79

0173

Yes

+5C

79

0072,0574,0
575,
0598,1192,1
193

Yes

-20C

g(c)

79

-20C

g(c)

79

+5C

79

+5C

79

+5C

79

100% CHO ; Vitamin D3

0072,0082,0
574,
0575,0598
99.5% CHO

0593,0993

99.6 % HO(CHNNaOS) ; Batch 1 is valid until 1 May 2013

2064,2090

+5C

79

6.01 microkatals per mg

0476,0694

Yes

+5C

79

150 mg

99.8 % CHO

2703

Yes

+5C

79

15 mg

(2S)-2-cyclohexyl-11b-hydroxy-3,20-dioxo-16bH-[1,3]dioxolo[4,5:16,17]
pregna-1,4-diene-21-yl 2-methylpropanoate (S-epimer of ciclesonide)

2703

+5C

79

10 mg

(2R)-2-cyclohexyl-11b,21-dihydroxy-16bH-[1,3]dioxolo[4,5:16,17]
pregna-1,4-diene-3,20-dione

2703

+5C

79

Y0001556 Ciclesonide impurity C

10 mg

(2R)-2-[(1RS)-cyclohex-3-enyl]-11b-hydroxy-3,20-dioxo-16bH-[1,3]dioxolo
[4,5:16,17]pregna-1,4-diene-21-yl 2-methylpropanoate

2703

+5C

79

Y0000040 Ciclopirox

100 mg

1407

+5C

79

C2162701 Ciclopirox impurity A

40 mg

()-2-(3-cyclohexyl-5-methyl-4,5-dihydroisoxazol-5-yl)acetic acid

1302,1407

+5C

79

C2162702 Ciclopirox impurity B

20 mg

6-cyclohexyl-4-methyl-2H-pyran-2-one

1302,1407

-20C

79

C2162700 Ciclopirox olamine

150 mg

+5C

79

C2163000 Ciclosporin

120 mg

+5C

79

Y0000361 Ciclosporin for system suitability

5 mg

0994

+5C

79

C2170000 Cilastatin sodium

10 mg

1408

+5C

79

C2174000 Cilazapril

50 mg

1499

+5C

79

C2174002 Cilazapril impurity A

25 mg

1,1-dimethylethyl(1S,9S)-9-[[(S)-1-ethoxycarbonyl-3-phenylpropyl]
amino]-10-oxo-octahydro-6H-pyridazino[1,2a][1,2]diazepine-1-caboxylate

1499

+5C

79

C2174005 Cilazapril impurity D

10 mg

(1S,9S)-9-[[(R)-1-ethoxycarbonyl-3-phenylpropyl]amino]-10- oxooctahydro-6H-pyridazino[1,2a][1,2]diazepine-1-carboxylic acid

1499

+5C

79

Council of Europe, all rights reserved 2013

Yes

1189
Yes

2064

1302
0994

98.5% CHNO

17

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Code
C2175000 Cimetidine

Reference Standard

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
50 mg
1

Information

Monograph Leaflet
0756

Storage
+5C

Extra
Price
charges
79
a

C2175500 Cimetidine hydrochloride

100 mg

1500

+5C

79

Y0001130 Cimetidine for peak identification

10 mg

0756

Yes

+5C

79

Y0001146 Cimetidine for system suitability

0.5085 mg

756

Yes

+5C

79

C2177000 Cinchocaine hydrochloride

60 mg

1088

+5C

79

Y0000176 Cineole

180 mg

1973

+5C

79

C2180000 Cinnarizine

100 mg

0816

+5C

79

Y0000362 Ciprofibrate

5 mg

2013

+5C

79

Y0000363 Ciprofibrate for system suitability

5 mg

2013

+5C

79

Y0000198 Ciprofloxacin

20 mg

100 mg

See leaflet ; Batch 4 is valid until 31 March 2014

Y0000199 Ciprofloxacin hydrochloride for peak identification

15 mg

Batch 1 is valid until 31 August 2013

C2190050 Ciprofloxacin impurity A

25 mg

7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic
acid (fluoroquinolonic acid)

C2210000 Cisplatin

100 mg

99.7% [PtCl(NH)]

0599

Y0001018 Cisplatin impurity A

15 mg

trans-diamminedichloroplatinum (II)

0599

Y0001019 Cisplatin impurity B

15 mg

94.1% [PtCl(NH)]-; amminetrichloroplatinate(-)

0599

Y0001008 Citalopram hydrobromide

5 mg

Y0001007 Citalopram hydrochloride

5 mg

Y0000855 Citalopram for system suitability

0.065 mg

2203,2288

A1202000 Citric acid (anhydrous)

50 mg

0455

C2219000 Citric acid monohydrate

50 mg

Y0000639 Cladribine

50 mg

Y0000609 Cladribine for peak identification

10 mg

Y0000610 Cladribine impurity C

5 mg

2-chloro-7H-purin-6-amine

2174

Y0000320 Clarithromycin

160 mg

97.7% CHNO

1651

Y0000321 Clarithromycin for peak identification

40 mg

1651

Y0000269 Clazuril for system suitability

10 mg

1714

Y0001193 Clazuril

10 mg

1714

C2221000 Clebopride malate

100 mg

C2223000 Clemastine fumarate

100 mg

New Y0001613 Clemastine for system suitability

0.165 mg

1190

C2248000 Clenbuterol hydrochloride

30 mg

1409

C2248010 Clenbuterol impurity B

10 mg

1-(4-amino-3,5-dichlorophenyl)-2-[(1,1-dimethylethyl)amino] ethanone

C2250000 Clindamycin hydrochloride

200 mg

94.4% CHClNOS

0582,0583,0
996

Yes

C2269000 Clindamycin phosphate

250 mg

95.7% CHClNOPS

0996

Yes

New C2190000 Ciprofloxacin hydrochloride

Council of Europe, all rights reserved 2013

Yes

+5C

79

0888,1353

1089
Yes

+5C

79

0888,1089

Yes

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

2288

+5C

79

2203

+5C

79

+5C

79

+5C

79

0888,1089,2
229
Yes
Yes

Yes

0456
99.1% CHClNO

18

+5C

79

2174

Yes

+5C

g(b)

79

2174

Yes

+5C

g(b)

79

+5C

g(b)

79

Yes

+5C

79

Yes

+5C

79

Yes

+5C

79

+5C

79

1303

+5C

79

1190

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

Yes

1409

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Code
Y0000364 Clioquinol

Reference Standard

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
5 mg
1

Information

Monograph Leaflet
2111

Y0000205 Clobazam - reference spectrum

n/a

Y0000241 Clobazam impurity A

10 mg

7-chloro-5-phenyl-1,5-dihydro-1,5-dihydro-3H-1,5-benzodiazepine-2,4-dione

1974

Y0000559 Clobetasol propionate

40 mg

99.6% CHClFO

2127

Y0000570 Clobetasol for peak identification

2 mg

2127

Y0000571 Clobetasol impurity J

0.4 mg

C2285000 Clobetasone butyrate

50 mg

1090

Y0001137 Clobetasone butyrate for system suitability

30 mg

1090

Y0000888 Clodronate disodium tetrahydrate

5 mg

Y0000885 Clodronate impurity D

5 mg

Y0000313 Clofazimine

150 mg

2054

Y0000358 Clofazimine for system suitability

10 mg

2054

C2300000 Clofibrate

0.5 ml

C2320000 Clomifene citrate

50 mg

C2332000 Clomifene citrate for performance test

50 mg

0997

C2360000 Clomipramine hydrochloride

100 mg

0889

Y0000132 Clomipramine impurity C

10 mg

94.5% CHClN; 3-(3-chloro-5H-dibenzo[b,f]azepin-5-yl)-N,Ndimethylpropan-1-amine

0889

Y0000133 Clomipramine impurity D

10 mg

3-(3,7-dichloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,Ndimethylpropan-1-amine ; Batch 1 is valid until 31 December 2012

0889

Y0000134 Clomipramine impurity F

5 mg

3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine

C2385000 Clonazepam - * psy

50 mg

Y0000286 Clonazepam - reference spectrum

n/a

C2385015 Clonazepam impurity B

5 mg

C2400000 Clonidine hydrochloride

100 mg

Y0000801 Clonidine impurity B

20 mg

Y0000833 Clopamide

40 mg

1747

Y0000848 Clopamide for system suitability

10 mg

1747

Y0001333 Clopidogrel hydrogen sulfate

60 mg

Y0001335 Clopidogrel impurity A

10 mg

Y0001334 Clopidogrel for system suitability

100 mg

2531

Y0000392 Closantel sodium dihydrate

20 mg

1716

Y0000393 Closantel for system suitability

20 mg

C2424400 Clostridia (multi-component) rabbit antiserum(for


vaccines-vet.use)BRP

1 mg

see information on the accompanying leaflet

C2424550 Clostridium tetani guinea pig antiserum (for vaccines human use) BRP
Council of Europe, all rights reserved 2013

1 mg

0.20 IU per vial (determined using toxin neutralisation test)

Storage
+5C

1974

(17R)-4'-chloro-5'-ethyl-9-fluoro-11-hydroxy-16-methylspiro
[androsta-1,4-diene-17,2'(3'H)-furan]-3,3'-dione (17 alpha-spiro compound)

(chloromethylene)bis(phosphonic acid)

44% of Z-isomer CHClNO

79

+5C

79

Yes

+5C

79

Yes

+5C

79

+5C

79

+5C

79

+5C

79

1777

+5C

79

1777

+5C

79

+5C

79

+5C

79

0318

+5C

79

0997,1046

+5C

79

+5C

79

+5C

79

Yes

+5C

79

Yes

+5C

79

0889

+5C

79

1974,0415

+5C

79

79

0890

+5C

79

0477

+5C

79

0477

+5C

79

+5C

79

+5C

79

2531

+5C

79

2531

+5C

79

+5C

79

+5C

79

2127

Yes

Yes

Yes

0890
3-Amino-4-(2-chlorophenyl)-6-nitro-1-quinolin-2-one
1-acetyl-2-[(2,6-dichlorophenyl)amino]-4,5-dihydro-1H-imidazole

(2S)-(2-chlorophenyl)[6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]acetic acid

19

Extra
Price
charges
79
g

Yes

Yes

1716

Yes

+5C

79

0362,0363,0
364, 0697

Yes

-20C

90

20708

Yes

-20C

90

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
C2424500 Clostridium tetani guinea pig antiserum (for vaccines vet. use) BRP

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
1 mg
1 34 IU per vial

Information

Monograph Leaflet

Storage

Extra
Price
charges
90
c

See leaflet,
0697

Yes

-20C

See leaflet,
0697

Yes

-20C

90

+5C

79

C2425600 Clostridium tetani rabbit antiserum (for vaccines - vet.


use) BRP

1 mg

C2430000 Clotrimazole

100 mg

0757

Y0000818 Clotrimazole impurity E

15 mg

0757

+5C

79

Y0000849 Clotrimazole for peak identification

1.005 mg

0757

Yes

+5C

79

C2450000 Cloxacillin sodium

200 mg

0661,0663,0
668, 2260

Yes

+5C

79

C2460000 Clozapine

60 mg

1191

Y0000758 Clozapine for peak identification

0.41 mg

1191

Y0001472 Coagulation Factors V, VIII, XI and XIII plasma

1 mg

Y0000162 Cocaine hydrochloride - reference spectrum

n/a

0073

C2480000 Cocoyl caprylocaprate

40 mg

1411

Y0000722 Codeine - * narc

20 mg

C2500000 Codeine - reference spectrum

n/a

Y0000334 Codeine impurity A

15 mg

C2500100 Codeine hydrochloride dihydrate - reference spectrum

n/a

C2510000 Codergocrine mesilate

60 mg

Y0001500 Coix seed HRS

1300 mg

C2580000 Colchicine

15 mg

Y0000209 Colchicine for system suitability

Y0000374 Colestyramine

C2600000 Colistimethate sodium

15 IU per vial

93.9% CHClNNaOS

+5C

79

Yes

+5C

79

Yes

-20C

90

79

+5C

79

+5C

79

79

+5C

79

79

1416,2060

+5C

79

2454

+5C

79

0758

+5C

79

10 mg

0758

+5C

79

10 mg

1775

+5C

79

20 mg

285000 IU per vial CHNNaOS

0319,20702

Yes

+5C

79

25 mg

See leaflet ; Batch 3 is valid until 28 February 2014

0320

Yes

-20C

79

C2700000 Colistin sulfate for microbiological assay

25 mg

576 000 IU per vial; For microbiological assay only

0320

Yes

-20 C

79

C2725000 Copovidone - reference spectrum

n/a

0891

79

C2800000 Cortisone acetate

250 mg

0321,0736,0
767

+5C

79

Y0000438 Coumarin

110 mg

+5C

79

C2900000 Cotton wool standard for neps

1000 mg

+5C

79

Y0001053 Crospovidone

5 mg

C2970000 Crotamiton

100 mg

99.2% CHNO (sum of E and Z-isomers); 3.5% Z-isomers CHNO

1194

C2970005 Crotamiton impurity A

70 mg

N-ethyl-N-(2-methylphenyl)but-3-enamide

1194

New Y0000277 Colistin sulfate

Council of Europe, all rights reserved 2013

Factor V : 0.73 IU per vial, Factor VIII : 0.74 IU per vial, Factor XI : 0.59 IU per 0903,1646,2
vial, Factor XIII : 0.79 IU per vial
0740,20722

0076,1839,1
841

See leaflet

Yes

0074,0075,0
076
7,8-didehydro-4,5 alpha-epoxy-3,6 alpha-dimethoxy-17-methylmorphinan

0074,0075,0
076, 1412
1412

Batch 1 is valid until 30 November 2013

2120

99.9% CHO

Yes

Yes

0036
0892

20

Yes

+5C

79

-20C

79

-20C

79

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0001061 Cyanidin chloride
C3000000 Cyanocobalamin

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
2
25 mg
1 93.3% CHClO ; Batch 1 is valid until 31 August 2013
4
20 mg
1 Vitamin B12

Monograph Leaflet
2394

Yes

Storage
+5C

Extra
Price
charges
79
a

0269,0270,0
547,
0710,1505

+5C

79

1092

+5C

79

C3090000 Cyclizine hydrochloride

50 mg

Y0000886 Cyclizine impurity A

15 mg

1-methylpiperazine

1092

+5C

g(b)

79

Y0000887 Cyclizine impurity B

10 mg

diphenylmethanol (benzhydrol)

1092

+5C

79

C3200000 Cyclobenzaprine hydrochloride

100 mg

C3230000 Cyclohexa-1,4-dienylglycine

15 mg

C3245000 Cyclopentolate hydrochloride

50 mg

1093

Y0001088 Cyclopentolate for system suitability

60 mg

1093

C3250000 Cyclophosphamide

50 mg

0711

C3280000 Cyproheptadine hydrochloride

30 mg

Y0001095 Cyproheptadine impurity C

5 mg

C3283000 Cyproterone acetate

30 mg

1094

Y0001390 Cyproterone acetate for peak identification

5 mg

1094

Yes

Y0001223 Cyproterone impurity mixture

0.01 mg

1094

Yes

C3290000 Cysteine hydrochloride monohydrate

100 mg

C3300000 Cystine

100 mg

C3350000 Cytarabine

150 mg

Y0000733 Dacarbazine

20 mg

Y0000734 Dacarbazine impurity A

20 mg

89.4% CHNO; 3,7-dihydro-4H-imidazo[4,5-d]-1,2,3-triazin-4-one (2azahypoxanthine)

1691

Yes

Y0000735 Dacarbazine impurity B

10 mg

87.9% CHO; 5-amino-1H-imidazole-carboxamide

1691

Yes

D0070000 Dalteparin sodium

250 mg

Y0000600 Danaparoid sodium

10 mg

D0100000 Dapsone

100 mg

D0125000 Daunorubicin hydrochloride

120 mg

98.5% CHClNO

0662

D0120000 Daunorubicinone

10 mg

Daunorubicin aglycone

D0160000 Deferoxamine mesilate

30 mg

D0201000 Dehydrohexetidine

50 mg

Y0000611 Dembrexine hydrochloride monohydrate

10 mg

D0300000 Demeclocycline hydrochloride

100 mg

D0350000 N-Demethylerythromycin A

10 mg

Council of Europe, all rights reserved 2013

0408,0464
86.7% CHNO; (2R)-amino(cyclohexa-1,4-dienyl)acetic acid (ddihydrophenylglycine)

+5C

79

-20C

79

+5C

79

+5C

79

+5C

79

0817,0846

+5C

79

0817

+5C

79

+5C

79

+5C

79

0814

Yes

Yes

+5C

79

0895

+5C

79

0998

+5C

79

0760

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

0662

+5C

79

0896

-20C

79

1221

+5C

79

+5C

79

+5C

79

+5C

79

Batch 1 is valid until 31 December 2013

1691

0828
147 anti-factor Xa units per ampoule, 4.3 anti-factor IIa units per ampoule

2090

Yes

0077

2-ethyl-N-[[1-(2-ethylhexyl)-4-methyl-4,5-dihydro-1H-imidazol-4-yl]methyl]
hexan-1-amine

Yes

2169
92.4% CHClNO

0176
0179,0274,0
490,
0552,1098

21

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000228 Demethylflumazenil - reference spectrum

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
n/a
1

Information

Monograph Leaflet

Storage

1917

Extra
Price
charges
79
l

D0406200 Deptropine citrate

60 mg

1308

+5C

79

D0430000 Dequalinium chloride

50 mg

1413

+5C

79

D0431000 Dequalinium chloride for performance test

50 mg

Y0001321 Dermatan sulfate and oversulfated chondroitin sulfate

1 mL

D0480000 Desacetylvinblastine

1 mg

Y0000879 Desflurane - reference spectrum

n/a

Y0000807 Desflurane impurity A

1 ml

D0500000 Desipramine hydrochloride

100 mg

D0600000 Deslanoside

150 mg

Y0001584 Desloratadine

100 mg

2570

D0630000 Desmethylmetrifonate

30 mg

1133

Y0001582 Desloratadine for system suitability

5 mg

2570

D0650000 Desmopressin

0.94 mg

0.94 mg per vial of CHNOS ; Batch 7 is valid until 1 March 2013

0712

Y0000509 Desogestrel

50 mg

99.9% CHO

10 mg

Batch 1 is valid until 30 April 2014

D0400000 Desoxycortone acetate

100 mg

Y0000001 Detomidine hydrochloride

100 mg

D0660020 Detomidine impurity B

20 mg

D0700000 Dexamethasone

50 mg

Y0001593 Dexamethasone for peak identification

10 mg

0388

D0710000 Dexamethasone acetate

100 mg

0548,0933,0
975, 2237

Y0001169 Dexamethasone acetate impurity E

0.013 mg

0548

Y0001177 Dexamethasone for system suitability

10 mg

0388

Y0000538 Dexamethasone isonicotinate

10 mg

2237

Y0000511 Dexamethasone isonicotinate for impurity C identification

10 mg

2237

D0718000 Dexamethasone pivalate

50 mg

D0720000 Dexamethasone sodium phosphate

100 mg

Y0001477 Dexamethasone sodium phosphate for peak


identification

10 mg

D0720800 Dexchlorpheniramine maleate

60 mg

New Y0000510 Desogestrel for system suitability

Council of Europe, all rights reserved 2013

1413

+5C

79

-20C

79

-80C

g(d)

79

79

1666

+5C

79

0481

+5C

79

0482

+5C

79

+5C

79

+5C

79

Yes

+5C

79

Yes

-20C

79

1717

Yes

+5C

79

1717

Yes

+5C

79

0322,0809,0
850, 1327

+5C

79

1414

+5C

79

1414

+5C

79

0312,0388,0
548,
0768,1376,2
237,0549

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

0332,0333

Dermatan sulfate 10 mg/mL


Oversulfated chondroitin sulfate 2.5 mg/mL

Yes

1276
1666
1,1'-oxybis(1,2,2,2-tetrafluoroethane)
98.8% CHO

(RS)-(1-benzyl-1H-imidazol-5-yl)(2,3-dimethylphenyl)methanol

9-fluoro-11beta,17-dihydroxy-16alpha-methyl-3,20-dioxopregn-4-en-21-yl
acetate

Yes

Yes

Yes
Yes

+5C

79

0549,0735,0
810

1327
Yes

+5C

79

0549

Yes

+5C

79

1196

+5C

79

88.3 % CHFNaOP

22

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Code
D0730000 Dexpanthenol

Reference Standard

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
4
5 mg
1

Information

Monograph Leaflet

Storage

Extra
Price
charges
79
a

0761

+5C

0999,1000,1
001

+5C

79

+5C

79

+5C

79

D0731000 Dextran

25 mg

D0731005 Dextran 1

50 mg

D0732000 Dextran Vo

10 mg

D0733000 Dextran 4 for calibration

50 mg

M 3050-M 3850

20239

Yes

+5C

79

D0734000 Dextran 10 for calibration

50 mg

M 8800 - M 10450

20239

Yes

+5C

79

D0735000 Dextran 40 for calibration

50 mg

M 30500- M 40900

20239

Yes

+5C

79

D0736000 Dextran 70 for calibration

50 mg

M 58900- M 70300

20239

Yes

+5C

79

D0737000 Dextran 250 for calibration

50 mg

M 121800- M 238200

20239

Yes

+5C

79

D0738000 Dextran 40 for performance test

50 mg

20239

+5C

79

D0739000 Dextran 60/70 for performance test

50 mg

20239

+5C

79

Y0000744 Dextranomer

50 mg

2338

+5C

79

D0740000 Dextromethorphan hydrobromide

100 mg

Batch 3 is valid until 31 January 2013

0020

+5C

79

5 mg

ent-3-methoxymorphinan ; Batch 1 is valid until 30 April 2014

0020

+5C

79

Y0001058 Dextropropoxyphene hydrochloride - * narc

10 mg

0713

+5C

79

Y0001150 Dextropropoxyphene for system suitability - * narc

5 mg

0713

+5C

79

D0940000 Diazepam - * psy

30 mg

0022

+5C

79

Y0000596 Diazepam for system suitability - * psy

0.5 mg

0022

+5C

79

D0950000 Diazoxide

50 mg

0550

+5C

79

D0970000 Dibenzocycloheptene

20 mg

0817

+5C

79

D1000000 Dibenzosuberone

100 mg

0464,0817,0
941

+5C

79

Y0000480 Dibrompropamidine diisetionate

10 mg

2300

+5C

79

Y0000481 Dibrompropamidine for system suitability

20 mg

2300

+5C

79

D1010000 Dibutyl phthalate

1 ml

0762

+5C

79

Y0000275 Dichlorodiaminocyclohexaneplatinum

15 mg

2017

+5C

79

Y0000264 Diclazuril for veterinary use - reference spectrum

n/a

1718

79

Y0000259 Diclazuril for system suitability

20 mg

1718

+5C

79

D1039990 Diclofenac potassium

100 mg

1508

+5C

79

D1040000 Diclofenac impurity A

0.005 mg

1-(2,6-dichlorophenyl)-1,3-dihydro-2H-indol-2-one ; Batch 7 is valid until 31


December 2013

1002,1281,1
508

+5C

79

D1050000 Dicloxacillin sodium

250 mg

94.7% CHClNNaOS

0661,0663,0
668

+5C

79

D1060000 Dicycloverine hydrochloride

100 mg

1197

+5C

79

Y0000439 Didanosine

10 mg

2200

+5C

79

New Y0000261 Dextromethorphan impurity A

Council of Europe, all rights reserved 2013

1506

Average molecule mass : 930-1000


Fraction with less than 3 glucose units : 8.0 to 10.5%
Fraction with more than 9 glucose units : 10.0 to 12.5%

Yes

20239

Batch 3 is valid until 1 April 2013

23

Yes
Yes

Yes

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000440 Didanosine for system suitability

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
10 mg
1

Information

Monograph Leaflet
2200

Yes

Storage
+5C

Extra
Price
charges
79
a

Y0000441 Didanosine impurity A

10 mg

1,7-dihydro-6H-purin-6-one (hypoxanthine)

2200

+5C

79

Y0000442 Didanosine impurity G

10 mg

9-(2,3-dideoxy--D-glycero-pentofuranosyl)-9H-purin-6-amine (2',3'dideoxyadenosine)

2200

+5C

79

D1200000 Dienestrol

150 mg

100% CHO

0484

+5C

79

D1300000 Diethylcarbamazine citrate

250 mg

99.9% CHNO

0271

+5C

79

Y0000217 Diethylene glycol (monoethyl ether) - reference spectrum

n/a

79

D1410000 Diethyl phthalate

1 ml

D1500000 Diethylstilbestrol

100 mg

D1600000 Diethylstilbestrol dimethyl ether

10 mg

D1700000 Diethylstilbestrol monomethyl ether

10 mg

Y0001423 Difloxacin hydrochloride

60 mg

Y0001429 Difloxacin impurity G

15 mg

D1750000 Diflunisal

30 mg

D1800000 Digitoxin

200 mg

Y0000640 Digoxigenin

5 mg

D1900000 Digoxin

30 mg

Y0000554 Digoxin for peak identification

10 mg

0079

D1940001 Dihydralazine sulfate (hydrated) - reference spectrum

n/a

1310

Y0000232 Dihydralazine for system suitability

10 mg

1310

Y0000216 Dihydrocodeine hydrogen tartrate - reference spectrum

n/a

Y0000053 17 alpha-dihydroequilin

10 mg

D1945000 Dihydroergocristine mesilate

250 mg

D1950000 Dihydroergotamine mesilate

100 mg

Y0000831 Dihydroergotamine for peak identification

10 mg

0551

D1952000 Dihydroergotamine tartrate

150 mg

100.0% CHNO. Dried at 100-105C at constant weight

0600

D1954000 Dihydrostreptomycin sulfate

25 mg

23.9 mg per vial of CHNOS

Y0000544 Dihydrotachysterol

30 mg

99.6% CHO

Y0000482 Dihydrotachysterol for system suitability

5 mg

D1980000 Diltiazem hydrochloride

300 mg

Y0001141 Diltiazem for system suitability

10 mg

Y0001439 Diltiazem impurity F

10 mg

D2000000 Dimenhydrinate

100 mg

Y0000234 N,N-Dimethylacetamide - reference spectrum

Y0001103 Dimenhydrinate for peak identification

Council of Europe, all rights reserved 2013

Yes

1198
0897

+5C

79

0483,0484

+5C

79

0484

+5C

79

0484

+5C

79

2239

+5C

79

2239

+5C

79

0864

+5C

79

+5C

79

+5C

79

Dried at 100-105C for 2 h. 100% CHO

7-chloro-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic
acid

0078,0117

99.4% CHO

Yes

0079
0079

+5C

79

Yes

+5C

79

79

Yes

+5C

79

79

1512

-20C

79

1416,2060

+5C

79

0551

+5C

79

Yes

+5C

79

Yes

+5C

79

0485

Yes

-20C

79

2014

Yes

-20C

g(d)

79

2014

Yes

-20C

g(d)

79

1004

+5C

79

Replaces Diltiazem impurity A CRS ; Batch 1 is valid until 31 August 2013

1004

+5C

79

(2S,3S)-5-[2-(dimethylamino)ethyl]-3-hydroxy-2-(4-methoxyphenyl)-2,3dihydro-1,5-benzothiazepin-4(5H)-one

1004

+5C

79

0601

+5C

79

n/a

1667

79

1 mg

0601

+5C

79

98.5% CHO

1776
98.2% CHO

24

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
D2050000 Dimethyl sulfoxide

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
2
1 ml
1

Information

Monograph Leaflet
0763

+5C

Y0001489 2-(Dimethylamino)ethyl methacrylate

50 mg

D2200000 Dimeticone

200 mg

D2205000 Dimetindene maleate

50 mg

D2255000 Dinoprost trometamol

60 mg

98.2% CHNO

D2250000 Dinoprostone

100 mg

99.8% CHO

D2250015 Dinoprostone impurity C

10 mg

(E)-7-[(1S,2R,3R)-3-hydroxy-2-[(E)-(3S)-3-hydroxyoct-1-enyl]- 5oxocyclopentyl]-hept-5-enoic acid (5-trans-PGE2 ; (5E)-PGE2)

Y0000094 Diosmin

70 mg

90.9% CHO

Y0000095 Diosmin for system suitability

5 mg

D2600000 Diphenhydramine hydrochloride

100 mg

Y0000135 Diphenhydramine impurity A

10 mg

0023,0601

D2630000 Diphenoxylate hydrochloride - reference spectrum

n/a

0819

Y0001415 Diphenoxylate hydrochloride - * narc

15 mg

0819

Y0001430 Diphenoxylate for system suitability - * narc

10 mg

Y0000258 Diphtheria toxin BRP

1 ml

Nominal concentration of Diphtheria toxin: 1 Lf/ml (0.4l/ml)


Systemic toxicity: 77.6 LD/ml (determined in the subcutaneous challenge
test in guinea pigs)
Maximum intradermal toxicity: 75,000Lr/Lf (determined in the guinea pig
intradermal skin test)
Toxicity in the Vero cell assay: concentrations of 5x10- Lf/ml and below
cause cytotoxic effects.

See leaflet,
0443

Yes

D2700000 Diphtheria vaccine (adsorbed) BRP

32 mg

97 IU per vial

See leaflet,
20706

Yes

Y0000376 Dipivefrine hydrochloride

100 mg

99.3% CHClNO

Y0000394 Dipivefrine for system suitability

10 mg

D2750100 Dipotassium clorazepate - reference spectrum

n/a

0898

D2800000 Diprophylline

100 mg

0486

D2850000 Dipyridamole

50 mg

1199

Y0000802 Dipyridamole for peak identification

2.04 mg

1199

D2880000 Dirithromycin

100 mg

D2900000 Disodium edetate

100 mg

D2920000 Disopyramide

100 mg

D2922000 Disopyramide phosphate

100 mg

D2950000 Disulfiram

100 mg

D2953000 Dithranol

55 mg

Council of Europe, all rights reserved 2013

Storage

1975

Extra
Price
charges
79
a

+5C

79

Yes

+5C

79

+5C

79

1312

Yes

-20C

79

1311

Yes

-20C

79

-20C

240

+5C

79

1611

+5C

79

0023,0601,1
190

+5C

79

+5C

79

79

+5C

79

+5C

79

+5C

g(b)

90

-20C

90

1719

+5C

79

1719

+5C

79

79

+5C

79

+5C

79

+5C

79

1313

+5C

79

0232

+5C

79

1006

+5C

79

1005

+5C

79

0603

+5C

79

1007

+5C

79

0138,1470

99.9% dimeticone

1417

1311,1488
1611

2-(diphenylmethoxy)-N-methylethanamine

Yes

0819

97.4% CHNO

Batch 1 is valid until 31 December 2012

25

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
D2953025 Dithranol impurity C

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
3
15 mg
1 Dithranol-dimer
4,4',5,5'-tetrahydroxy-9,9'-bianthracenyl-10,10'(9H,9'H)-dione ; Batch 2 is
valid until 1 June 2013

Monograph Leaflet
1007

Yes

D2953050 Dithranol impurity D

20 mg

D2954000 Dobutamine hydrochloride

100 mg

1200

Y0001239 Dobutamine impurity mixture

0.1 mg

1200

Yes

Y0001133 Docetaxel trihydrate

160 mg

93.5% CHNO ; Batch 1 is valid until 30 November 2013

2449,2593

Y0001155 Docetaxel for system suitability

10 mg

Batch 1 is valid until 1 March 2013

2449,2593

Y0001452 Docetaxel impurity E

15 mg

5,20-epoxy-4-(acetyloxy)-1,7,10,13-tetrahydroxy-9-oxotax-11-en-2-yl
benzoate (10-desacetyl-baccatin III)

D2954600 Docosahexaenoic acid ethyl ester

150 mg

93.1% DHA ethyl ester

D2954500 Docusate sodium - reference spectrum

n/a

1418

Y0000365 Dodecyl gallate

30 mg

2078

D2955000 Domperidone

150 mg

1009

D2957000 Domperidone maleate

150 mg

D2960000 Dopamine hydrochloride

50 mg

Y0000612 Dopexamine dihydrochloride

10 mg

Y0000613 Dopexamine impurity B

10 mg

2-methoxy-4-[2-[[6-[(2-phenylethyl)amino]hexyl]amino]ethyl]phenol

Y0000614 Dopexamine impurity F

10 mg

4-chloro-5-[2-[[6-[(2-phenylethyl)amino]hexyl]amino]ethyl]benz -ene-1,2-diol

Y0000726 Dorzolamide hydrochloride

50 mg

Y0000727 Dorzolamide impurity A

5 mg

Y0000750 Dorzolamide for system suitability

5 mg

2359

D2962000 Dosulepin hydrochloride

100 mg

1314

30 mg

Y0001385 Angelica pubescent root

500 mg

D2963000 Doxapram hydrochloride

50 mg

Y0000208 Doxapram impurity B

10 mg

(4RS)-1-ethyl-4-[2-[(2-hydroxyethyl)amino]ethyl]-3,3-diphenylpyrolidin-2-one

1201

Y0000553 Doxazosin mesilate

60 mg

See leaflet CHNOS

2125

Y0000551 Doxazosin impurity D

10 mg

6,7-dimethoxyquinazoline-2,4(1H,3H)-dione

2125

New Y0000552 Doxazosin impurity F

15 mg

2-chloro-6,7-dimethoxyquinazolin-4-amine ; Batch 1 is valid until 30 April 2014

2125

Y0000838 Doxepin hydrochloride

5 mg

1096

Y0000851 Doxepin for system suitability

1 mg

1096

Yes

D2975000 Doxorubicin hydrochloride

150 mg

99.4% CHClNO

0714,0662,1
590

D3000000 Doxycycline hyclate

50 mg

92.9% CHClNO corresponding to 85.9% CHNO

0272,0820

New D2962005 Dosulepin impurity A

Council of Europe, all rights reserved 2013

94.9% CHO; 1-hydroxyanthracen-9(10H)-one ; Batch 3 is valid until 31


December 2013

1007

(4R,6R)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2sulphonamide 7,7-dioxide

+5C

Extra
Price
charges
79
g

+5C

79

+5C

79

+5C

79

Yes

+5C

79

Yes

+5C

79

+5C

79

-20C

79

79

+5C

79

+5C

79

1008

+5C

79

0664,1200

+5C

79

1748

+5C

79

1748

-20C

79

1748

-20C

79

2359

+5C

79

2359

+5C

79

+5C

79

+5C

79

2593
2063,20429

Batch 1 is valid until 31 March 2014

Storage

Yes

Yes

1314

Yes

+5C

79

2557

Yes

+5C

79

1201

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

Yes

-20C

g(c)

79

Yes

+5C

79

(E)-3-(6,11-dihydrodibenzo[b,e]thiepin-11-ylidene)-N,N'dimethylpropan-1-amine -oxide ; Batch 1 is valid until 30 April 2014

26

Yes
Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0001492 Doxylamine for system suitability

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
100 mg
1

Information

Monograph Leaflet
1589

Yes

Storage
+5C

Extra
Price
charges
79
a

Y0000163 Doxylamine hydrogen succinate - reference spectrum

n/a

1589

79

D3100000 Droperidol

150 mg

1008,1009,1
010, 1172

+5C

79

Y0001105 Drospirenone

60 mg

99.9% CHO

2404

+5C

79

Y0001115 Drospirenone impurity E

0.06 mg

3-oxo-6alpha,7alpha,15alpha,16alpha-tetrahydro-3'H,3''H-dicyclopropa
[6,7:15,16]pregn-4-ene-21,17- carbolactone (17-epidrospirenone)

2404

+5C

79

Y0001453 Duloxetine hydrochloride

120 mg

99.8 % CHClNOS

2594

Yes

+5C

79

Y0001454 Duloxetine for system suitability

40 mg

2594

Yes

+5C

79

Y0001455 Duloxetine impurity A

10 mg

(3R)-N-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine ;
Batch 1 is valid until 31 March 2014

2594

+5C

79

Y0001004 Dydrogesterone

50 mg

99.5% CHO

2357

+5C

79

Y0001005 Dydrogesterone impurity A

6 mg

9,10-pregna-4,6,8(14)-triene-3,20-dione

2357

+5C

79

Y0001006 Dydrogesterone impurity B

5 mg

pregna-4,6-diene-3,20-dione

2357

+5C

79

Y0000249 Ebastine - reference spectrum

n/a

79

Y0000247 Ebastine impurity C

10 mg

4-(diphenylmethoxy)piperidine

2015

+5C

79

Y0000248 Ebastine impurity D

10 mg

1-[4-(1,1-dimethylethyl)phenyl]-4-(4-hydroxypiperidin-1-yl)butan-1-one

2015

+5C

79

Y0001236 Econazole

10 mg

2049

+5C

79

E0050000 Econazole nitrate

100 mg

0513,0665,0
921, 0935,
1017,1018

+5C

79

Y0000254 Econazole for system suitability

20 mg

200 mg

Y0000537 Emedastine difumarate

10 mg

Y0000512 Emedastine impurity E

10 mg

E0100000 Emetine hydrochloride

100 mg

E0110000 Enalapril for system suitability

Y0001211 Enalapril impurity mixture


E0109000 Enalapril maleate

2015

0665,2049

Yes

+5C

79

2063,20429

Yes

-20C

79

2242

+5C

79

2242

+5C

79

0081,0093,
0094,1530,1
875

+5C

79

20 mg

1420

+5C

79

0.06 mg

+5C

79

50 mg

1420

+5C

79

Y0000615 Enalaprilat dihydrate

100 mg

1749

+5C

79

Y0000629 Enalaprilat for system suitability

10 mg

1749

+5C

79

Y0000678 Enalaprilat impurity G

0.005 mg

1749

+5C

79

Y0000136 Enilconazole

60 mg

1720

+5C

79

Y0000137 Enilconazole impurity E

20 mg

(1RS)-1-(2,4-dichlorophenyl)-2-(-1H-imidazol-1-yl)ethanol

1720

+5C

79

E0150000 Endotoxin standard BRP

10 mg

10 000 IU per vial ; Batch 4 is valid until 31 December 2012

20614

-20C

79

New E0085000 Eicosapentaenoic acid ethyl ester

Council of Europe, all rights reserved 2013

97.5% CHO ; Batch 3 is valid until 17 December 2013


1-(2-ethoxyethyl)-2-(hexahydro-1H-1,4-diazepin-1yl)benzimidazole.

1420

Batch 1 is valid until 30 November 2013

(2SR)-2-[(3SR,8aRS)-3-methyl-1,4-dioxohexahydropyrrolo[1,2-a] pyrazin-2
(1H)-yl]-4-phenylbutanoic acid

27

Yes

Yes

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
E0180000 Enoxaparin sodium

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
5
200 mg
1 Batch 4 is valid until 30 November 2013

Monograph Leaflet
0828,1097

Yes

Storage
+5C

Extra
Price
charges
79
a

E0180500 Enoxolone

100 mg

1511

+5C

79

Y0001259 Enrofloxacin

5 mg

2229

+5C

79

Y0001160 Enrofloxacin for system suitability

10 mg

2229

Yes

+5C

79

Y0001249 Entacapone

160 mg

99.9% CHNO

2574

Yes

+5C

79

Y0001250 Entacapone impurity A

10 mg

Z isomer of entacapone

2574

+5C

79

E0200000 Enterokinase BRP

200 mg

0350

+5C

79

E0305000 Ephedrine hydrochloride (racemic) - * Drug Precursor

50 mg

E0300000 Ephedrine hydrochloride - * Drug Precursor

150 mg

99.8% CHClNO

E0400000 4-Epianhydrotetracycline hydrochloride

20 mg

87.1% CHNO.HCl

E0440000 4-Epidemeclocycline hydrochloride

20 mg

E0500000 6-Epidoxycycline hydrochloride

50 mg

Y0001139 Epinastine hydrochloride

20 mg

Y0001128 Epinastine hydrochloride for system suitability

10 mg

E0530000 4-Epioxytetracycline

40 mg

81.1% CHNO

E0550000 Epirubicin hydrochloride

100 mg

96.4% CHClNO

E0600000 4-Epitetracycline hydrochloride

30 mg

Y0000052 Equilin

15 mg

Y0001325 Equisetum palustre

200 mg

E0850010 Eq Influenza Subtype 1 Strain A/eq/Newmarket/77


Horse Antiserum BRP

1 mg

Assigned SRH antibody titre: 125 mm +/-20%; Common standard OIE


Strain A/eq/Newmarket/77

See leaflet,
0249

E0850021 Eq Influenza Subtype 2 American-like/Newmarket


Horse Antiserum BRP

1 mg

Assigned SRH antibody titre: 180 mm +/- 20%; Common standard OIE
Strain A/eq/Newmarket/1/93

E0850022 Eq Influenza Subtype 2 European-like/Newmarket


Horse Antiserum BRP

1 mg

Assigned SRH antibody titre: 155 mm +/- 20%; Common standard OIE
Strain A/eq/Newmarket/2/93

Y0000712 Eq Influenza Subtype 2 American-like/South Africa


Horse Antiserum BRP

1 mg

E0900000 Ergocalciferol

500 mg

E1000000 Ergometrine maleate - * Drug Precursor

50 mg

0223

E1100000 Ergosterol

20 mg

0082

E1200000 Ergotamine tartrate - * Drug Precursor

100 mg

0224, 0551

+5C

Y0000051 Erysipelas ELISA coating antigen BRP

0.4 mg

Council of Europe, all rights reserved 2013

0715

+5C

79

Yes

+5C

79

Yes

+5C

79

0176

+5C

79

0272,0820

+5C

79

2411

+5C

79

0487,0488,0
489,1367,24
51
0210,0211,1
654

2411

Yes

+5C

79

0198,0199

Yes

+5C

79

0662,0714,1
590

Yes

-20C

79

+5C

79

-20C

79

+5C

79

Yes

-20C

90

See leaflet,
0249

Yes

-20C

90

See leaflet,
0249

Yes

-20C

90

See leaflet,
0249

Yes

-20C

90

0082,0574,0
575,
0598,1192,1
193

Yes

-20C

g(c)

79

+5C

79

-20C

g(c)

79

79

0210,0211,1
654
1512

99.7% CHO

Yes

1825

99.7% CHO ; Vitamin D2 ; Batch 7 is valid until 31 August 2013

0.5ml Freeze dried (0.367g protein)


28

90
See leaflet,
Yes
-20C
c
0064
For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Code
Y0000177 Erythritol

Reference Standard

E1300000 Erythromycin for microbiological assay

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
1000 mg
1 99.8% CHO
4
250 mg
1 960 IU per mg

Information

Monograph Leaflet

Storage

1803

Yes

+5C

Extra
Price
charges
79
a

20702

Yes

-20C

79

E1305000 Erythromycin A

250 mg

97.0% CHNO

0179,0274,0
293,
0490,0552,1
098

Yes

-20C

79

E1310000 Erythromycin B

50 mg

98.4% CHNO

0179,0274,0
490,
0552,1098

Yes

-20C

79

E1320000 Erythromycin C

50 mg

97.6% CHNO

0179,0274,0
490,
0552,1098

Yes

-20C

79

E1400000 Erythromycin estolate

100 mg

0552

+5C

79

E1500000 Erythromycin ethylsuccinate

10 mg

0274

+5C

79

E1500800 Erythromycin stearate

50 mg

0490

+5C

79

E1515000 Erythropoietin BRP

37.5 mg

-20C

150

Y0000324 Esketamine hydrochloride - reference spectrum

n/a

79

Y0000338 Esketamine impurity D

10 mg

1742

+5C

79

Y0001028 Esomeprazole magnesium trihydrate

10 mg

2372

+5C

79

Y0000749 Essential oil

1000 mg

2098

+5C

79

E1600000 Estradiol benzoate

250 mg

0139

+5C

79

Y0000852 Estradiol benzoate for system suitability

10 mg

0139

+5C

79

Y0000045 Estradiol butyrate

10 mg

1614

+5C

79

E1620000 Estradiol hemihydrate

100 mg

0821,1203

+5C

79

Y0000314 Estradiol for peak identification

10 mg

0821

+5C

79

Y0000046 Estradiol valerate

50 mg

1614

+5C

79

E1680000 Estriol

50 mg

1203

+5C

79

E1680005 Estriol impurity A

20 mg

See leaflet; 9,11-didehydroestriol ; Batch 1 is valid until 31 August 2013

E1700000 Estrone

15 mg

100.0% CHO

E1800000 Etacrynic acid

100 mg

0457

Y0001263 Etacrynic acid for system suitability

10 mg

0457

E1830000 Etamsylate

30 mg

E1840000 Ethacridine lactate monohydrate

50 mg

E1850000 Ethambutol hydrochloride

250 mg

Y0000803 Ethambutol for system suitability

10 mg

A1202800 Ethanol (anhydrous) - reference spectrum

E1860100 Ethanol 96% - reference spectrum

Council of Europe, all rights reserved 2013

1316

35280 IU per vial

Yes

1742
(2R)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone ((R)-ketamine)

Yes
Yes

Yes

1203

Yes

+5C

79

1512,0140

Yes

+5C

79

+5C

79

+5C

79

1204

+5C

79

1591

+5C

79

0553

+5C

79

0553

+5C

79

n/a

1318

79

n/a

1317

79

29

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
E1900000 Ethinylestradiol

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
4
200 mg
1 99.8% CHO

Information

Monograph Leaflet

Storage

Extra
Price
charges
79
g

0140,0821,0
940

Yes

+5C

0140

Yes

+5C

79

Y0001124 Ethinylestradiol for system suitability

1.0124 mg

E2000000 Ethionamide

100 mg

0141

+5C

79

E2150000 Ethosuximide

30 mg

0764

+5C

79

E2250000 Ethosuximide impurity A

30 mg

0764

+5C

79

E2195000 Ethyl acetate - reference spectrum

n/a

79

E2195900 Ethylcellulose - reference spectrum

n/a

E2202000 1-N-Ethylgaramine sulfate

50 mg

77.6% of 1-N-Ethylgaramin sulphate

E2205500 1,1'-Ethylidenebistryptophan

0.002 mg

0.00182 mg per vial of CHNO ; Batch 4 is valid until 1 May 2013

Y0000617 Ethyl indole-3-carboxylate

10 mg

2102

E2300000 Ethylmorphine hydrochloride - reference spectrum

n/a

0491

E2400000 Ethylnicotinamide

150 mg

0233

E2425000 Ethyl parahydroxybenzoate

150 mg

E2450000 Etifenin

25 mg

75 mg

Batch 1 is valid until 30 April 2014

E2451010 Etilefrine impurity A

20 mg

2-ethylamino-1-(3-hydroxyphenyl)ethanone

Y0000572 Etidronate disodium

10 mg

E2470000 Etodolac

60 mg

E2470050 Etodolac impurity H

10 mg

Y0000768 Etodolac for peak identification

10 mg

1422

E2499900 Etofenamate

40 mg

1513

E2499901 Etofenamate for peak identification

20 mg

E2499914 Etofenamate impurity G

25 mg

E2500000 Etofylline

100 mg

E2503000 Etomidate

50 mg

E2503004 Etomidate impurity B

25 mg

methyl 1-[(1RS)-1-phenylethyl]-1H-imidazole-5-carboxylate
97,8% CHO

0823
0823

New E2451000 Etilefrine hydrochloride

New E2600000 Etoposide

Batch 1 is valid until 1 May 2013

(2RS)-2-ethyl-2-methylbutanedioic acid

0899
0822

79

1351

Yes

+5C

79

1272,1383

Yes

+5C

79

+5C

79

79

+5C

79

+5C

79

0585

+5C

79

1205

+5C

79

1205

+5C

79

1778

+5C

79

1422

+5C

79

1422

+5C

79

+5C

79

+5C

79

0409,0431,0
900,
1262,1263,2
134

100.0% CHO

2-(7-ethylindol-3-yl)ethanol

1513
2-hydroxyethyl 2-[[3-(trifluoromethyl)phenyl]amino]-benzoate ; Batch 1 is
valid until 30 November 2013

Yes

Yes

+5C

79

1513

Yes

+5C

79

0486

+5C

79

1514

+5C

79

1514

+5C

79

Yes

+5C

79

Yes

+5C

79

150 mg

Y0001365 Etoposide for system suitability

10 mg

E5000000 Eugenol

500 l

1100

+5C

79

F0005000 Famotidine

100 mg

1012

+5C

79

Y0000382 Famotidine for system suitability

10 mg

+5C

79

Y0000409 Famotidine impurity D

10 mg

3-[[[2-[(diaminomethylene)amino]thiazol-4-yl]methyl]sulphanyl]propanamide

+5C

79

110 mg

99.9% CHNOS
30

Y0000556 Febantel
Council of Europe, all rights reserved 2013

1012
1012

Yes

79
2176
+5C
a
For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000660 Febantel for system suitability

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
10 mg
1

Information

Monograph Leaflet

+5C

2304

+5C

79

2304

+5C

79

10 mg

Y0000732 Felbinac impurity A

20 mg

F0030000 Felodipine

120 mg

Y0000415 Felypressin

0.994 mg

F0040000 Fenbendazole

150 mg

F0040010 Fenbendazole impurity A

20 mg

methyl(1-benzimidazol-2-yl)carbamate

F0040020 Fenbendazole impurity B

25 mg

methyl[5(6)-chlorobenzimidazol-2-yl]carbamate

F0041000 Fenbufen

100 mg

F0048000 Fenofibrate

100 mg

100.0% CHClO

1322

F0048005 Fenofibrate impurity A

20 mg

(4-chlorophenyl)(4-hydroxyphenyl)methanone

1322

F0048010 Fenofibrate impurity B

10 mg

2[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid (fenofibric acid)

F0048035 Fenofibrate impurity G

25 mg

1-methylethyl 2-[[2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoyl]
oxy]-2-methylpropanoate

Y0000756 Fenoterol for peak identification

1.2 mg

F0050000 Fenoterol hydrobromide

100 mg

F0054990 Fentanyl - reference spectrum

n/a

1210

Y0001509 Fentanyl for system suitability - * narc

25 mg

1210,1103

F0055000 Fentanyl citrate - reference spectrum

n/a

1103

F0060000 Fenticonazole nitrate

50 mg

F0060040 Fenticonazole impurity D

0.01 mg

F0100000 Ferrous gluconate

100 mg

Y0001013 Ferulic acid

20 mg

99.8% CHO

1834,2558

Y0000789 Fexofenadine hydrochloride

60 mg

99.8% CHClNO

2280

Y0000751 Fexofenadine impurity A

5 mg

2-[4-[4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butanoyl]phenyl]-2methylpropanoic acid

Y0000752 Fexofenadine impurity B

0.01 mg

Y0000753 Fexofenadine impurity C

5 mg

Y0001173 Filgrastim

Y0000090 Finasteride

Y0000091 Finasteride for system suitability

Y0000736 Flavoxate hydrochloride

Y0000737 Flavoxate impurity A


Y0000738 Flavoxate impurity B
F0120000 Flecainide acetate
Council of Europe, all rights reserved 2013

1013

+5C

79

-20C

79

1208,1458

+5C

79

1208

+5C

79

1208

+5C

79

1209

+5C

79

+5C

79

+5C

79

1322

+5C

79

1322

+5C

79

0901

+5C

79

+5C

79

79

79

79

1634

0.994 mg CHNOS

0901

contains 1.3% of impurity A

Extra
Price
charges
79
a

2176

Y0000731 Felbinac

4-acetyl biphenyl

Storage

Yes

Yes

Yes
Yes

+5C

1211

+5C

79

1211

+5C

79

0493

+5C

79

Yes

+5C

79

Yes

+5C

79

2280

+5C

79

2-[3-[(1RS)-1-hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl]
phenyl]-2-methylpropanoic acid

2280

+5C

79

(1RS)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]-1-[4-(1-methylethyl)
phenyl]butan-1-ol

2280

+5C

79

0.2 ml

1.95 mg per ml of CHNOS

2206

Yes

-80C

79

60 mg

99.7% CHNO

1615

Yes

+5C

79

120 mg

Contains 0.9% of impurity A ; Batch 2 is valid until 31 August 2013

1615

Yes

10 mg

10 mg

10 mg

10 mg

Batch 1 is valid until 30 November 2013


31

()-1-[2-(2,4-dichlorophenyl)-2-hydroxyethyl]-3-[4-(phenyl suphanyl)
benzyl]imidazolium nitrate ; Batch 1 is valid until 30 November 2013

+5C

79

1692

+5C

79

3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylic acid

1692

+5C

79

ethyl 3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylate

1692

+5C

79

79
1324
Yes
+5C
a
For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
F0120005 Flecainide impurity A

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
3
50 mg
1 3-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-1,5,6,7,8,8a-hexahydroimidazo[1,5a]pyridine ; Batch 2 is valid until 1 May 2013

F0120010 Flecainide impurity B

Y0001274 Flecainide for system suitability


Y0001606 Fleeceflower root HRS

Monograph Leaflet

Storage

Extra
Price
charges
79
a

1324

+5C

1324

+5C

79

25 mg

10 mg

1324

Yes

+5C

79

300 mg

2433

Yes

+5C

79

Y0000138 Flubendazole

25 mg

1721

+5C

79

Y0000139 Flubendazole for system suitability

20 mg

1721

+5C

79

Y0000892 Flucloxacillin magnesium octahydrate

5 mg

2346

+5C

79

Y0000889 Flucloxacillin impurity C

5 mg

6-aminopenicillanic acid

2346

+5C

79

Y0000890 Flucloxacillin impurity D

5 mg

3-(2-chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxylic acid

2346

+5C

79

Y0000891 Flucloxacillin impurity E

5 mg

6-aminopenicillanic acid flucloxacillin amide

2346

Yes

+5C

79

F0150000 Flucloxacillin sodium

250 mg

95.1% CHClFNNaOS

0661,0663,0
668,2346

Yes

-20C

79

Y0000557 Fluconazole

50 mg

2287

+5C

79

Y0000558 Fluconazole for peak identification

10 mg

2287

Yes

+5C

79

Y0000573 Fluconazole impurity B

10 mg

See leaflet; 2-[2-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-bis(1H-1,2,4 triazol-1-yl)propan-2-ol ; Batch 2 is valid until 31 March 2014

2287

Yes

+5C

79

Y0000574 Fluconazole impurity C

5 mg

1,1'-(1,3-phenylene)di-1H-1,2,4-triazole

2287

+5C

79

F0175000 Flucytosine

100 mg

0766

+5C

79

Y0001262 Flucytosine for system suitability

0.3 mg

Y0000419 Fludarabine phosphate

120 mg

Y0001536 Fludarabine for system suitability

15 mg

F0180000 Fludrocortisone acetate

100 mg

F0188000 Flumazenil - reference spectrum

n/a

Y0000335 Flumazenil impurity B

5 mg

F0189000 Flumequine

60 mg

F0189020 Flumequine impurity B

0.1 mg

F0188500 Flumetasone pivalate

100 mg

F0189900 Flunarizine dihydrochloride

100 mg

Y0000265 Flunarizine dihydrochloride - reference spectrum

Y0000266 Flunarizine dihydrochloride for system suitability

F0190000 Flunitrazepam - * psy

Y0000169 Flunitrazepam - reference spectrum

Y0000443 Flunixin meglumine


Y0000444 Flunixin impurity B
New Y0000445 Flunixin impurity C
Council of Europe, all rights reserved 2013

(RS)-(piperidin-2-yl)methanamine

Yes

0766

+5C

79

1781

Yes

+5C

79

1781

Yes

+5C

79

0767

+5C

79

79

1326

+5C

79

1517

+5C

79

1517

+5C

79

1327

+5C

79

0816

+5C

79

n/a

1722

79

20 mg

1722

+5C

79

100 mg

1280

+5C

79

n/a

0717

79

10 mg

10 mg

2-methyl-3-(trifluoromethyl)aniline

55 mg

ethyl 2-chloropyridine-3-carboxylate ; Batch 1 is valid until 30 April 2014


79
1696
+5C
f
32
For extra charges, please see supply terms and conditions.

98.3% CHFNOP

1326
ethyl 8-hydroxy-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]
benzodiazepine-3-carboxylate
ethyl(RS)-9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-benzo[i,j]
quinolizine-2-carboxylate

Yes

1696

+5C

79

1696

+5C

79

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
F0200000 Fluocinolone acetonide

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
3
100 mg
1

Information

Monograph Leaflet

Storage

0494

+5C

Extra
Price
charges
79
f

F0230000 Fluocortolone pivalate

100 mg

1212

+5C

79

Y0000796 Fluorescein

120 mg

99.2% CHO

2348

+5C

79

Y0000804 Fluorescein impurity C

0.01 mg

2-(2,4-dihydroxybenzoyl)benzoic acid

2348

+5C

79

Y0000454 Diacetylfluorescein

100 mg

99.6% CHO

1213

+5C

79

F0245000 Fluoresceine sodium - reference spectrum

n/a

1213

79

F0250000 Fluorouracil

40 mg

0611,0766

+5C

79

Y0000762 Fluorouracil impurity A

10 mg

pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid)

0611

+5C

79

Y0000763 Fluorouracil impurity B

15 mg

dihydropyrimidine-2,4,5(3H)-trione (isobarbituric acid or 5-hydroxyuracil)

0611

+5C

79

Y0000764 Fluorouracil impurity C

10 mg

pyrimidine-2,4(1H,3H)-dione (uracil)

0611

+5C

79

Y0000765 Fluorouracil impurity F

10 mg

2-ethoxy-5-fluoropyrimidin-4(1H)-one (2-ethoxy-5-fluorouracil)

0611

+5C

79

Y0000791 Fluorouracil impurity mixture

0.0002 mg

0611

Yes

+5C

79

F0253000 Fluoxetine hydrochloride

250 mg

99.9% CHClFNO

1104

Yes

+5C

79

F0253020 Fluoxetine impurity B

10 mg

methyl(3-phenylpropyl)amine

1104

+5C

79

F0253030 Fluoxetine impurity C

5 mg

()-methyl-[3-phenyl-3-(3-trifluoromethylphenoxy)-propyl] amine

1104

+5C

79

Y0000064 Flupentixol dihydrochloride

100 mg

43.6% of Z-isomer CHClFNOS

1693

+5C

79

Y0000067 Flupentixol impurity D

15 mg

2-[2-[4-[3-[(EZ)-2-(trifluoromethyl)-9H-thioxanthen-9-ylidene]propyl]
piperazin-1-yl]ethoxy]ethanol

1693

+5C

79

Y0000078 Flupentixol impurity F

25 mg

80.9% CHFNOS; 2-[4-[(EZ)-3-[(9RS)-2-(trifluoromethyl)-9Hthioxanthen-9-yl] prop-2-enyl]piperazin-1-yl]ethanol

1693

+5C

79

F0260000 Fluphenazine decanoate

60 mg

1014,1015

+5C

g(b)

79

Y0000009 Fluphenazine enantate

100 mg

F0280000 Fluphenazine dihydrochloride

50 mg

Y0000708 Fluphenazine impurity mixture

0.07 mg

20 mg

Y0000299 Fluphenazine sulfoxide

10 mg

Y0000211 Flurazepam monohydrochloride - reference spectrum

F0285200 Flurbiprofen

F0285202 Flurbiprofen impurity A

25 mg

Y0000236 Fluspirilene

20 mg

Y0000375 Fluspirilene impurity C

10 mg

8-[4,4-bis(4-fluorophenyl)butyl]-3-(hydroxymethyl)-1-phenyl-1,3,8triazaspiro[4.5]decan-4-one

100 mg

See leaflet ; Batch 1 is valid until 31 December 2013

1423

New Y0000298 Fluphenazine octanoate

New F0285600 Flutamide

Yes

Yes

1014,1015

+5C

79

Batch 1 is valid until 30 November 2013

0904,1014

+5C

79

+5C

79

Batch 3 is valid until 28 February 2014

1014,1015

+5C

79

0904,1014,1
015

+5C

79

n/a

0905

79

50 mg

1519

+5C

79

1519

+5C

79

1723

+5C

79

1723

+5C

79

+5C

79

+5C

79

+5C

79

0904

(2RS)-2-(biphenyl-4-yl)propanoic acid ; Batch 1 is valid until 30 November


2013

F0285603 Flutamide impurity C

20 mg

N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide

1423

Y0000284 Fluticasone propionate

100 mg

99.6% CHFOS

1750

Council of Europe, all rights reserved 2013

Yes

33

Yes

Yes
Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000221 Fluticasone impurity D

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
2
20 mg
1 S-methyl 6a,9a-difluoro-11b-hydroxy-16a-methyl-3-oxo-17apropionyloxy-androsta-1,4-diene-17-carbothioate
(S-methyl derivative)

Monograph Leaflet

Storage

Extra
Price
charges
79
a

1750

+5C

1424

+5C

79

1424

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

F0290000 Flutrimazole

100 mg

F0290010 Flutrimazole impurity B

60 mg

Y0001090 Fluvastatin sodium

110 mg

2333

Y0001082 Fluvastatin for system suitability

0.5 mg

2333

Y0000854 Fluvoxamine maleate

5 mg

1977

Y0000853 Fluvoxamine for system suitability

1.004 mg

1977

Y0000916 Fluvoxamine impurity D

10 mg

5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one

1977

+5C

79

Y0000386 Foeniculin for peak identification

100 mg

Anise oil

0804

Yes

+5C

79

F0300000 Folic acid

300 mg

91.3 % CHNO

0067

Yes

+5C

79

Y0001242 Folic acid impurity A

15 mg

(2S)-2-[(4-aminobenzoyl)amino]pentanedioic acid (N-(4-aminobenzoyl)-lglutamic acid)

0067

+5C

79

Y0001243 Folic acid impurity D

70 mg

4-[[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino]benzoic acid
(pteroic acid)

0067

+5C

79

F0372000 Formoterol fumarate dihydrate

10 mg

1293,1724

+5C

79

Y0000339 Formoterol for impurity I identification

10 mg

1724

+5C

79

Y0000340 Formoterol fumarate for system suitability

10 mg

1724

Yes

+5C

79

F0380000 Formylfolic acid

30 mg

0978,1606

Yes

F0389000 Foscarnet sodium hexahydrate

50 mg

F0389004 Foscarnet impurity B

10 mg

Y0001222 Foscarnet impurity D

50 mg

Y0001213 Foscarnet impurity mixture

0.012 mg

1520

Y0000782 Fosfomycin calcium

10 mg

1328

F0399950 Fosfomycin sodium - reference spectrum

(RS)-(2-fluorophenyl)(4-fluorophenyl)phenylmethanol

91.4% CHNO; 10-Formylfolic acid


disodium (ethoxyoxydophosphanyl)formate

Yes
Yes

Yes

-20C

79

1520

+5C

79

1520

+5C

79

1520

+5C

79

+5C

79

+5C

79

79

+5C

79

Yes

n/a

New F0400000 Fosfomycin trometamol

1500 mg

Y0001227 Fosinopril sodium

60 mg

1751

+5C

79

Y0001228 Fosinopril impurity A

5 mg

(2S,4S)-4-cyclohexyl-1-[[(R)-hydroxy(4-phenylbutyl)phosphoryl]acetyl]
pyrrolidine-2-carboxylic acid

1751

+5C

79

Y0001229 Fosinopril impurity B

5 mg

(2RS,4RS)-4-cyclohexyl-1-[[(RS)-[(1SR)-2-methyl-1-(1-oxopropoxy)
propoxy](4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid

1751

+5C

79

Y0001230 Fosinopril impurity C

10 mg

mixture of (2S,4S)-4-cyclohexyl-1-[[(S)-[(1S)-2-methyl-1-(1-oxopropoxy)
propoxy](4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid and
(2S,4S)-4-cyclohexyl-1-[[(R)-[(1R)-2-methyl-1-(1-oxopropoxy)propoxy](4phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid

1751

+5C

79

Y0001231 Fosinopril impurity D

10 mg

(2S,4R)-4-cyclohexyl-1-[[(R)-[(1S)-2-methyl-1-(1-oxopropoxy)propoxy](4phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid

1751

+5C

79

Council of Europe, all rights reserved 2013

1329
1425

See leaflet ; Batch 2 is valid until 30 April 2014

34

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0001232 Fosinopril impurity I

Effective from 2013/11/12


Batch n Quantity Sale
Information
Monograph Leaflet
per vial Unit
1
5 mg
1 [(RS)-[(1SR)-2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphoryl]
1751
acetic acid

Y0001233 Fosinopril impurity K

5 mg

Y0001212 Fosinopril impurity mixture

0.02 mg

25 mg

F0550000 Fructose

100 mg

Y0001399 Fulvestrant

120 mg

2443

Y0001413 Fulvestrant for system suitability

40 mg

2443

F0600000 Fumaric acid

120 mg

0365,0902,1
190, 1592

F0700000 Furosemide

100 mg

Y0001493 Furosemide for peak identification

10 mg

F0702000 Furosemide impurity A

5 mg

Y0001411 Fusidic acid

10 mg

Y0001394 Fusidic acid for peak identification

5 mg

0798,0848

Y0001384 Fusidic acid impurity mixture

0.0475 mg

0798,0848

Y0001280 Gabapentin

300 mg

99.9% CHNO

2173

Y0001281 Gabapentin impurity A

20 mg

2-azaspiro[4.5]decan-3-one

2173

Y0001348 Gabapentin impurity B

20 mg

(1-cyanocyclohexyl)acetic acid

2173

Y0001349 Gabapentin impurity D

10 mg

[1-[(3-oxo-2-azaspiro[4.5]dec-2-yl)methyl]cyclohexyl]acetic acid

2173

G0049000 Galactitol

50 mg

G0050000 Galactose

60 mg

Y0001279 Galantamine hydrobromide

10 mg

2366

Y0001190 Galantamine natural for system suitability

10 mg

2366

Y0001201 Galantamine racemic mixture

10 mg

2366

Y0001191 Galantamine synthetic for system suitability

5 mg

2366

Yes

G0150000 Gammacyclodextrin

60 mg

1070,1487

Yes

Y0001129 Ganciclovir

220 mg

Y0001144 Ganciclovir impurity mixture

0.005 mg

1752

Y0000675 Gemcitabine hydrochloride

50 mg

99.9% CHClFNO

2306

Y0000676 Gemcitabine impurity A

20 mg

4-aminopyrimidin-2(1H)-one (cytosine)

Y0000513 Gemfibrozil

5 mg

New F0450000 Framycetin sulfate

Council of Europe, all rights reserved 2013

(2S,4S)-4-cyclohexyl-1-(2,2-dimethyl-1-oxopropyl)pyrrolidine-2-carboxylic
acid
See leaflet ; Batch 5 is valid until 31 March 2014

1751

Batch 1 is valid until 31 January 2013

91,2% CHO ; Batch 1 is valid until 1 June 2013

79

+5C

79

0180,0197,2
0702

Yes

-20C

79

+5C

79

Yes

+5C

79

Yes

+5C

79

+5C

79

+5C

79

+5C

79

0391

+5C

79

0798

-20C

79

Yes

-20C

79

Yes

-20C

79

Yes

+5C

79

+5C

79

-20C

79

+5C

79

1381

+5C

79

1215

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

Yes

+5C

79

Yes

+5C

79

2306

+5C

79

1694

+5C

79

0391,2185
Yes

Yes

1752

35

+5C
Yes

0391
2-chloro-4-(furfurylamino)-5-sulphamoylbenzoic acid

+5C

Extra
Price
charges
79
a

1751

0177,0178,0
187,
0188,0204,0
209,
0924,1061,1
570
98.8% CHFOS

Storage

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
New Y0000514 Gemfibrozil for system suitability
G0200000 Gentamicin sulfate

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
2
0.196 mg 1 Batch 1 is valid until 11 December 2013
8
25 mg
2 16500 IU per vial ; Batch 7 is valid until 31 January 2013

Monograph Leaflet

Storage

Extra
Price
charges
79
g

1694

Yes

+5C

0331,20702

Yes

-20C

79

1726

Yes

+5C

79

Y0001112 Gestodene

100 mg

Y0001363 Gentamicin for peak identification

10 mg

0331

Yes

-20C

79

Y0001110 Gestodene for system suitability

10 mg

1726

Yes

+5C

79

Y0001116 Gestodene impurity I

0.01 mg

+5C

79

Y0001012 Ginkgo dry extract for peak identification

150 mg

Y0001010 Ginkgolic Acids

20 mg

Y0001029 Ginseng dry extract HRS

500 mg

Y0001347 Ginsenoside Rb1

30 mg

G0300000 Gitoxin

30 mg

0078,0079,2
168

G0325000 Glibenclamide

100 mg

0718

Y0001511 Glibenclamide for peak identification

30 mg

0718

G0325010 Glibenclamide impurity A

10 mg

4-[2-(5-chloro-2-methoxybenzamido)ethyl]benzene- sulphonamide ; Batch 2


is valid until 31 December 2012

0718

Y0000242 Glibenclamide impurity B

20 mg

methyl [[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]
sulphonyl]carbamate

0718

G0326000 Gliclazide

20 mg

G0326004 Gliclazide impurity B

25 mg

2-nitroso-octahydrocyclopenta[c]pyrrole

G0326012 Gliclazide impurity F

50 mg

Y0000515 Glimepiride

60 mg

Y0000516 Glimepiride for system suitability

0.012 mg

G0340000 Glipizide

50 mg

G0342000 Glipizide impurity A

10 mg

4-[2-(5-methylpyrazine-2-carboxamido)ethyl]benzene sulphonamide

Y0000523 Glipizide impurity C

10 mg

Y0000643 Glipizide impurity D

10 mg

Y0001140 Glipizide impurity mixture

0.002 mg

0906

Y0001406 Glucosamine hydrochloride

10 mg

2446

Y0000191 Human glucagon

2.94 mg

Y0001381 Glucosamine for system suitability

40 mg

2446,2447

Y0001407 Glucosamine sulfate sodium chloride

15 mg

2447

Council of Europe, all rights reserved 2013

99.4%

13-ethyl-17-hydroxy-5-methoxy-18,19-dinor-5alpha,17alpha-pregn-15-en-20yn-3-one

1726
1827

Yes

-20C

79

1827

Yes

-20C

79

2356

Yes

-20C

79

2356

Yes

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

1524

+5C

79

1524

+5C

79

1-(hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-3-[(2-methylphenyl) sulphonyl]
urea

1524

+5C

79

99.4% CHNOS

2223

+5C

79

Batch 2 is valid until 31 January 2013

2223

+5C

79

0906

+5C

79

0906

+5C

79

ethyl [2-[4-[(cyclohexylcarbamoyl)sulphamoyl]phenyl]ethyl] carbamate

0906

+5C

79

6-methyl-N-[2-(4-sulphamoylphenyl)ethyl]pyrazine-2-carboxamide

0906

+5C

79

+5C

79

+5C

79

-20C

79

+5C

79

+5C

79

0.37% of ginkgolic acid C17


88.1 % CHO

2.94 mg pure human glucagon per vial CHNOS

36

1635

Yes

Yes

Yes

Yes
Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Code
G0350500 Glucose

Reference Standard

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
2
100 mg
1

Information

Monograph Leaflet

Storage

0177,0178,0
187,
0188,0204,0
209,
1061,1215,1
570

+5C

Extra
Price
charges
79
a

G0355000 Glutamic acid

50 mg

0750,0797,1
445, 2076

+5C

79

Y0000517 Glutathione

10 mg

1670

+5C

79

G0360000 Glutethimide - * psy

50 mg

1291

+5C

79

Y0001391 Glycerol formal

20 mg

1671

+5C

79

Y0000794 Glycerol monocaprylate

500 mg

Y0000795 Glycerol monocaprylocaprate

500 mg

G0400006 Glycerol monolinoleate

2000 mg

G0400007 Glycerol mono-oleate

2500 mg

G0400008 Glycerol monostearate 40-55

2000 mg

G0400101 Glyceryl trinitrate - reference spectrum

n/a

G0400100 Glyceryl trinitrate solution

0.5 ml

G0450000 Glycine

50 mg

Y0001308 Glycopyrronium bromide

10 mg

Y0001309 Glycopyrronium for peak identification

10 mg

Y0001358 Glycopyrronium impurity N

10 mg

Y0000433 Ammonium glycyrrhizate

70 mg

G0460000 Glycyrrhizate (monoammonium)

300 mg

78.6% CHNO

G0525000 Gonadorelin

5 mg

4.96 mg per vial of CHNO

Y0000125 Goserelin

1.87 mg

1636

Y0000126 Gosereline - reference spectrum

n/a

1636

Y0000019 4-D-Ser-goserelin

0.1 mg

1636

Y0000194 Goserelin validation mixture

1 mg

Supplied with the Ph. Eur. reference chromatogram

1636

Y0001473 Goserelin for NMR identification

14 mg

replace Y0000126

1636

G0550000 Gramicidin

250 mg

1081 IU per mg

Y0000396 Granisetron hydrochloride

120 mg

Y0000477 Granisetron impurity A

1 mg

Council of Europe, all rights reserved 2013

In the chromatogram supplied within the leaflet (Rev 02) of the current CRS
batch 1, some peaks have been mislabelled, the correct version of the leaflet
(Rev 03) is now available on the website. The quality of the product itself is
not questioned and can still to be used.
Batch 1 is valid until 1 April 2013

2213

Yes

+5C

79

2392

Yes

+5C

79

1429

+5C

79

1430

+5C

79

0495

+5C

79

79

+5C

79

0614,0752

+5C

79

1783

+5C

79

1331
1331,1355

1% m/m in ethanol CHNO

94.0% CHNO+; (3RS)-3-[(2RS)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)


oxy]-1,1-dimethylpyrrolidinium

Yes

1783

Yes

+5C

79

1783

Yes

+5C

79

+5C

79

1772
0277,1536,
2378

Yes

+5C

79

0827

Yes

-20C

79

-20C

79

79

-20C

79

-20C

79

-20C

79

Yes

0907,1662,2
0702

Yes

+5C

79

99.8% CHClNO

1695

Yes

+5C

79

2-methyl-N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-2Hindazole-3-carboxamide

1695

+5C

79

37

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000478 Granisetron impurity B

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
2
1 mg
1 N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3carboxamide

Y0000395 Granisetron impurity E

15 mg

G0600000 Griseofulvin
Y0000619 Guaiacol

50 mg

1500 mg

G0700000 Guaifenesin

100 mg

Y0000117 Halofantrine hydrochloride

125 mg

99.6% CHClFNO

Y0000118 Halofantrine impurity C

10 mg

[1,3-dichloro-6-(trifluoromethyl)phenantren-9-yl]methanol

H0100000 Haloperidol

60 mg

Batch 1 is valid until 1 July 2013

H0100100 Haloperidol decanoate

60 mg

Y0001518 Haloperidol for peak identification

Y0001517 Haloperidol for system suitability

H0150000 Halothane - reference spectrum


Y0000673 Harpagoside

Monograph Leaflet
1695

Yes

1695

(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine

0182
99.6% CHO ; Batch 1 is valid until 30 November 2013

Storage
+5C

Extra
Price
charges
79
a

+5C

79

+5C

79

1978

Yes

+5C

79

0615

Yes

+5C

79

1979

+5C

79

1979

+5C

79

0616,0995,1
178, 1503

+5C

79

1397,1431

+5C

79

25 mg

0616

Yes

+5C

79

25 mg

0616

Yes

+5C

79

n/a

79

1.03 mg

1.01mg per vial CHO

1095, 1871

Yes

+5C

79

H0185000 Heparin Low-Molecular-Mass for assay BRP

1 mg

Anti-IIa activity : 31 IU per vial; Anti-Xa activity : 104 IU per vial ; Batch 7 is
valid until 30 November 2013

0828

Yes

+5C

90

H0190000 Heparin Low-Molecular-Mass for calibration CRS

25 mg

Mna = 3800 ; Batch 2 is valid until 30 November 2013

H0200000 Heparin sodium BRP

2 ml

1010 IU per ml

Y0001287 Heparin calcium for NMR identification

30 mg

Y0001283 Heparin sodium for NMR identification

30 mg

New Y0001282 Heparin for physico-chemical analysis

0393

0828

Yes

+5C

90

0569, 20705

Yes

+5C

79

0332

Yes

+5C

79

0333

Yes

+5C

79

300 mg

Batch 1 is valid until 31 March 2014

+5C

79

H0205010 Hepatitis A vaccine (inactivated, adsorbed) Type B BRP

0.5 ml

262 IU per ml; Please contact us for information on the type needed for your
use

See leaflet,
20714

Yes

+5C

90

Y0001192 Hepatitis A Vaccine (Inactivated, Non-Adsorbed) BRP

0.8 ml

To be stored below -50C

20714,1526,
1935, 1107

Yes

-80C

90

Y0001624 Hepatitis A virus Coating Reagent for ELISA - BRR

1 mL

Yes

-20C

79

Y0001623 Set of Hepatitis A virus Detection Antibodies for ELISA BRR

420 L

Yes

-20C

79

Y0000389 Hepatitis B vaccine (rDNA) BRP method A (thiomersal


free)

0.5 ml

16.6 micrograms per ml

See leaflet,
20715

Yes

+5C

90

H0210010 Hepatitis B vaccine (rDNA) BRP method B

1 ml

20 micrograms per ml

See leaflet,
1056

Yes

+5C

90

H0220000 Heptadecanol

600 mg

97.9% CHO

0801,0802,0
847

+5C

79

Y0000063 Heptaminol hydrochloride

150 mg

1980

+5C

79

Y0000057 Heptaminol impurity A

20 mg

93.4% CHN; (2RS)-6-methylhept-5-en-2-amine

1980

+5C

79

Y0001203 Hesperidin

20 mg

89,9% CHO

2430

+5C

79

H0330000 Hexamidine diisetionate

20 mg

Batch 1 is valid until 31 January 2013

1436

+5C

79

Council of Europe, all rights reserved 2013

38

0333

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Code
H0325000 Hexetidine

Reference Standard

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
2
100 mg
1

Information

Monograph Leaflet

Storage

1221

+5C

Extra
Price
charges
79
a

H0420000 Hexylresorcinol

100 mg

1437

+5C

79

H0500000 Hide powder

500 mg

20814

+5C

79

H0600000 Histamine dihydrochloride

250 mg

0143

+5C

79

H0750000 Histidine

100 mg

0911

+5C

79

H0755000 Histidine hydrochloride monohydrate

100 mg

0910

+5C

79

H0800000 Homatropine hydrobromide

100 mg

0500,0720

+5C

79

H0830000 Homatropine methylbromide

25 mg

0720

+5C

79

Y0001383 Homatropine methylbromide for system suitability

5 mg

0720

+5C

79

H0837000 L-Homocysteine thiolactone hydrochloride - reference


spectrum

n/a

1617

79

Y0001290 Honokiol

20 mg

99.6% CHO

H0900000 Human albumin for electrophoresis BRP

1 ml

96,7% to 99,2% of the total protein is the main band (albumin), protein
content : 5%

Y0000219 Human anti-D immunoglobulin BRP

40 mg

Y0000667 Human coagulation factor VII concentrate BRP

25 mg

H0920000 Human coagulation factor VIII concentrate BRP

H0920500 Human coagulation factor IX concentrate BRP

Batch 1 is valid until 31 December 2012


Batch 1 is valid until 31 January 2014

Yes

2567,2568

Yes

-20C

g(c)

79

0255

Yes

-20C

79

285 IU anti-D immunoglobulin per ampoule


1uc=40 mg

See leaflet,
20713

Yes

-20C

90

9.9 IU per vial

See leaflet,
20710

Yes

-20C

79

37 mg

10.4 IU per vial

See leaflet,
20704

Yes

-20C

90

30 mg

7.9 IU/vial; Common standard with FDA and WHO (4th IS)

See leaflet,
20711, 1223

Yes

-20C

90

H0950000 Human hepatitis A immunoglobulin BRP

10 mg

10.2 IU per vial

See leaflet,
0338, 0769

Yes

-20C

90

Y0001504 Human immunoglobulin BRP (ACA and Molecular size)

1 uc

See leaflet,
0338, 0918

Yes

+5C

90

Y0001512 Human Immunoglobulin BRP (Fc Function and


Molecular size)

9000 mg

See leaflet,
0338, 0918

Yes

+5C

90

H1000000 Human immunoglobulin for electrophoresis BRP

96 mg

75.7% to 80.9% of the total protein is the main band (Ig),


protein content: 5%

0338,0918

Yes

+5C

79

Y0000488 Human immunoglobulin (molecular size) BRP

700 mg

Each vial contains 0.7 gram of immunoglobulin G

See leaflet,
0338,
0918,1928

Yes

+5C

90

H1005000 Human Plasma Pools for NAT validation

3502 mg

Set of 103 plasma pool samples

See leaflet,
20621

Yes

-20C

400

H1100000 Human rabies immunoglobulin BRP

170 mg

91 IU per vial

See leaflet,
0723

Yes

-20C

90

H1110000 Human tetanus immunoglobulin BRP

87 mg

120 IU per vial

0398

Yes

-20C

90

Y0000502 Human vaccinia immunoglobulin

1 ml

23 IU per vial

See leaflet

Yes

-20C

270

H1115000 Hyaluronidase BRP

50 mg

328 IU per mg

0912

Yes

+5C

79

Council of Europe, all rights reserved 2013

39

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
H1120000 Hydralazine hydrochloride

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
20 mg
1

Information

Monograph Leaflet
0829

Storage
+5C

Extra
Price
charges
79
g

Y0001151 Hydrastine hydrochloride

20 mg

91,7% CHClNO

1831,2500

Yes

-20C

79

H1200000 Hydrochlorothiazide

300 mg

99.8% CHClNOS ; Batch 6 is valid until 31 August 2013

0394

Yes

+5C

79

Batch 1 is valid until 30 April 2014

0394

Yes

+5C

79

+5C

79

+5C

79

+5C

79

Yes

+5C

79

Yes

+5C

79

Yes

+5C

79

New Y0001494 Hydrochlorothiazide for peak identification

10 mg

Y0000646 Hydrocodone hydrogen tartrate 2.5-hydrate - * narc

10 mg

Y0000710 Hydrocodone for peak identification - * narc

10 mg

1784

H1300000 Hydrocortisone

100 mg

0335,0353,0
561

Y0001092 Hydrocortisone for peak identification

5 mg

Batch 1 is valid until 31 December 2012

H1400000 Hydrocortisone acetate

125 mg

99% CHO; Hydrocortisone acetate CRS 8 is suitable for monographs


0321,0334,0
01/2011:0335, 01/2008:334, 01/2008:0321, 01/2008:0767 and 01/2008:0734
335,
only.
0734,0767

Y0001482 Hydrocortisone acetate for peak identification

15 mg

0334

H1425000 Hydrocortisone hydrogen succinate

100 mg

0768,1131

-20C

79

H1426000 Hydrogenated wool fat

250 mg

0969

+5C

79

Y0000446 Hydromorphone hydrochloride - * narc

10 mg

2099

+5C

79

B0650000 Hydrous benzoyl peroxide - reference spectrum

n/a

0704

79

H1428000 Hydroxocobalamin

10 mg

0913,0914,0
915

+5C

79

Y0000119 Hydroxycarbamide

175 mg

1616

+5C

79

H1429400 Hydroxyethyl salicylate

125 mg

1225

+5C

79

H1429700 4-Hydroxyphenoxymethylpenicillin potassium

20 mg

98.4% CHKNOS

-20C

79

H1430000 D-alpha-(4-Hydroxy-phenyl)glycine

50 mg

(2R)-2-amino-2-(4-hydroxyphenyl)acetic acid - Cefadroxyl impurity A

0813

+5C

79

Y0001277 Hydroxyethyl starch (medium MW)

1200 mg

Average Mw 130100 Da

1785

Yes

+5C

79

Y0001322 Hydroxyethyl starch (high Mw)

800 mg

507900 Da

1785

Yes

+5C

79

Y0000186 Hydroxypropylbetadex

200 mg

Batch 1 is valid until 30 June 2013

1804

+5C

79

H1435000 Hydroxyzine hydrochloride

600 mg

0916,1086,1
092

+5C

79

Y0000011 Hymecromone

100 mg

1786

+5C

79

Y0000012 Hymecromone impurity A

25 mg

Resorcinol

1786

+5C

79

Y0000013 Hymecromone impurity B

25 mg

7-hydroxy-2-methyl-4H-1-benzopyran-4-one.

1786

+5C

79

Y0000483 Hyoscine

10 mg

2167

+5C

79

Y0000484 Hyoscine impurity A

10 mg

2167

+5C

79

H1450000 Hyoscine butylbromide

20 mg

0737

+5C

79

Y0000447 Hyoscine butylbromide impurity E

10 mg

0737

+5C

79

H1500000 Hyoscine hydrobromide

50 mg

0106,0500

+5C

79

Council of Europe, all rights reserved 2013

1784

0335

99.9% CHNO

0148,0149

(1R,2R,4S,5S,7s)-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl
(2S)-3-hydroxy-2-phenylpropanoate (norhyoscine)
(1R,2R,4S,5S,7s)-9-butyl -3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl (2S)-3hydroxy-2-phenylpropanoate (N-butylhyoscine)

40

Yes

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000448 Hyoscine hydrobromide impurity B

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
1
10 mg
1 (1R,2R,4S,5S,7s)-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl
(2S)-3-hydroxy-2-phenylpropanoate

Monograph Leaflet

Storage

Extra
Price
charges
79
a

0106

+5C

0501

+5C

79

0501

+5C

79

H1600000 Hyoscyamine sulfate

100 mg

Y0000449 Hyoscyamine impurity E

10 mg

Y0000915 Hypromellose phthalate

10 mg

347

+5C

79

I0020000 Ibuprofen

250 mg

0721

+5C

79

B1220000 Ibuprofen impurity B

1.1 mL

solution of 0.06% m/V in acetonitrile - to be diluted as appropriate. CHO;


(2RS)-2-(4-Butylphenyl)propanoic acid ; Batch 6 is valid until 31 August 2013

0721

+5C

79

Y0000140 Ibuprofen impurity F

5 mg

3-[4-(2-methylpropyl)phenyl]propanoic acid

0721

+5C

79

Y0000881 Ibuprofen for peak identification

0.09 mg

+5C

79

I0050000 Idoxuridine

50 mg

0669

+5C

79

I0060000 Ifosfamide

50 mg

1529

+5C

79

I0060100 Ifosfamide - reference spectrum

n/a

79

I0060002 Ifosfamide impurity A

100 mg

3-[(2-chloroethyl)amino]propyl dihydrogen phosphate

1529

-20C

g(c)

79

I0060004 Ifosfamide impurity B

40 mg

bis[3-[(2-chloroethyl)amino]propyl] dihydrogen diphosphate ; Batch 1 is valid


until 31 January 2014

1529

+5C

79

I0060010 Ifosfamide impurity E

20 mg

3-chloro-N-(2-chloroethyl)propan-1-amine

1529

+5C

79

I0060012 Ifosfamide impurity F

10 mg

(RS)-2-chloro-3-(2-chloroethyl)-1,3,2-oxazaphosphinane 2-oxide

1529

+5C

79

I0086000 Imidazole

100 mg

0757,1424,
2270

+5C

79

I0090000 Imipenem

100 mg

1226

-20C

79

I0100000 Imipramine hydrochloride

50 mg

0029,0408,0
817,
0889,1787

+5C

79

Y0000893 Imipramine for system suitability

10 mg

0029

+5C

79

Y0001153 Immunoglobulin for anti-A, anti-B antibodies limit test


BRP

45 mg

20620

Yes

-20C

79

Y0001152 Immunoglobulin panel for anti-A, anti-B antibodies test

96 mg

20620

Yes

-20C

120

Y0000540 Immunoglobulin panel for anti-D antibodies test BRP

2000 mg

See leaflet,
20626

Yes

-20C

90

Y0001205 Imperatorin

20 mg

98.8 % CHO

2556

Yes

+5C

79

I0150000 Indapamide

150 mg

97.6% CHClNOS

1108

Yes

+5C

79

I0150020 Indapamide impurity B

5 mg

4-chloro-N-(2-methyl-1H-indol-1-yl]-3-sulphamoylbenzamide

1108

+5C

79

Y0000788 Indinavir

100 mg

97.2% CHNO

2214

+5C

79

Y0000880 Indinavir sulfate - reference spectrum

n/a

2214

79

Y0000746 Indinavir for system suitability

20 mg

2214

+5C

79

I0200000 Indometacin

50 mg

0092,0922,1
686

+5C

79

Council of Europe, all rights reserved 2013

(1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl(2S)-3-hydroxy-2-phenyl
-propanoate

0721
100.0% CHClNOP

Yes

1529

92.9% CHNOS

41

Yes

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Code
Y0000349 Insulin aspart

Reference Standard

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
2
8 mg
1 7.45 mg of insulin aspart + B28iso insulin aspart + A21Asp insulin aspart +
B3Asp insulin
8 aspart + B3iso Asp insulin aspart per vial

Monograph Leaflet

Storage

2084

Yes

-20C

Extra
Price
charges
90
c

I0305000 Insulin (bovine)

7.99 mg

7.99 mg insulin + A21 desamido per vial CHNOS

0854,1637

Yes

-20C

90

I0310000 Insulin (human)

8 mg

6.94 mg insulin + A21 desamido per vial CHNOS

0838,0854,1
637, 1638

Yes

-20C

90

Y0000348 Insulin lispro

5.75 mg

5.75 mg per vial of CHNOS ; Batch 1 is valid until 1 June 2013

2085

Yes

-20C

90

Y0001542 Insulin glargine

15 mg

14,98 mg

1571

Yes

-20C

79

Y0001544 Insulin glargine for peak identification

3.2 mg

-20C

79

I0320000 Insulin (porcine)

8.61 mg

8.61 mg insulin + A21-desamido per vial


see recommandations for use on accompagnying leaflet CHNOS

I0320301 Interferon alfa-2b

200 L

Y0001101 Interferon beta-1a

0.5 mL

I0320330 Interferon gamma 1b

0.5 mL

I0320331 Interferon gamma-1b validation solution

I0328000 Iobenguane sulfate

2571
0838,0854,1
637, 1638

Yes

-20C

90

About 9.74 mg per mL

1110

Yes

-80C

90

335 g of interferon beta-1a per mL CHNOS ; Batch 1 is valid until


30 November 2012

1639

Yes

-80C

90

about 1 mg per ml

1440

Yes

-80C

90

0.6 mg

The CRS is available in the freeze-dried form.


About 1 mg per ml after reconstitution following instructions provided in the
leaflet. ; Batch 2 is valid until 31 December 2013

1440

Yes

-20C

79

25 mg

97.2% CHINOS

+5C

79

Y0000839 Iobenguane sulfate - reference spectrum

n/a

79

Y0001294 Iodixanol

60 mg

2215

+5C

79

Y0001292 Iodixanol impurity C

10 mg

5-[acetyl[3-[[3,5-bis[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl]
amino]-2-hydroxypropyl]amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6triiodobenzene-1,3-dicarboxamide

2215

+5C

79

Y0001291 Iodixanol impurity E

10 mg

5-[acetyl[3-[acetyl[3-carbamoyl-5-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6triiodophenyl]amino]-2-hydroxypropyl]amino]-N,N'-bis(2,3dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide

2215

+5C

79

Y0001293 Iodixanol impurity H

10 mg

5-[acetyl[3-[acetyl[3-[[3-[3-[acetyl[3,5-bis[(2,3-dihydroxypropyl)
carbamoyl]-2,4,6-triiodophenyl]amino]-2-hydroxypropoxy]-2-hydroxypropyl]
carbamoyl]-5-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl]
amino]-2-hydroxypropyl]amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6triiodobenzene-1,3-dicarboxamide

2215

+5C

79

I0320800 Iohexol

150 mg

1114

+5C

79

I0320810 Iohexol impurity A

50 mg

5-acetamido-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-tri-iodo benzene-1,3dicarboxamide

1114

+5C

79

I0320820 Iohexol impurity J

125 mg

5-amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-tri-iodobenzene-1,3dicarboxamide

1114,2215

+5C

79

Y0000672 Iohexol for peak identification

10 mg

+5C

79

I0329000 Iopamidol

50 mg

I0329010 Iopamidol impurity A

10 mg

Council of Europe, all rights reserved 2013

1111,1112,11
13,2351
2351

1114

Yes

79
1115
+5C
a
N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-amino-2,4,6-tri79
1115, 1754
+5C
a
iodoisophthalamide
42
For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000406 Iopamidol impurity H

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
1
10 mg
1 4-chloro-N,N'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-(2hydroxypropanoyl)amino)2,6-diiodobenzenz-1,3-dicarboxamide

I0330000 Iopanoic acid

Y0001297 Iopentol
Y0001020 Iopromide

Monograph Leaflet

Storage

Extra
Price
charges
79
a

1115

+5C

0700

+5C

79

+5C

79

+5C

79

100 mg

10 mg

100 mg

98.7% CHINO

1753

Y0001077 Iopromide impurity A

0.125 mg

5-amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-N-methylbenzene-1,3dicarboxamide

1753

+5C

79

Y0001021 Iopromide for system suitability 1

5 mg

1753

+5C

79

Y0001022 Iopromide for system suitability 2

5 mg

1753

+5C

79

Y0000555 Iotrolan

100 mg

+5C

79

Y0000658 Iotrolan for system suitability

5 mg

+5C

79

Y0000141 Ioxaglic acid

125 mg

Y0000142 Ioxaglic acid impurity A

20 mg

I0360000 Ipratropium bromide

120 mg

Y0000276 Ipratropium impurity A

10 mg

(1R,3r,5S,8r)-3-hydroxy-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]
octane

I0361000 Ipratropium bromide impurity B

10 mg

(1R,3r,5S,8s)-3-[[(2RS)-3-hydroxy-2-phenylpropanoyl]oxy]-8-methyl-8-(1methylethyl)-8-azoniabicyclo[3.2.1]octane

Y0001166 Irbesartan

60 mg

Y0001156 Irbesartan impurity A

10 mg

Y0001616 Irisflorentin

15 mg

I0375000 Isoconazole

200 mg

I0380000 Isoconazole nitrate

200 mg

I0400000 Isoemetine hydrobromide

25 mg

Y0000858 Isoflurane

Y0000037 Isoflurane - reference spectrum

I0460000 Isoleucine
I0465000 Isomalt
Y0000070 Isomaltooligosaccharide
I0500000 Isoniazid
I0599990 Isoprenaline hydrochloride
I0600000 Isoprenaline sulfate

2215

97.2%

1754

Yes

Yes

1754
2009

+5C

79

2009

+5C

79

0919

+5C

79

0772

+5C

79

0919

+5C

79

2465

+5C

79

1-(pentylamino)-N-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]
cyclopentanecarboxamide ; Batch 1 is valid until 31 October 2013

2465

+5C

79

99,5% CHO

2561

3-amino-5-[(2-hydroxyethyl)carbamoyl]-2,4,6-triiodobenzoic acid

Yes

+5C

79

1018

+5C

79

1017

+5C

79

0080,0081

+5C

79

1.4 ml

1666

+5C

g(b)

79

n/a

1673

79

50 mg

+5C

79

3000 mg

+5C

79

0.9 mg

1506

+5C

79

100 mg

0146

+5C

79

50 mg

1332

+5C

79

500 mg

0502

+5C

79

I0725000 Isopropyl hexadecanoate

100 mg

94.3% CHO

0839

Yes

+5C

79

I0750000 Isopropyl tetradecanoate

2 ml

97.9% CHO

0725

Yes

+5C

79

Y0001568 Isoquercitroside

15 mg

97% CHO

2528,2667

Yes

+5C

79

I0775000 Isosorbide dinitrate

350 mg

40,8% CHNO ; Batch 2 is valid until 1 June 2013

1117,1118

Yes

+5C

79

150 mg

99.9% CHNO; Isosorbide-5-nitrate ; Batch 3 is valid until 31 January 2013


79
1117,1118
Yes
+5C
h
43
For extra charges, please see supply terms and conditions.

I0775010 Isosorbide mononitrate


Council of Europe, all rights reserved 2013

Yes

0770
97.0 % CHO ; Batch 4 is valid until 1 May 2013

1531

Yes

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
I0775020 Isosorbide-2-nitrate

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
3
50 mg
1

Information

Monograph Leaflet
1118

+5C

I0800000 Isotretinoin

60 mg

0693,1019

Y0001218 Isotretinoin for peak identification

10 mg

1019

I0900000 Isoxsuprine hydrochloride

50 mg

Y0000366 Isradipine

125 mg

99.2% CHNO

2110

Y0000367 Isradipine impurity D

5 mg

methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl)


-2,6-dimethylpyridine-3,5-dicarboxylate

2110

I7000000 Itraconazole

20 mg

Batch 2 is valid until 28 February 2014

1335

Y0001100 Itraconazole for system suitability

25 mg

Batch 1 is valid until 30 September 2013

1335

Yes

I8000010 Ivermectin

150 mg

90.6% of CHO (component H2B1a)

1336

Yes

Y0000575 Ivy leaf standardised tincture

2 ml

0.20% (m/m) of hederacoside C; Ivy leaf standardised tincture CRS has been
replaced with Ivy leaf dry extract HRS Y0001592. ; Batch 1 is valid until 31
October 2013

2148

Y0000041 Josamycin

150 mg

1000 Ph. Eur. units per mg

1982,1983,2
0702

Y0000042 Josamycin propionate

150 mg

975 Ph. Eur. units per mg

Y0001315 Josamycin for peak identification

25 mg

K0100000 Kanamycin B sulfate

20 mg

K0200000 Kanamycin monosulfate

150 mg

Y0000450 Ketamine hydrochloride - * narc

10 mg

K0551000 Ketamine impurity A

50 mg

Y0000246 Ketobemidone hydrochloride - reference spectrum

n/a

Y0000244 Ketobemidone impurity B

5 mg

1-[4-(3-hydroxyphenyl)-1-methylpiperidin-4-yl]ethanone

Y0000245 Ketobemidone impurity C

5 mg

1-[4-(3-hydroxyphenyl)piperidin-4-yl]propan-1-one

K0600000 Ketoconazole

150 mg

K2000000 Ketoprofen

50 mg

K2000010 Ketoprofen impurity A

10 mg

K2000015 Ketoprofen impurity C

15 mg

Y0000486 Ketorolac trometamol

10 mg

Y0000626 Ketorolac trometamol for peak identification

5 mg

Y0000164 Ketotifen hydrogen fumarate - reference spectrum

n/a

Council of Europe, all rights reserved 2013

Storage

Yes

1119
Yes

Extra
Price
charges
79
g

+5C

g(b)

79

+5C

g(b)

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

-20C

g(c)

79

Yes

-20C

79

1982,1983,2
0702

Yes

+5C

79

1983

Yes

+5C

79

0032,0033,0
645

+5C

79

+5C

79

799 IU per mg of CHNOS,HO

0032,0033,0
053,
0485,0645,1
289,
1290,20702

Yes

1020

+5C

79

1020,1742

+5C

79

79

1746

+5C

79

1746

+5C

79

0921,1067,1
270

+5C

79

0922,1157,1
209

+5C

79

1-(3-benzoylphenyl)ethanone

0922

+5C

79

3-[(1RS)-1-carboxyethyl]benzoic acid

0922

+5C

79

1755

+5C

79

+5C

79

79

1-[(2-chlorophenyl)(methylimino)methyl]cyclopentanol

1746

Batch 1 is valid until 31 December 2012

1755
1592

44

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000161 Ketotifen impurity G

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
4
0.0225 mg 1 4-(1-methylpiperidin-4-ylidene)-4H-benzo(4,5)cyclohepta(1,2-b)
thiophen-9,10-dione ; Batch 3 is valid until 31 August 2013

Monograph Leaflet

Storage

Extra
Price
charges
79
g

1592

Yes

+5C

2434,2483

Yes

-20C

79

Yes

+5C

79

+5C

79

+5C

79

Y0001200 Kudzuvine root dry extract

200 mg

See leaflet

L0050000 Labetalol hydrochloride

120 mg

99.6 % CHClNO ; Batch 1 is valid until 31 March 2013

0923

Y0001548 Labetalol impurity A

10 mg

2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)-amino]ethyl]benzoic
acid

0923

L0129000 Lactitol monohydrate

60 mg

93.8% CHO

1337

Y0000257 Lactobionic acid

100 mg

1647

+5C

79

A1206000 Lactose (anhydrous)

100 mg

1061

+5C

79

L0100000 Lactose

100 mg

0177,0178,0
187,
0188,0204,0
209,
1215,1570

+5C

79

L0130000 Lactulose

3000 mg

Y0001510 Lactulose for peak identification

2600 mg

Y0000188 Lactulose for system suitability

12 mg

Y0000425 Lamivudine

150 mg

Y0000518 Lamivudine for system suitability 1

10 mg

Y0000426 Lamivudine for system suitability 2

10.3 mg

Y0001030 Lamotrigine

10 mg

Y0001031 Lamotrigine for peak identification

Y0001085 Lamotrigine for system suitability

Y0001032 Lamotrigine impurity E


Y0000773 Lansoprazole
Y0000774 Lansoprazole for peak identification
Y0001474 Lauric acid

Yes

0924,1230

Yes

+5C

79

0924

Yes

+5C

79

1230

Yes

+5C

79

2217

+5C

79

2217

+5C

79

2217

+5C

79

1756

+5C

79

20 mg

1756

Yes

+5C

79

10 mg

1756

Yes

+5C

79

15 mg

1756

+5C

79

60 mg

2219

+5C

79

1.01 mg

Batch 1 is valid until 31 December 2013

2219

Yes

+5C

79

1500 mg

97.9%

1848

Yes

+5C

79

Y0000654 Leflunomide

100 mg

100,0% CHFNO

2330

+5C

79

Y0000487 Leflunomide impurity A

25 mg

4-(trifluoromethyl)aniline

2330

+5C

79

Y0000674 Leflunomide for peak identification

1 mg

Y0000685 Letrozole

70 mg

L0375000 Leucine

50 mg

L0376000 Leuprorelin

1 mg

L0376001 Leuprorelin - reference spectrum

n/a

Y0000047 Levamisole hydrochloride for system suitability

60 mg

L0380000 Levamisole hydrochloride

50 mg

0726

Y0000048 Levamisole - reference spectrum

n/a

1728

Y0001253 Levetiracetam

110 mg

Council of Europe, all rights reserved 2013

99.7% CHO

99.7% CHNOS

2,3-dichlorobenzoic acid

99.7% CHN
0.99 mg per vial of pure leuprorelin peptide CHNO

2330

Yes

+5C

79

2334

Yes

+5C

79

0771,0874

+5C

79

1442

-20C

79

79

+5C

79

+5C

79

79

79

1442
Batch 3 is valid until 31 December 2013

100.0% CHNO
45

0726,1728

2535

Yes

Yes

+5C

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0001254 Levetiracetam impurity A

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
2
10 mg
1 (2RS)-2-(2-oxopyrrolidin-1-yl)butanoic acid ; Batch 1 is valid until 1 March
2013

Monograph Leaflet

Storage

2535

+5C

Extra
Price
charges
79
a

New Y0001255 Levetiracetam impurity B

15 mg

(2Z)-2-(2-oxopyrrolidin-1-yl)but-2-enamide ; Batch 1 is valid until 31 March


2014

2535

+5C

79

New Y0001256 Levetiracetam impurity C

15 mg

pyridin-2-ol ; Batch 1 is valid until 30 April 2014

2535

+5C

79

Y0001257 Levetiracetam impurity D

15 mg

(2R)-2-(2-oxopyrrolidin-1-yl)butanamide ((R)-etiracetam) ; Batch 1 is valid


until 1 October 2013

2535

+5C

79

L0390000 Levocabastine hydrochloride

125 mg

1484

+5C

79

L0390008 Levocabastine impurity D

20 mg

1484

+5C

79

L0399900 Levocarnitine

125 mg

1339

+5C

79

L0399905 Levocarnitine impurity A

50 mg

1339

+5C

79

L0400000 Levodopa

100 mg

0038

+5C

79

L0420000 Levodropropizine

60 mg

1535

+5C

79

L0420002 Levodropropizine impurity A

25 mg

(2R)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol (dextrodropropizine) ; Batch


2 is valid until 30 November 2013

1535

+5C

79

Y0001033 Levodropropizine impurity B

50 mg

1-phenylpiperazine

1535

+5C

79

Y0001048 Levodropropizine impurity C

300 mg

2,3-epoxypropan-1-ol

1535

-20C

g(c)

79

L0500000 Levomepromazine hydrochloride

100 mg

0505

+5C

79

L0505000 Levomepromazine maleate

50 mg

0925

+5C

79

L0551000 Levonorgestrel

30 mg

0926

+5C

79

Y0001379 Levonorgestrel impurity B

10 mg

+5C

79

Y0001431 Levonorgestrel for system suitability

10 mg

+5C

79

Y0001618 Levonorgestrel for system suitability 2

10 mg

L0570000 Levothyroxine sodium

100 mg

Y0001382 Levothyroxine for peak identification

10 mg

L0595000 Lidocaine

50 mg

L0600000 Lidocaine hydrochloride

L0650000 Lincomycin hydrochloride

1-[cis-4-cyano-4-(4-fluorophenyl)cyclohexyl]-4-phenylpiperidine-4-carboxylic
acid
(E)- or (Z)-4-(trimethylammonio)but-2-enoate

13-ethyl-17-hydroxy-18,19-dinor-17-alpha-pregn-5(10)-en-20-yn-3-one

0926
0926

Yes

0926

Yes

+5C

79

0401,0728

Yes

-20C

79

0401

Yes

-20C

79

0727

+5C

79

100 mg

0227,1242,1
363

+5C

79

250 mg

Y0001393 Lincomycin hydrochloride for system suitability

10 mg

L0700000 Liothyronine sodium

50 mg

Y0000860 Liothyronine for peak identification

0.0046 mg

0728

L0702000 Lisinopril dihydrate

50 mg

1120

Y0001235 Lisinopril for system suitability

2 mg

Council of Europe, all rights reserved 2013

89.3% CHINNaO

95.4% CHClNOS

0582,0583,0
996

Yes

+5C

79

0583

Yes

-20C

79

96.6 % CHINNaO

0401,0728

Yes

-20C

79

-20C

79

+5C

79

+5C

79

Lisinopril for performance test CRS 3 renamed as lisinopril for system


suitability CRS 1 for the implementation of 01/2011:1120 ; Batch 1 is valid
until 30 November 2013
46

1120

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0001234 Lisinopril impurity F

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
1
0.01 mg
1 (2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-cyclohexylpropyl]amino]
hexanoyl]pyrrolidine-2-carboxylic acid (cyclohexyl analogue)

L0720000 Lithium clavulanate

125 mg

L0720800 Lithocholic acid

60 mg

Y0000112 Lobeline hydrochloride

50 mg

L0745000 Lomustine

50 mg

Y0001438 Long pepper for system suitability HRS

600 mg

L0750000 Loperamide hydrochloride

Y0000322 Loperamide hydrochloride for system suitability


Y0000341 Loperamide oxide monohydrate

Monograph Leaflet
1120

+5C

79

1189,1275

+5C

79

1988

+5C

79

0928

+5C

79

2477, 2453

+5C

79

50 mg

0921,0929,1
729

+5C

79

15 mg

0929

+5C

79

20 mg

1729

+5C

79

Y0001498 Lopinavir

200 mg

2615

Yes

+5C

79

Y0001506 Lopinavir for peak identification

10 mg

2615

Yes

+5C

79

Y0001505 Lopinavir for system suitability

10 mg

2615

Yes

+5C

79

Y0000688 Loratadine

60 mg

2124

+5C

79

Y0000603 Loratadine for system suitability

20 mg

+5C

79

Y0000604 Loratadine impurity F

10 mg

ethyl 4-[(11RS)-8-chloro-11-fluoro-6,11-dihydro-5H-benzo[5,6]cyclohepta
[1,2-b]pyridin-11-yl]piperidine-1-carboxylate

2124

+5C

79

Y0000605 Loratadine impurity H

50 mg

ethyl 4-oxopiperidine-1-carboxylate

2124

+5C

79

L0750500 Lorazepam - * psy

100 mg

1121

+5C

79

Y0000576 Lorazepam for system suitability - * psy

0.8032 mg

Batch 1 is valid until 31 December 2013

1121

+5C

79

Y0000718 Lorazepam impurity D

10 mg

(5RS)-7-chloro-5-(2-chlorophenyl)-4,5-dihydro-1H-1,4-benzodiazepine-2,3dione

1121

+5C

79

Y0001062 Losartan potassium

50 mg

2232

+5C

79

Y0001072 Losartan impurity D

6 mg

2232

+5C

79

Y0001076 Losartan for system suitability

0.0015 mg

L0790000 Lovastatin

60 mg

Y0001136 Lovastatin for peak identification

20 mg

Y0001284 Lufenuron

140 mg

Y0001261 Lufenuron for peak identification

0.4028 mg

Y0001265 Lufenuron impurity G

15 mg

L0800000 Lynestrenol

50 mg

Y0001034 Lynestrenol for peak identification

Y0000397 Lysine acetate

L0900000 Lysine hydrochloride


Y0000745 Macrogol 40 sorbitol heptaoleate
Council of Europe, all rights reserved 2013

95.3 % CHNO

2124

2-butyl-4-chloro-1H-imidazole-5-carbaldehyde
99.5% CHO
99.5% CHClFNO

Yes

Extra
Price
charges
79
a

+5C

97.6% CHLiNO; 1 mg of CHLiNO corresponds to 1.157 mg of CHKNO

1140,1653

Storage

Yes

Yes

2232

Yes

+5C

79

1538,1563

Yes

-20C

79

1538

Yes

-20C

79

2177

Yes

+5C

79

2177

Yes

+5C

79

2177

+5C

79

0558

+5C

79

20 mg

0558

+5C

79

60 mg

2114

+5C

79

50 mg

0805,0806,0
930, 1654

+5C

79

20 mg

2396

+5C

79

2,5-dichloro-4-[[[(2,6-difluorophenyl)carbonyl]carbamoyl]amino]phenyl
phenyl carbonate

Batch 2 is valid until 31 August 2013

47

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0001157 Macrogol polyvinyl alcohol grafted copolymer

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
400 mg
1

Information

Monograph Leaflet

Storage

2523

+5C

Extra
Price
charges
79
a

Y0001369 Macrogol 30 dipolyhydroxystearate

100 mg

2584

+5C

79

M0088000 Magnesium aspartate dihydrate

60 mg

1445

+5C

79

Y0001289 Magnolol

20 mg

99.5% CHO

2567,2568

Yes

-20C

g(c)

79

M0120000 Malathion

250 mg

99.4% CHOPS

1343

Yes

+5C

79

M0120005 Malathion impurity A

10 mg

diethyl (2RS)-2-[(methoxy)(methylsulfanyl)-S-phosphinothioyl] butane dioate

1343

-20C

g(c)

79

M0120010 Malathion impurity B

10 mg

diethyl (2RS)-2-(dimethoxy-S-phosphinothioyl)-butanedioate

1343

-20C

g(c)

79

M0100000 Maleic acid

100 mg

0365,0925

+5C

79

Y0000143 Malic acid - reference spectrum

n/a

2080

79

M0160000 Maltitol

1200 mg

99.7% CHO

M0200000 Mannitol

1200 mg

98.8% CHO

M0206000 Maprotiline hydrochloride

100 mg

M0206040 Maprotiline impurity D

25 mg

Y0000819 Marbofloxacin

10 mg

Y0000820 Marbofloxacin for peak identification

20 mg

M0210000 Measles vaccine (live) BRP

80 mg

M0215000 Mebendazole

20 mg

1208,1254

Y0000144 Mebendazole for system suitability

20 mg

0845

Y0001086 Mebrofenin

120 mg

2393

M0220000 Meclozine dihydrochloride

150 mg

Renamed for 01/2011:0622 ; Batch 1 is valid until 1 May 2013

Y0001310 Meclozine impurity B

15 mg

4-chlorobenzhydrol

Y0001311 Meclozine impurity H

15 mg

1-(4-chlorobenzhydryl)piperazine

M0240000 Medronic acid

20 mg

Y0001107 Medronic acid impurity A

60 l

Y0001106 Medronic acid impurity B

40 l

M0250000 Medroxyprogesterone acetate

100 mg

Y0000598 Medroxyprogesterone acetate for system suitability

10 mg

M0252600 Mefenamic acid

50 mg

Y0001081 Mefenamic acid impurity A

100 mg

2,3-dimethylaniline

M0253000 Mefloquine hydrochloride

100 mg

Batch 1 is valid until 31 December 2012

1241

Y0001514 Megestrol acetate

120 mg

99.1 % CHO

1593

Yes

Y0001524 Megestrol acetate for system suitability

50 mg

1593

Y0001507 Megestrol acetate for peak identification

25 mg

1593

Y0001209 Meglumine

10 mg

Y0001080 Meloxicam

50 mg

Council of Europe, all rights reserved 2013

3-(9,10-dihydro-9,10-ethanoanthracen-9-yl)-N-methylprop-2- en-1-amine

4.3 log (ie 20000) infective viral units per vial

1235,1236

Yes

+5C

79

0435,0559,1
381, 1531

Yes

+5C

79

1237

+5C

79

1237

+5C

79

2233

+5C

79

2233

Yes

+5C

79

1057,0213,2
442

Yes

-20C

90

+5C

79

+5C

79

+5C

79

0622

+5C

79

0622

+5C

79

Yes

0622

+5C

79

0641, 2350

+5C

79

Tris(1-methylethoxy)phosphane

2350

+5C

79

Tetrakis(1-methylethyl)methhylenediphosphonate

2350

+5C

79

Batch 2 is valid until 30 November 2013

0673

+5C

79

-20C

79

1240

+5C

79

1240

+5C

79

+5C

79

+5C

79

Yes

+5C

79

Yes

+5C

79

2055

+5C

79

2373

+5C

79

0673

48

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0001035 Meloxicam impurity A
Y0001036 Meloxicam impurity B

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
1
5 mg
1 ethyl 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate 1,1-dioxide
1
5 mg
1 5-methylthiazol-2-amine

Monograph Leaflet

Storage

2373

Yes

+5C

Extra
Price
charges
79
g

2373

Yes

+5C

79

Y0001037 Meloxicam impurity C

5 mg

N-[(2Z)-3,5-dimethylthiazol-2(3H)-ylidene]-4-hydroxy-2-methyl-2H-1,2benzothiazine-3-carboxamide 1,1-dioxide

2373

Yes

+5C

79

Y0001039 Meloxicam impurity D

5 mg

N-[(2Z)-3-ethyl-5-methylthiazol-2(3H)-ylidene]-4-hydroxy-2-methyl-2H-1,2benzothiazine-3-carboxamide 1,1-dioxide

2373

Yes

+5C

79

Y0001158 Melphalan hydrochloride

100 mg

99.4% CHClNO

1698

Yes

+5C

79

Y0001513 Melphalan - reference spectrum

1 uc

1698

79

Y0001457 Melphalan for system suitability

10 mg

1698

Yes

+5C

79

M0300000 Menadione

100 mg

0507

+5C

79

M0350000 Menthol

150 mg

0619,0623

+5C

79

M0370000 Mepivacaine hydrochloride

100 mg

1242

+5C

79

M0370020 Mepivacaine impurity B

60 mg

1242

+5C

79

M0400000 Meprobamate - * psy

100 mg

0407,1689

+5C

79

M0500000 Mepyramine maleate

1000 mg

0278

+5C

79

Y0000679 Mepyramine impurity A

10 mg

N-(4-methoxybenzyl)pyridin-2-amine

0278

+5C

79

Y0000680 Mepyramine impurity C

10 mg

pyridin-2-amine

0278

+5C

79

Y0001252 Meropenem trihydrate

110 mg

87.0% CHNOS,3HO

+5C

79

Y0000297 Mesalazine

125 mg

1699,1993

+5C

79

Y0001563 Mesalazine impurity A

15 mg

1699

+5C

79

Y0001569 Mesalazine impurity C

15 mg

1699

+5C

79

Y0001040 Mesityl oxide

100 mg

2358

+5C

g(b)

79

Y0000337 Mesna - reference spectrum

n/a

1674

79

Y0000316 Mesna impurity C

10 mg

2-(acetylsulphanyl)ethanesulphonic acid

1674

+5C

79

Y0000317 Mesna impurity D

10 mg

2,2'-(disulphanediyl)bis(ethanesulphonic acid)

1674

+5C

79

Y0000227 Meso-rich exametazime

0.5 mg

1925

Yes

+5C

79

Y0000097 Mesterolone

120 mg

99.8% CHO

1730

Yes

+5C

79

Y0000096 Mesterolone impurity A

30 mg

17-hydroxy-1alpha-methylandrost-4-en-3-one

1730

+5C

79

M0600000 Mestranol

100 mg

0509

+5C

79

Y0000301 Metacresol - reference spectrum

n/a

2077

79

M0600500 Metacycline hydrochloride

50 mg

0272,0820

+5C

79

M0600900 Metamizole sodium

100 mg

1346

+5C

79

M0600905 Metamizole impurity A

15 mg

4-formylamino-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one

1346

+5C

79

Y0001481 Metamizole impurity E

0.01 mg

4-N-demethylanalgin ; Batch 1 is valid until 31 August 2013

1346

M0605000 Metformin hydrochloride

50 mg

Y0001590 Metformin impurity A

25 mg

Council of Europe, all rights reserved 2013

(RS)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide

Cyanoguanidine
49

2234

Yes

+5C

79

0931

Yes

+5C

79

0931

+5C

79

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0001600 Metformin impurity F

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
72 mg
1 Dimethylamine hydrochloride
N-methylmethanamine

Information

Monograph Leaflet

Storage

Extra
Price
charges
79
a

0931

+5C

1128

+5C

79

+5C

Y0000770 Methacrylic acid-ethyl acrylate copolymer (1:1) - type A

200 mg

Y0000323 Methacrylic acid-ethyl acrylate copolymer (1:1) - type B

200 mg

1128

79

M0610000 Methacrylic acid-ethylacrylate copolymer(1:1) reference spectrum

n/a

1128

79

M0610030 Methacrylic acid-ethylacrylate copolymer (1:1),


dispersion 30%-ref.sp

n/a

1129

79

M0620000 Methacrylic acid-methylmethacrylate copolymer(1:1)reference spectrum

n/a

1127

79

M0630000 Methacrylic acid-methylmethacrylate copolymer(1:2)reference spectrum

n/a

1130

79

M0800000 Methadone hydrochloride - reference spectrum

n/a

0408,1787

79

Y0000428 Methanol - reference spectrum

n/a

1989

79

Y0000754 Methenamine

10 mg

1545

+5C

79

M0950000 DL-Methionine

50 mg

0624

+5C

79

M0960000 Methionine

50 mg

Batch 1 is valid until 28 February 2014

0788,1027

+5C

79

M1000000 Methotrexate

100 mg

88.2 % CHNO ; Batch 5 is valid until 31 January 2013

Y0000602 Methotrexate for peak identification

20 mg

Y0000663 Methotrexate impurity C

10 mg

(2S)-2-[[4-[[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]methylamino]
benzoyl]amino]pentanedioic acid (N-methylfolic acid, methopteridine)

M1000008 Methotrexate impurity D

10 mg

Y0000664 Methotrexate impurity E

10 mg

M1300000 Methylatropine bromide

100 mg

M1450000 Methylcarbidopa

1 mg

M1470000 Methyl 2-(4-chlorophenoxy)-2-methylpropionate

Y0001488 Methyl methacrylate

M1500000 Methyldopa

Y0001374 Racemic methyldopa

Y0001083 Methyldopa for system suitability


M1550000 Methylene chloride

0560

Yes

+5C

79

0560

Yes

+5C

79

0560

+5C

79

4-[[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]methylamino]benzoic
acid (N10-methylpteroic acid)

0560

+5C

79

4-[[(2,4-diaminopteridin-6-yl)methyl]methylamino]benzoic acid (4-aminoN10-methylpteroic acid, APA)

0560

+5C

79

0919

+5C

79

0755

+5C

79

0.5 ml

0318

+5C

79

50 mg

1975

+5C

79

50 mg

0045,0755

+5C

79

5 mg

0045

+5C

79

0.024 mg

0045

+5C

79

2 ml

0932

+5C

79

M1556000 Methyl 12-hydroxystearate

100 mg

1497

+5C

79

Y0000398 Methyl nicotinate

25 mg

2129

+5C

79

Y0000776 Methylergometrine maleate

10 mg

1788

+5C

79

Y0000777 Methylergometrine for system suitability

0.53 mg

1788

+5C

79

M1625000 Methylnitrosoindoline

110 mg

1108

+5C

79

Council of Europe, all rights reserved 2013

50

Yes

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
M1650000 Methyl parahydroxybenzoate

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
3
150 mg
1 100.0% CHO; batch 2 valid until 31/12/10 for use with monograph 2134
and 1999.

Y0001017 Methylphenidate hydrochloride - * narc

Y0001490 Methylphenidate impurity C


Y0000910 Methylphenidate impurity mixture

Monograph Leaflet
0409,1262,2
134,1999

40 mg

10 mg

0.04 mg

M1700000 Methylphenobarbital - * psy

500 mg

0189

M1750000 Methylprednisolone

150 mg

0312,0561

M1755000 Methylprednisolone acetate

100 mg

0933

Y0001602 Methylprednisolone for system suitability

10 mg

0561

M1755200 Methylprednisolone hydrogen succinate

125 mg

M1755220 Methylprednisolone hydrogen succinate for


performance test

50 mg

Y0001376 2-methylpyrazine

100 mg

Y0000190 N-Methylpyrrolidone - reference spectrum

n/a

1675

M1770180 Methyl ricinoleate

125 mg

0051,2367

Y0000418 Methylrosanilinium chloride

40 mg

1990

Y0000407 Methylrosanilinium for system suitability

10 mg

1990

M1770200 Methyl stearate

100 mg

M1800000 Methyltestosterone

100 mg

Y0000861 Methyltestosterone for system suitability

10 mg

0410

M1800900 Methylthioninium chloride

50 mg

1132

M1800902 Methylthioninium impurity A

20 mg

M1808000 Metixene hydrochloride

75 mg

M1824990 Metoclopramide

100 mg

M1825000 Metoclopramide hydrochloride

50 mg

M1824995 Metoclopramide impurity A

25 mg

M1825010 Metoclopramide impurity E

40 mg

Y0000701 Metolazone

Y0000702 Metolazone for system suitability

Y0000171 Metoprolol succinate - reference spectrum


M1830000 Metoprolol tartrate

Yes

2235

+5C

Extra
Price
charges
79
a

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

0768,1131

+5C

79

1131

+5C

79

2446,2447

+5C

79

79

+5C

79

+5C

79

+5C

79

0051,1497

+5C

79

0410

+5C

79

+5C

79

+5C

79

2235

(2RS)-2-phenyl-2-[(2R)-piperidin-2-yl]ethanamide

Storage

2235

Yes

Yes

Yes

Yes

1132

+5C

79

1347

+5C

79

1348

+5C

79

0674,0856,1
303

+5C

79

4-(acetylamino)-5-chloro-N-(2-diethylaminoethyl)-2-methoxy benzamide ;
Batch 1 is valid until 31 August 2013

1348

+5C

79

N,N-diethylethane-1,2-diamine

1575

+5C

79

80 mg

99.4% CHClNOS

1757

+5C

79

10 mg

1757

+5C

79

n/a

1448

79

60 mg

1028

+5C

79

Y0000145 Metoprolol impurity A

5 mg

+5C

79

M1845000 Metrifonate

100 mg

1133

+5C

79

M1850000 Metronidazole

50 mg

0675,0934

+5C

79

50 mg

M1851000 Metronidazole benzoate


Council of Europe, all rights reserved 2013

3-(dimethylamino)-7-(methylamino)phenothiazin-5-ylium

(2RS)-1-(ethylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol ; Batch 2 is
valid until 31 December 2013

51

1028,1448

Yes

Yes

79
1424
+5C
a
For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000069 Metronidazole benzoate - reference spectrum

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
n/a
1

Information

Monograph Leaflet
0934

Y0000087 Metronidazole impurity A

10 mg

M1860000 Mexiletine hydrochloride

100 mg

Y0000202 Mexiletine impurity C

2 mg

Y0000203 Mexiletine impurity D

2 mg

M1875000 Mianserin hydrochloride

100 mg

Y0001041 Mianserin impurity B

10 mg

Y0000862 Mianserin for system suitability

1.01 mg

M1880000 Miconazole

70 mg

M1900000 Miconazole nitrate

100 mg

M2200000 Midazolam - * psy

50 mg

0.08 mg

Y0000599 Midazolam for system suitability - * psy

1 mg

Y0000539 Milk thistle standardised dry extract

120 mg

Content silibinin A and silibinin B: 26.9 % of ; Batch 2 is valid until 31


December 2012

M2280000 Minocycline hydrochloride

125 mg

90.9 % CHClNO ; Batch 2 is valid until 31 December 2012

M2300000 Minoxidil

50 mg

0937

Y0001432 Minoxidil for system suitability

10 mg

0937

Y0000705 Mirtazapine

10 mg

2338

Y0000721 Mirtazapine for system suitability

10 mg

Y0000490 Misoprostol

60 mg

Y0001162 Misoprostol for system suitability

5 mg

Y0000378 Mitomycin

120 mg

99.3% CHNO ; Batch 1 is valid until 31 December 2012

M2305000 Mitoxantrone hydrochloride

50 mg

M2305005 Mitoxantrone impurity A

5 mg

Y0000635 Modafinil

110 mg

Y0000636 Modafinil for system suitability

0.1 mg

Y0000251 Molgramostim

0.3 ml

Y0000821 Molsidomine

5 mg

1701

Y0000822 Molsidomine impurity B

10 mg

N-nitrosomorpholine

1701

Y0000823 Molsidomine impurity D

10 mg

morpholine-4-carbaldehyde

M2900000 Mometasone furoate

100 mg

Y0001436 Montelukast dicyclohexylamine

150 mg

99.4% CHClNOS

2583

Y0001433 Montelukast racemate

10 mg

Batch 1 is valid until 31 August 2013

2583

New Y0000562 Midazolam impurity C

Council of Europe, all rights reserved 2013

Storage

Extra
Price
charges
79
l

0675, 0934

+5C

79

1029

+5C

79

1,1'-[(3,3',5,5'-tetramethylbiphenyl-4,4'-diyl)bisoxy]dipropan-2-amine

1029

+5C

79

(2RS)-2-(2,6-dimethylphenoxy)propan-1-amine

1029

+5C

79

0846

+5C

79

0846

+5C

79

+5C

79

0935

+5C

79

0513,1148

+5C

79

2-methyl-4-nitroimidazole

(14bRS)-2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]
azepine-8-sulfonic acid

0846

Yes

0936,1065
acide 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a]
[1,4]benzodiazepine-3-carboxylique ; Batch 2 is valid until 30 April 2014

+5C

79

0936

Yes

+5C

79

0936

Yes

+5C

79

2071,1860

Yes

-20C

79

1030

Yes

+5C

79

+5C

79

+5C

79

+5C

79

Yes

2338

Yes

+5C

79

1731

Yes

-20C

g(c)

79

1731

Yes

-20C

g(c)

79

1655

Yes

+5C

79

97.7% CHClNO

1243

Yes

+5C

79

1-amino-5,8-dihydroxy-4-[[2-[(2-hydroxyethyl)amino]ethyl] amino]
anthracene-9,10-dione

1243

+5C

79

100.0% CHNOS

2307

+5C

79

98.5% CHO

13.45 mg protein per ml CHNOS

52

2307

Yes

+5C

79

1641

Yes

-80C

79

+5C

79

+5C

g(b)

79

1701

+5C

79

1449

+5C

79

+5C

79

+5C

79

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0001434 Montelukast sodium
Y0001435 Montelukast for peak identification

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
2
20 mg
1 Batch 1 is valid until 31 August 2013
2
20 mg
1 Batch 1 is valid until 31 August 2013

Monograph Leaflet
2583
2583

+5C
Yes

79

+5C

79

+5C

79

+5C

79

+5C

79

Yes

+5C

79

Yes

+5C

79

2254

Yes

+5C

79

2254

Yes

+5C

79

1758

+5C

79

1758

+5C

79

-80C

90

79

50 mg

Y0000451 Morphine hydrochloride (trihydrate) - * narc

25 mg

Y0000452 Morphine sulfate - * narc

40 mg

1244,1784

Y0000830 Morphine for system suitability - * narc

15 mg

1244, 0097

Yes

Y0000772 Moxidectin

70 mg

1656

Y0000747 Moxidectin for system suitability

10 mg

1656

Y0000703 Moxifloxacin hydrochloride

110 mg

Y0000717 Moxifloxacin for peak identification

10 mg

Y0000226 Moxonidine

50 mg

99.7% CHClNO

Y0000222 Moxonidine impurity A

10 mg

4,6-dichloro-N-(imidazolidin-2-ylidene)-2-methylpyrimidin-5-amine

M3600000 Mumps vaccine (live) BRP

165 mg

4.6 log (ie40000) infective viral units per vial

M3805000 Mupirocin - reference spectrum

n/a

M3805500 Mupirocin calcium - reference spectrum

n/a

M3806000 Mupirocin lithium

100 mg

Y0000489 Mycophenolate mofetil

30 mg

1700

Y0000519 Mycophenolate mofetil for peak identification

10 mg

1700

Yes

Y0000692 Mycoplasma fermentans BRP

1 ml

20607

Y0000690 Mycoplasma hyorhinis BRP

1 ml

20607

Y0000691 Mycoplasma orale BRP

1 ml

Y0000689 Mycoplasma synoviae BRP

1 ml

Y0000485 Myo-inositol

1020 mg

99.8% CHO

1805

N0020000 Nabumetone

60 mg

99.8% CHO

1350

N0020020 Nabumetone impurity D

10 mg

(E)-4-(6-methoxynaphthalen-2-yl)but-3-en-2-one

N0020030 Nabumetone impurity F

10 mg

6,6'-dimethoxy-2,2'-binaphthalenyl ; Batch 3 is valid until 31 May 2013

Y0000146 Nadolol

100 mg

1789

Y0001215 Nadolol impurity mixture

0.01 mg

1789

N0025000 Nadroparin calcium

250 mg

Y0000077 Naftidrofuryl - reference spectrum

n/a

Y0000120 Naftidrofuryl impurity A

10 mg

2-[(naphtalen-1-yl)methyl]-3-(tetrahydrofuran-2-yl)propanoic acid

1594

Y0000121 Naftidrofuryl impurity B

25 mg

ethyl 2-[(naphtalen-1-yl)methyl]- 3-(tetrahydrofuran-2-yl)propanoate ; Batch


1 is valid until 31 December 2012

1594

Y0000331 Naftidrofuryl impurity F

10 mg

2-[(diethylamino)ethyl 2-[(naphthalen-2-yl)methyl]-3- (tetrahydrofuran-2-yl)


propanoate

N0050000 Nalidixic acid

100 mg

Council of Europe, all rights reserved 2013

1546
0097,1839,1
841

97.4% CHNO
96.1 % CHClFNO

0538,1057

Yes

Yes

1450
1451

79

+5C

79

+5C

79

+5C

79

Yes

-80C

120

Yes

-80C

120

20607

Yes

-80C

120

20607

Yes

-80C

120

+5C

79

+5C

79

1350

+5C

79

1350

+5C

79

+5C

79

+5C

79

+5C

79

79

+5C

79

+5C

79

1594

+5C

79

0701

+5C

79

1450,1451

93.7% CHOLi

0828,1134

Batch 1 is valid until 30 November 2013

Yes

Yes

Yes

1594

53

Extra
Price
charges
79
a

+5C

Y0000028 Morantel hydrogen tartrate

See leaflet

Storage

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
N0075000 Naloxone hydrochloride dihydrate

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
2
100 mg
1

Information

Monograph Leaflet
0729,2099

+5C

Y0000695 Naloxone for peak identification

10 mg

0729

Y0000400 Naltrexone hydrochloride

50 mg

1790

Y0000410 Naltrexone impurity C

15 mg

Y0000542 Nandrolone decanoate

5 mg

Y0000547 Nandrolone decanoate for peak identification

10 mg

1992

Y0000548 Nandrolone decanoate for system suitability

10 mg

1992

N0080000 Naphazoline hydrochloride

50 mg

N0100000 Naphazoline nitrate

10 mg

N0200000 Naphazoline impurity A

15 mg

N0250000 Naproxen

100 mg

Y0000399 Naproxen (racemic)

10 mg

Y0000631 Naproxen impurity L

10 mg

1-(6-methoxynaphthalen-2-yl)ethanone

Y0001378 Naringin

20 mg

88.3% CHO

2563

Yes

Y0001437 Nateglinide

200 mg

99.9% CHNO

2575

Yes

Y0001440 Nateglinide impurity A

10 mg

trans-4-(1-methylethyl)cyclohexanecarboxylic acid

2575

Y0001441 Nateglinide impurity B

15 mg

N-[[trans-4-(1-methylethyl)cyclohexyl]carbonyl]-Lphenylalanine (Lphenylalanine isomer)

2575

Y0001442 Nateglinide impurity C

10 mg

N-[[cis-4-(1-methylethyl)cyclohexyl]carbonyl]-D-phenylalanine (cis-isomer)

N0300000 Neamine

0.5 mg

76.3% CHNO

N0399000 Neohesperidin-dihydrochalcone

125 mg

N0399004 Neohesperidin-dihydrochalcone impurity B

10 mg

N0400000 Neomycin sulfate

50 mg

N0401000 Neomycin sulfate for microbiological assay

25 mg

N0500000 Neostigmine bromide

50 mg

N0550000 Neostigmine metilsulfate

50 mg

N0559000 Netilmicin sulfate

25 mg

14656 IU per vial

1351,20702

Y0000520 Nevirapine (anhydrous)

30 mg

99.8% CHNO

2255, 2479

Y0000521 Nevirapine for peak identification

0.058 mg

Y0001499 Nevirapine hemihydrate

15 mg

Y0000388 Newcastle Disease Vaccine (inactivated) BRP

40 mg

Council of Europe, all rights reserved 2013

Storage

+5C

79

+5C

79

1790

+5C

79

1992

-20C

79

-20C

79

-20C

79

0730,1162

+5C

79

0147

+5C

79

N-(2-aminoethyl)-2-(naphthalen-1-yl)acetamide
(naphthylacetylethylenediamine)

0147,0730

+5C

79

Batch 1 is valid until 1 June 2013

0731,1702

+5C

79

0731,1702

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

N-(3-butenyl)-noroxymorphone

Yes

Extra
Price
charges
79
a

Yes

0731,1702

+5C

79

0180,0197

2575
Yes

+5C

79

89.9% CHO

1547

Yes

-20C

79

86.4% CHO ; 7-[[2-O-(6-deoxy--L-mannopyranosyl) --Dglucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1benzopyran-4-one (neodiosmin)

1547

Yes

+5C

79

Not to be used for microbiological assay

0032,0033,0
053,
0180,0197,0
485, 0645

Yes

-20C

79

19850 IU per vial ; Batch 3 is valid until 31 August 2013

0197,20702

Yes

-20C

79

+5C

79

0046
0626

2255, 2479

Yes

54

0870

79

79

+5C

79

Yes

+5C

79

+5C

79

Yes

-20C

180

2479
The kit contains :1 vial BRP1 NDV reference antigen, 1 vial BRP1 NDV control
antigen, 1 vial BRP1 NDV coating antibody, 1 vial BRP1 NDV conjugated,
detection antibody

+5C
-20C

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Code
Y0001373 Nicergoline

Reference Standard

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
50 mg
1

Information

Monograph Leaflet

Storage

Extra
Price
charges
79
g

1998

+5C

1998

+5C

79

1998

+5C

79

Y0001356 Nicergoline impurity D

20 mg

Y0001362 Nicergoline for peak identification

1 mg

Y0001352 Nicergoline for system suitability

10 mg

1998

+5C

79

N0560000 Niclosamide (anhydrous)

50 mg

0679,0680

+5C

79

N0600000 Nicotinamide

50 mg

0047

+5C

79

N0590000 Nicotine - reference spectrum

n/a

1452,1792

79

N0590200 Nicotine ditartrate

120 mg

+5C

79

Y0001425 Nicotine ditartrate dihydrate

15 mg

2599

+5C

79

Y0001023 Nicotine for system suitability

1 mg

1452, 1792,
2599

-20C

g(c)

79

N0700000 Nicotinic acid

100 mg

0459

+5C

79

Y0001268 Nicotinic acid impurity mixture

0.12 mg

0459

+5C

79

N0750000 Nifedipine

50 mg

0627,1013

+5C

79

N0750010 Nifedipine impurity A

20 mg

Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylate

0627

+5C

79

N0750015 Nifedipine impurity B

25 mg

Dimethyl 2,6-dimethyl-4-(2-nitrosophenyl)pyridine-3,5-dicarboxylate

0627

+5C

79

Y0000824 Niflumic acid

10 mg

2115

+5C

79

Y0000825 Niflumic acid impurity A

10 mg

2-chloropyridine-3-carboxylic acid

2215

+5C

79

Y0000826 Niflumic acid impurity B

10 mg

2-hydroxy-N-(3-(trifluoromethyl)phenyl)pyridine-3-carboxamide

2115

+5C

79

Y0000827 Niflumic acid impurity E

15 mg

6-((3-(trifluoromethyl)phenyl)amino)pyridine-3-carboxylic acid

Y0000836 Nifuroxazide

10 mg

N0800000 Nikethamide

1 ml

Y0000829 Nilutamide

110 mg

100.0% CHFNO

Y0000894 Nilutamide impurity B

5 mg

4-nitro-3-(trifluoromethyl)aniline

N0845000 Nimesulide

100 mg

Y0001237 Nimesulide for peak identification

10 mg

N0845008 Nimesulide impurity D

0.004 mg

N0850000 Nimodipine

50 mg

N0850010 Nimodipine impurity A

1 mL

N0900000 Nitrazepam - * psy

100 mg

N0905000 Nitrendipine

60 mg

Y0001456 Nitrendipine for peak identification

10 mg

N0905005 Nitrendipine impurity A

30 mg

N0930000 Nitric oxide - reference spectrum

n/a

Council of Europe, all rights reserved 2013

5-bromopyridine-3-carboxylic acid

1792

92.8% CHN x 2 CHO ; Batch 3 is valid until 1 May 2013

Yes

Yes
Yes

Yes

2115

+5C

79

1999

+5C

79

0233

+5C

79

2256

+5C

79

2256

+5C

79

1548

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

0415,0898,1
121

+5C

79

1246

+5C

79

+5C

79

+5C

79

79

1548

Yes

1548

4-nitro-2-phenoxyaniline

1245
1245

2-methoxyethyl 1-methylethyl 2,6-dimethyl-4-(3-nitrophenyl)


pyridine-3,5-dicarboxylate ; Batch 3 is valid until 1 June 2013

1246
ethyl methyl-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5- dicarboxylate;
(nitrophenylpyridine analogue)

1246
1550

55

Yes

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Code
N0950000 Nitrofural

Reference Standard

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
100 mg
1 99.8% CHNO

Information

Monograph Leaflet

Storage

1135

+5C

Extra
Price
charges
79
a

Y0001377 Nitrofural for peak identification

0.11 mg

1135

+5C

79

N1000000 Nitrosotriaminopyrimidine

50 mg

0058

+5C

79

N1090000 Nizatidine

250 mg

+5C

79

Y0001278 Nizatidine for system suitability

10 mg

+5C

79

N1090060 Nizatidine impurity F

10 mg

(EZ)-N,N'-[thiazole-2,4-diylbis(methylenesulphanediylethylene)]bis(N'methyl-2-nitroethene-1,1-diamine)

1453

+5C

79

New N1080000 Nomegestrol acetate

1453

99.3% CHNOS

1453

Yes

100 mg

Batch 1 is valid until 31 March 2014

1551

+5C

79

N1080005 Nomegestrol acetate impurity A

50 mg

6alpha-methyl-3,20-dioxo-19-norpregn-4-en-17-yl acetate

1551

+5C

79

Y0001314 1-nonadecanol

400 mg

0801,0802,0
847

+5C

79

Y0000670 Nonivamide

10 mg

+5C

79

Y0000755 Nonoxinol 9

10 mg

1454

+5C

79

N1100000 Noradrenaline tartrate

200 mg

0254,0285,0
732, 2303

+5C

79

Y0000681 Noradrenaline impurity D

15 mg

+5C

79

Y0000682 Noradrenaline impurity E

10 mg

4[(1R)-2-amino-1-methoxyethyl]benzene-1,2-diol (noradrenaline methyl ether) 0285,0732


2-chloro-1-(3,4-dihydroxyphenyl)ethanone
0285,0732

+5C

79

Y0000686 Noradrenaline impurity F

10 mg

N-benzyl-1-phenylmethanamine

0285,0732

+5C

79

N1130000 Norcyclobenzaprine

25 mg

0941

+5C

79

N1140000 Nordazepam -* psy

50 mg

Dipotassium clorazepate impurity B

0898,1466

+5C

79

N1200000 Norethisterone

50 mg

0234,1212,0
926

+5C

79

N1225000 Norethisterone acetate

100 mg

0850

Y0000522 Norethisterone for system suitability

10 mg

0234

N1230000 Norfloxacin

50 mg

N1230010 Norfloxacin impurity A

20 mg

Y0001015 Norfloxacin for system suitability

8 mg

1248

Y0001301 Norfloxacin for peak identification

10 mg

1248

Y0000724 Norgestimate

10 mg

1732

Y0000725 Norgestimate for system suitability

5 mg

1732

N1250000 Norgestrel

30 mg

0940

N1279000 Norpseudoephedrine hydrochloride - * psy

50 mg

0683

N1280000 Nortriptyline hydrochloride

10 mg

0941

Y0001296 Nortriptyline for system suitability

20 mg

N1300000 Noscapine

100 mg

Council of Europe, all rights reserved 2013

1859,2336,2
337, 2529

99.1% CHNO

7-chloro-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
(corresponding also to pefloxacin impurity F)

Cathine hydrochloride

56

Yes

+5C

79

-20C

79

1248

+5C

79

1460

+5C

79

Yes

+5C

79

Yes

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

0941

+5C

79

0102,0515,0
516

+5C

79

Yes

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Code
N1400000 Nystatin

Reference Standard

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
7
100 mg
1 5880 IU per mg ; Batch 6 is valid until 31 August 2013

O0100900 Octoxinol 10

Y0000368 Octyl gallate


O0101000 Octyldodecanol

Monograph Leaflet
0517,1292,2
0702

300 mg

30 mg

400 mg

O0120000 Ofloxacin

50 mg

O0120010 Ofloxacin impurity A

20 mg

(RS)-9,10-difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido [1,2,3-de][1,4]
benzoxazine-6-carboxylic acid (FPA)

New O0120050 Ofloxacin impurity E

20 mg

Y0001370 Olanzapine

200 mg

Y0001392 Olanzapine impurity A

5 mg

Y0001380 Olanzapine for system suitability

10 mg

2258

Y0001204 Oleanolic acid

20 mg

90.9% CHO

2472

Y0001479 Oleic acid

2000 mg

98.3% CHO

2579

Y0001113 Triolein

30 mg

98.7 % CHO

2454

Y0000805 Oleuropein

20 mg

82.2% CHO

Y0001405 Olmesartan medoxomil

100 mg

99.3 % CHNO

Y0001424 Olmesartan medoxomil for system suitability

10 mg

O0146000 Olsalazine sodium

70 mg

O0146010 Olsalazine sodium for performance test

60 mg

1457

O0150000 Omeprazole

50 mg

0942,1032,2
372, 2374

Y0001043 Omeprazole magnesium

10 mg

2374

Y0001042 Omeprazole for peak identification

10 mg

0942,1032,2
372, 2374

O0151000 Omeprazole impurity D

10 mg

Omeprazole sulphone

Y0000218 Ondansetron hydrochloride dihydrate

200 mg

89,9% CHClNO ; Batch 3 is valid until 1 June 2013

Y0000197 Ondansetron for LC system suitability

10 mg

Y0000196 Ondansetron for TLC system suitability

30 mg

Y0001345 Ondansetron impurity A

10 mg

(3RS)-3-[(dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4Hcarbazol-4-one

Y0000195 Ondansetron impurity D

10 mg

Y0001326 Ondansetron impurity E

10 mg

Y0001320 Ondansetron impurity F

10 mg

Y0001346 Ondansetron impurity G

10 mg

Council of Europe, all rights reserved 2013

Yes

1553

Storage
-20C

Extra
Price
charges
79
c

+5C

79

+5C

79

+5C

79

1455

+5C

79

1455

+5C

79

(RS)-9-fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido
[1,2,3-de][1,4]benzoxazine-6-carboxylic acid ; Batch 3 is valid until 30 April
2014

1455

+5C

79

99.8% CHNS

2258

+5C

79

5-methyl-2-[(2-nitrophenyl)amino]thiophene-3-carbonitrile

2258

+5C

79

Yes

+5C

79

Yes

+5C

79

Yes

+5C

79

Yes

-20C

79

1878

Yes

+5C

79

2600

Yes

+5C

79

2600

Yes

+5C

79

+5C

79

Yes

+5C

79

Yes

-20C

79

+5C

79

-20C

79

-20C

79

2057
1136

94.8% CHO

Yes

Yes

1457

Batch 1 is valid until 30 November 2013

Yes

0942,1032,2
372, 2374
2016

+5C

79

2016

+5C

79

2016

+5C

79

2016

+5C

79

9-methyl-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one

2016

+5C

79

Imidazole

2016

+5C

79

2016

+5C

79

2016

+5C

79

(3RS)-3-[(1H-imidazol-1-yl)methyl]-9-methyl-1,2,3,9-tetrahydro-4Hcarbazol-4-one (C-demethylondansetron)
57

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Code
Y0001125 Orbifloxacin

Reference Standard

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
200 mg
1

Information

Monograph Leaflet
2259

Y0001147 Orbifloxacin impurity mixture

0.0008 mg

2259

O0180000 Orciprenaline sulfate

100 mg

1033,1332

Y0000895 Orciprenaline for system suitability

5 mg

1033

Y0001501 Orientvine stem HRS

600 mg

2450

Y0000100 Orphenadrine hydrochloride

100 mg

Y0000101 Orphenadrine citrate

100 mg

Y0001337 Oseltamivir phosphate (impurity B free)

300 mg

Y0001181 Orphenadrine for peak identification

0.42 mg

Y0001338 Oseltamivir impurity A

10 mg

(3R,4R,5S)-5-acetamido-4-amino-3-(1-ethylpropoxy)cyclohex-1-ene-1carboxylic acid

Y0000102 Orphenadrine impurity E

60 mg

(RS)-N,N-dimethyl-2-[(3-methylphenyl)phenylmethoxy] ethanamine (metamethylbenzyl isomer) ; Batch 1 is valid until 1 May 2013

Y0001339 Oseltamivir impurity B

10 mg

Y0001340 Oseltamivir impurity C

10 mg

Y0001341 Oseltamivir impurity H

Y0001207 Osthole

O0200000 Ouabain
Y0000638 Oxacillin sodium monohydrate
Y0000560 Oxacillin for peak identification
Y0000271 Oxaliplatin

Storage
+5C

Yes

Extra
Price
charges
79
a

+5C

79

+5C

79

Yes

+5C

79

Yes

+5C

79

1760

+5C

79

1759

+5C

79

2422

Yes

+5C

79

1759,1760

Yes

+5C

79

2422

+5C

79

1759,1760

+5C

79

ethyl (1R,2R,3S,4R,5S)-4-acetamido-5-amino-2-azido-3(1-ethylpropoxy)cyclohexanecarboxylate

2422

+5C

79

(3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)cyclohex-1-ene-1carboxylic acid

2422

+5C

79

30 mg

tributylphosphane oxide

2422

+5C

79

20 mg

98.3 % CHO

2557

Yes

+5C

79

150 mg

80.0% CHO

0048

Yes

+5C

79

110 mg

93.8% CHNNaOS

2260

Yes

+5C

79

10 mg

2260

Yes

+5C

79

250 mg

99.9% CHNOPt ; Batch 3 is valid until 1 June 2013

2017

Yes

+5C

79

Y0000272 Oxaliplatin impurity B

22 mg

94.4% CHNOPt; (SP-4-2)-diaqua[(1R,2R)-cyclohexane-1,2-diaminekN,kN']


platinum (diaquodiaminocyclohexaneplatinum) ; Batch 7 is valid until 1 June
2013
Batch 8 is valid until 31 December 2013

2017

Yes

+5C

79

Y0000273 Oxaliplatin impurity C

25 mg

(OC-6-33)-[(1R,2R)-cyclohexane-1,2-diamine-kN,kN'][ethane-dioato(2-)kO1,kO2]dihydroxyplatinum ; Batch 4 is valid until 1 April 2013

2017

+5C

79

Y0000274 Oxaliplatin impurity D

10 mg

(SP-4-2)-[(1S,2S)-cyclohexane-1,2-diamine-kN,kN'][ethanedioato(2-)-kO1,kO2]platinum (S,S-enantiomer of oxaliplatin) ; Batch 3 is valid


until 31 December 2013

2017

+5C

79

O0225000 Oxazepam - * psy

50 mg

+5C

79

Y0000543 Oxazepam for peak identification

0.008 mg

Batch 1 is valid until 1 March 2013

0778

Yes

+5C

79

Y0001576 Oxcarbazepine

120 mg

99.8 % CHNO

2577

Yes

+5C

79

Y0001549 Oxcarbazepine impurity mixture

0.008 mg

2577

Yes

+5C

79

Y0000350 Oxeladin hydrogen citrate

50 mg

1761

+5C

79

Y0000404 Oxeladin impurity C

10 mg

1761

+5C

79

Council of Europe, all rights reserved 2013

99.7% CHNOP

0778

2-(diethylamino)ethyl 2-ethyl-2-phenylbutanoate
58

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000390 Oxeladin impurity D
O0225800 Oxfendazole for veterinary use

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
1
20 mg
1 2-(2-diethylaminoethoxy)ethyl 2-phenyl-butyrate dihydrogen citrate
2

50 mg

10 mg

Y0000225 Oxfendazole with impurity D

10 mg

Y0000709 Oxitropium bromide

50 mg

Y0000715 Oxitropium bromide impurity B

15 mg

(1R,2R,4S,5S,7s)-7-[[(2S)-3-hydroxy-2-phenylpropanoyl]oxy]-9,9dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane (methylhyoscine)

Y0000713 Oxitropium bromide impurity D

10 mg

(1R,2R,4S,5S,7s,9r)-9-ethyl-9-methyl-7-[(2-phenylprop-2-enoyl)oxy]-3oxa-9-azoniatricyclo[3.3.1.02,4]nonane (apo-N-ethylhyoscine)

O0240000 Oxolinic acid

50 mg

O0240005 Oxolinic acid impurity A

20 mg

O0240010 Oxolinic acid impurity B

20 mg

O0250000 Oxprenolol hydrochloride

50 mg

O0260000 Oxibendazole

O0270000 Oxybuprocane hydrochloride

O0288000 Oxybutynin hydrochloride


O0288005 Oxybutynin impurity A
Y0000492 Oxycodone hydrochloride - * narc

Monograph Leaflet
1761

Storage
+5C
+5C

79

+5C

79

1458

+5C

79

2170

+5C

79

2170

+5C

79

2170

+5C

79

1353

+5C

79

8-hydroxy-1,3-dioxolo[4,5-g]quinoline-7-carboxylic acid

1353

+5C

79

ethyl 5-ethyl-8-oxo-5,8-dihydro-1,3-dioxolo[4,5-g]quinoline-7- carboxylate

1353

+5C

79

0628,0876,1
072

+5C

79

100 mg

1386

+5C

79

150 mg

1251

+5C

79

150 mg

+5C

79

20 mg

+5C

79

100 mg

1793

+5C

79

50 mg

1793

+5C

79

O0290000 Oxymetazoline hydrochloride

80 mg

0943

+5C

79

Y0001044 Oxymetazoline impurity A

15 mg

N-(2-aminoethyl)-2-[4-(1,1-dimethylethyl)-3-hydroxy-2,6-dimethylphenyl]
acetamide

0943

+5C

79

O0400000 Oxytetracycline

100 mg

89.9% CHNO ; Batch 6 is valid until 31 December 2012

+5C

79

O0500000 Oxytetracycline hydrochloride

20 mg

+5C

79

O0700000 Oxytocin

1 mg

0.96 mg per vial of CHNOS

-20C

g(c)

90

O0770000 Oxytocin/Desmopressin validation mixture

20 mg

about 0.1 mg oxytocin + 0.1 mg desmopressin per vial ; Batch 3 is valid until
30 November 2013

-20C

79

Y0000698 Paclitaxel

40 mg

99.4% CHNO

1794

+5C

79

Y0000699 Paclitaxel impurity C

5 mg

N-debenzoyl-N-hexanoylpaclitaxel

1794

Y0000700 Paclitaxel natural for peak identification

10 mg

Y0000719 Paclitaxel semi-synthetic for peak identification

10 mg

Y0000739 Paclitaxel semi-synthetic for system suitability

1.013 mg

New Y0000224 Oxfendazole impurity B

New Y0000453 Oxycodone impurity D

Council of Europe, all rights reserved 2013

1458

Extra
Price
charges
79
g

See leaflet; methyl [5-(phenylsulphonyl)-1H-benzimidazole-2-yl]carbamate ;


Batch 1 is valid until 30 April 2014

1458

Yes

1354
90.7% CHNO; 4-(diethylamino)but-2-ynyl()-2-(cyclohex-3-enyl)-2cyclohexyl-2-hydroxyacetate ; Batch 3 is valid until 31 December 2013
7,8-didehydro-4,5 alpha-epoxy-14-hydroxy-3-methoxy -17methylmorphinan-6-one (14-hydroxycodeinone) ; Batch 2 is valid until 31
March 2014

1354

0198,0199

Yes

Yes

0198,1030

Batch 1 is valid until 1 April 2013

59

0779,0780

Yes

0712,0779,0
780
Yes

+5C

79

1794

Yes

+5C

79

1794

Yes

+5C

79

1794

Yes

+5C

79

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Code
P0090000 Palmitic acid

Reference Standard

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
4
100 mg
1

Information

Monograph Leaflet
0229,0882,1
474,
1663,2058,

Storage
+5C

Y0000524 Pamidronate disodium pentahydrate

10 mg

+5C

79

P0100000 Pancreas powder (amylase and lipase) BRP

2000 mg

41.4 Ph. Eur. U. lipolytic activity per mg; 56.3 Ph. Eur. U. amylolytic activity
per mg

0350

Yes

+5C

79

Y0001632 Pancreas powder (amylase) BRP

2000 mg

92.8 Ph. Eur. units/mg ; Batch 3 is valid until 28 February 2014

0350

Yes

+5C

79

Y0001631 Pancreas powder (lipase) BRP

2000 mg

65.4 Ph. Eur.units per mg ; Batch 3 is valid until 28 February 2014

0350

Yes

+5C

79

2000 mg

See leaflet ; Batch 3 is valid until 30 April 2014

0350

Yes

+5C

79

P0250000 Pancuronium bromide

20 mg

Vecuronium impurity B

0681,1769

+5C

79

Y0000577 Pancuronium bromide for system suitability

20 mg

0681

+5C

79

Y0000835 Pantoprazole sodium sesquihydrate

20 mg

+5C

79

Y0001001 Pantoprazole for system suitability

0.5055 mg

+5C

79

P0270000 Papaverine hydrochloride

25 mg

0102,0573

+5C

79

P0300000 Paracetamol

50 mg

0049

+5C

79

Y0000780 Paraffin (hard)

10 mg

1034

+5C

79

Y0000058 Paraffin (liquid) - reference spectrum

n/a

0239,0240

79

Y0000913 Paraffin (White soft)

10 mg

1799

+5C

79

Y0000912 Paraffin (Yellow soft)

10 mg

1554

+5C

79

0828,1252

+5C

79

2283

+5C

79

New P0200000 Pancreas powder (protease) BRP

New P0305000 Parnaparin sodium

1779

Extra
Price
charges
79
a

2296
2296

Batch 4 is valid until 31 December 2013


Batch 3 is valid until 31 December 2012

Yes

200 mg

Y0000578 Paroxetine hydrochloride (anhydrous)

100 mg

Y0000281 Paroxetine hydrochloride hemihydrate

200 mg

97.4% CHClFNO

2018,2283

+5C

79

Y0000233 Paroxetine impurity A

15 mg

(3S,4R)-3-[[1,3-benzodioxol-5-yloxy]methyl]-4-phenylpiperidine
(desfluoroparoxetine)

2018,2283

+5C

79

Y0000579 Paroxetine hydrochloride (anhydrous) impurity C

10 mg

(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-1-benzyl-4-(4-fluo- rophenyl)
piperidine (N-benzylparoxetine)

2283

+5C

79

Y0000256 Paroxetine impurity D

5 mg

(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
((+)-trans-paroxetine)

2018,2283

+5C

79

Y0000580 Paroxetine impurity E

5 mg

(3RS,4RS)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4fluorophe- nyl)piperidine
(cis-paroxetine)

2283

+5C

79

Y0000581 Paroxetine hydrochloride (anhydrous) impurity H

10 mg

[(3S,4R)-1-benzyl-4-(4-fluorophenyl)piperidin-3-yl]methanol

2283

+5C

79

Y0000630 Paroxetine for system suitability

5 mg

2018

+5C

79

P0309000 Pefloxacin mesilate dihydrate

200 mg

1460

+5C

79

P0309020 Pefloxacin impurity B

10 mg

1-ethyl-6-chloro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydro- quinoline-3carboxylic acid (chlorinated homologue of pefloxacin)

1460

+5C

79

P0309030 Pefloxacin impurity C

0.01 mg

1-ethyl-6-fluoro-5-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydro- quinoline-3carboxylic acid (isopefloxacin)

1460

+5C

79

Y0001539 Pemetrexed disodium heptahydrate

200 mg

78.6 %

2637

+5C

79

Y0001538 Pemetrexed for system suitability

20 mg

+5C

79

Council of Europe, all rights reserved 2013

Batch 1 is valid until 31 March 2014

2637
60

Yes

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0001535 Pemetrexed impurity mixture

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
0.002 mg 1

Information

Monograph Leaflet
2637

Yes

Storage
+5C

P0307000 Penbutolol sulfate

100 mg

P0307005 Penbutolol impurity A

20 mg

P0310000 Penicillamine

100 mg

P0320000 Penicillamine disulfide

100 mg

93.0% CHNOS; 3,3-(disulphanediyl)bis[(2S)-2-amino-3methylbutanoic] acid

P0400100 Pentaerythrityl tetranitrate diluted

600 mg

10.0% CHNO

P0405000 Pentamidine diisetionate

30 mg

P0405500 Pentazocine - reference spectrum

n/a

P0405510 Pentazocine hydrochloride - reference spectrum

n/a

Y0000417 Pentazocine lactate - reference spectrum

n/a

2000

Y0001051 Pentetate sodium calcium

100 mg

2353

+5C

P0500000 Pentobarbital - * psy

500 mg

0200,0419

P0510000 Pentoxifylline

100 mg

0851

Y0000076 Pentoxyverine hydrogen citrate - reference spectrum

n/a

Y0000098 Pentoxyverine impurity A

10 mg

1-phenylcyclopentanecarboxylic acid

1621

Y0000099 Pentoxyverine impurity B

10 mg

2-(diethylamino)ethyl 1-phenylcyclopentanecarboxylate (caramiphen)

1621

P0525000 Pepsin powder

2000 mg

0.99 Ph. Eur. U. per mg

0682

Yes

Y0000010 Pergolide mesilate

150 mg

99.9% CHNOS

1555

Yes

Y0000237 Perindopril impurity A

10 mg

(2S,3aS,7aS)-octahydro-1Hindole-2-carboxylic acid ; Batch 1 is valid until 1


May 2013

2019

Y0000207 Perindopril for stereochemical purity

40 mg

Batch 1 is valid until 1 June 2013

2019

Y0000238 Perindopril tert-butylamine

40 mg

2019

Y0000771 Perindopril for peak identification

5 mg

2019

P0550000 Perphenazine

100 mg

0629,0904

Y0001045 Perphenazine for system suitability

5 mg

0629

Yes

Y0000021 Pertussis toxin BRP

0.05 mg

See leaflet,
1356, 1595,
1931, 1932,
1933, 1934,
2065, 2067,
2329

Yes

P0600000 Pethidine hydrochloride - reference spectrum

n/a

P0600002 Pethidine impurity A

20 mg

P0800000 Phenazone

20 mg

Y0001138 Phenazone impurity A

20 mg

P0850000 Pheniramine maleate

250 mg

Council of Europe, all rights reserved 2013

(2S)-1-[2-(cyclopent-1-enyl)phenoxy]-3-[(1,1-dimethylethyl) amino]
propan-2-ol ; Batch 1 is valid until 7 February 2013

1461

+5C

79

1461

+5C

79

0566

+5C

79

+5C

79

1355

+5C

79

1137,1436

+5C

79

1462

79

1463

79

0566

Yes

79

79

+5C

79

+5C

79

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

-20C

g(d)

90

79

0420

+5C

79

0421

+5C

79

0421

+5C

79

1357

+5C

79

1621

Yes
Yes

0420
1-methyl-4-phenylpiperidine (MPP)
5-methyl-2-phenyl-2,4-dihydro-3-pyrazol-3-one

61

Extra
Price
charges
79
a

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0001428 Pheniramine impurity A

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
20 mg
1 2-benzylpyridine

Information

Monograph Leaflet

Storage

Extra
Price
charges
79
a

1357

+5C

0189,0201,0
630

+5C

79

P0900000 Phenobarbital - * psy

200 mg

Y0001350 Phenobarbital impurity A

15 mg

+5C

79

Y0001351 Phenobarbital impurity B

15 mg

0201

+5C

79

P0950000 Phenoxyethanol

1 mL

0781

+5C

79

P1000000 Phenoxymethylpenicillin

250 mg

0148

+5C

79

P1100000 Phenoxymethylpenicillin potassium

250 mg

+5C

79

Y0001127 Phentolamine mesilate

10 mg

1138

+5C

79

Y0001251 Phentolamine mesilate for system suitability

10 mg

1138

+5C

79

P1109000 Phentolamine mesilate - reference spectrum

n/a

1138

79

P1150000 Phenylalanine

60 mg

0782,0796,1
161,2575

+5C

79

P1200000 Phenylbutazone

100 mg

0422,1574

+5C

79

Y0000147 Phenylbutazone impurity B

20 mg

0422

+5C

79

P1240000 Phenylephrine

60 mg

1035

+5C

79

P1250000 Phenylephrine hydrochloride

50 mg

0632,1205

+5C

79

Y0000683 Phenylephrine hydrochloride for peak identification

2 mg

0632,1035

+5C

79

Y0000229 Phenylmercuric acetate - reference spectrum

n/a

2042

79

P1255100 Phenylmercuric borate - reference spectrum

n/a

0103

79

P1260000 Phenylpropanolamine hydrochloride - * Drug Precursor

50 mg

0683

+5C

79

P1290000 Phenytoin

100 mg

1253,1988

+5C

79

Y0001167 Phenytoin for system suitability

20 mg

0521,1253

+5C

79

P1300000 Phenytoin sodium

250 mg

0521

+5C

79

Y0000493 Phloroglucinol (anhydrous)

210 mg

2301,2302

+5C

79

Y0000761 Pholcodine - * narc

10 mg

0522

+5C

79

Y0000798 Pholcodine for peak identification - * narc

10 mg

Y0000766 Phthalic acid

20 mg

P1500000 Phthalylsulfathiazole

100 mg

P1600000 Physostigmine salicylate

100 mg

New P1609000 Phytomenadione

150 mg

99.9 % phytomenadione C31H46O2 CHO; Vitamin K1 ; Batch 3 is valid


until 28 February 2014

1036

New P1609010 trans-Epoxyphytomenadione

Batch 2 is valid until 30 April 2014

0113,0114,0
148, 0149

99.2% CHKNOS

(4-butyl-4-hydroxy-1,2-diphenyl-3,5)-pyrazolidinedione

Norephedrin hydrochloride

Yes

Yes

Yes

+5C

79

+5C

79

0352

+5C

79

0286

+5C

79

+5C

79

1036

+5C

79

1358

+5C

79

+5C

79

+5C

79

5 mg

125 mg

P1645005 Picotamide impurity A

25 mg

Y0001508 Picrotin

40 mg

0522

Yes

2348

P1645000 Picotamide monohydrate

Council of Europe, all rights reserved 2013

0201

79.1% CHNO

benzene-1,2-dicarboxylic acid

4-methoxybenzene-1,3-dicarboxylic acid

Yes

1358
2486

62

Yes

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Code
Y0001528 Picrotoxinin

Reference Standard

Y0000124 Pidolate impurity B

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
1
40 mg
1 98.3 % CHO
2
60 mg
1 (2S)-2-[[[(2S)-5-oxopyrrolidin-2-yl]carbonyl]amino]pentane-dioic acid

Monograph Leaflet
2486

Yes

Storage
+5C

Extra
Price
charges
79
g

1619

+5C

79

Y0000123 Pidolic acid

125 mg

1619

+5C

79

P1650000 Pilocarpine hydrochloride

50 mg

0633

+5C

79

P1700000 Pilocarpine nitrate

50 mg

0104

+5C

79

Y0000106 Pilocarpine nitrate for system suitability

20 mg

0104,0633

+5C

79

Y0000525 Pimobendan

10 mg

2179

+5C

79

Y0000401 Pimobendan for system suitability

0.1 mg

2179

+5C

79

P1750000 Pimozide

150 mg

1254

+5C

79

P1800000 Pindolol

100 mg

0634,0871,1
789

+5C

79

Y0001520 Pioglitazone hydrochloride

120 mg

2601

Yes

+5C

79

Y0001519 Pioglitazone for system suitability

15 mg

2601

Yes

+5C

79

Y0001476 Pipemidic acid trihydrate

15 mg

1473

+5C

79

Y0000061 Pipemidic acid trihydrate - reference spectrum

n/a

1743

79

New P1890000 Piperacillin

99.8% CHClNOS

100 mg

+5C

79

P1900000 Piperazine adipate

250 mg

0423

+5C

79

P2000000 Piperazine citrate

250 mg

0424

+5C

79

P2100000 Piperazine hydrate

250 mg

0425

+5C

79

Y0001217 Piperine

30 mg

99.0% CHNO

+5C

79

Y0000288 Piracetam

150 mg

99.9% CHNO ; Batch 2 is valid until 31 December 2013

+5C

79

Y0000038 Pirenzepine dihydrochloride monohydrate

250 mg

2001

+5C

79

P2120000 Piretanide

100 mg

1556

+5C

79

Y0001458 Piretanide for system suitability

10 mg

+5C

79

P2130000 Piroxicam

50 mg

Batch 2 is valid until 31 January 2013

+5C

79

Y0001475 Piroxicam for system suitability

15 mg

Y0001475 replaces P2130100

P2150000 Pivampicillin

50 mg

99.2% CHNOS

P2152000 Pivmecillinam hydrochloride

100 mg

99.6% CHClNOS

1359

P2152015 Pivmecillinam impurity C

10 mg

methylene 2,2-dimethylpropanoate (2RS,4S)-2-[[[(hexahydo- 1H-azepin-1-yl)


methylene]amino]methyl]-5,5-dimethylthiazolidin-4-carboxylate

1359

P2155001 Plastic additive 01

2 ml

(2RS)-2-ethylhexyl) benzene-1,2-dicarboxylate

P2155003 Plastic additive 03

100 mg

E0800000 Plastic additive 04

500 mg

P2155005 Plastic additive 05

500 mg

P2155008 Plastic additive 08

500 mg

Council of Europe, all rights reserved 2013

1168,1169

94.4% CHNOS ; Batch 3 is valid until 28 February 2014

Yes

2453,2477
1733

1556

Yes

Yes

0944
0944

Yes

+5C

79

0808,0852

Yes

+5C

79

-20C

79

+5C

79

90001,9000
2, 30114

+5C

79

N,N'-ethylenedialcanamide

90001,30114

+5C

79

Epoxidised soya oil

90001,30114

+5C

79

Epoxidised linseed oil

90001,30114

+5C

79

ethylene bis[3,3-bis[3-(1,1-dimethylethyl)-4-hydroxyphenyl]butanoate]
63

79
30103,3010
+5C
a
4,
30105,3010
For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
P2155009 Plastic additive 09

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
3
250 mg
1 pentaerythrityl tetrakis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate]

P2155010 Plastic additive 10

250 mg

4,4',4''-(2,4,6-trimethylbenzene-1,3,5-triyltrismethylene)trio[2,6-bis(1,1dimethylethyl)phenol]

P2155011 Plastic additive 11

500 mg

Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-propionate

P2155012 Plastic additive 12

250 mg

Tris (2,4-di-1,1-dimethylethylphenyl) phosphite R

P2155013 Plastic additive 13

250 mg

1,3,5-tris(3,5-di-1,1-dimethylethyl-4-hydroxybenzyl)-1H,3H,5H-1,3,5triazine-2,4,6-trione

P2155014 Plastic additive 14

250 mg

2,2'-Di(octadecycloxy)-5,5'-spirobi(1,3,2-dioxaphosphorinane) R

P2155015 Plastic additive 15

500 mg

Dioctadecyl disulphide

P2155016 Plastic additive 16

250 mg

Didodecyl 3,3'-thiodipropionate R

P2155017 Plastic additive 17

250 mg

Dioctadecyl 3,3'-thiodipropionate R

P2155018 Plastic additive 18

100 mg

Batch 1 is valid until 22 July 2013

O0140000 Plastic additive 20

100 mg

Oleamide R

E1260000 Plastic additive 21

100 mg

Erucamide R

P2155022 Plastic additive 22

100 mg

Copolymer of dimethyl butanedioate and 1-(2-hydroxyethyl)-2,2,6,6tetramethylpiperidin-4-ol


Synonyms: copolymer of dimethyl succinate and (4-hydroxy-2,2,6,6tetramethylpiperidin-1-yl)ethanol

P2155023 Plastic additive 23

200 mg

P2160000 Poliomyelitis vaccine (inactivated) BRP

0.5 ml

P2161000 Poliomyelitis vaccine (oral) BRP

P2163920 Poloxamer 124


P2164009 Poloxamer 188

Monograph Leaflet
30103,3010
5,
30106,3010
30103,3010

Yes

Storage
+5C

Extra
Price
charges
79
a

+5C

79

+5C

79

+5C

79

+5C

79

30103,3010
5, 30106

+5C

79

30103,3010
4,
30105,3010
30103,3010

+5C

79

+5C

79

30103,3010
5, 30106

+5C

79

30103

+5C

79

30103,3010
5,
30106,3010
30103,30107

+5C

79

+5C

79

30103

+5C

79

di(isooctyl)2,2'-[(dioctylstannylene)bis(thio)]diacetate
containing about 27% of (tri(isooctyl)2,2',2''- [monooctyl- stannylidyne)tris
(thio)] triacetate.

30110,30111

+5C

79

320-67-282 Ph. Eur. D-Antigen Units per ml for types 1-2-3, respectively

0214,2066,2
065,
2328,2061,2
067,
1934,2329,2
0720

Yes

-80C

90

1 ml

log CCID50/ml for types 1,2,3 and total virus content: 6.99, 6.06, 6.83 and
7.20, respectively

See leaflet,
0215

Yes

-20C

90

30 mg

1464

+5C

79

100 mg

1464

+5C

79

P2164020 Poloxamer 237

100 mg

1464

+5C

79

P2164021 Poloxamer 338

100 mg

1464

+5C

79

P2164030 Poloxamer 407

100 mg

1464

+5C

79

Council of Europe, all rights reserved 2013

5,
30106,3010
30103,3010
5,
30106,3010
30103,3010
5,
30106,3010
30103,3010
5, 30106

5, 30106

64

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
P2170000 Polyacrylate - reference spectrum

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
n/a
1

Information

Monograph Leaflet

Storage

0733

Extra
Price
charges
79
l

P2400000 Polymyxin B sulfate

25.1 mg

65.1% polymyxin B1, 12.5% polymyxin, 3.3% polymyxin B3, 9.1% polymyxin
B1-I

0203

Yes

+5C

79

Y0000355 Polymyxin B sulfate for microbiological assay

25 mg

205000 IU per vial

20702

Yes

-20C

79

Y0000289 Polysorbate 20 - reference spectrum

n/a

0426

79

Y0000290 Polysorbate 40 - reference spectrum

n/a

1914

79

Y0000291 Polysorbate 60 - reference spectrum

n/a

0427

79

Y0000007 Polysorbate 80 - reference spectrum

n/a

0428

79

Y0001557 Poly (vinyl acetate)

100 mg

1962

+5C

79

Y0000792 Poly(vinyl acetate) dispersion 30 per cent

1500 mg

2152

+5C

79

Y0001550 Poly(vinyl alcohol)

100 mg

1961

+5C

79

P2600000 Poly(vinyl chloride)

100 mg

90001,9000
2, 30114

+5C

79

P2649610 Potassium clavulanate - reference spectrum

n/a

1140

79

Y0001168 Potassium clavulanate impurity G

5 mg

1653,1140

-20C

g(c)

79

Y0000315 Potassium hydrogen aspartate hemihydrate

50 mg

2076

+5C

79

P2650000 Potassium sorbate

100 mg

Batch 1 is valid until 30 November 2012

0618

+5C

79

Y0001275 Potassium sucrose octasulfate

100 mg

92.6% CHKOS

1796

P2660000 Povidone

50 mg

Y0000466 Povidone (iodinated)

10 mg

Y0001266 Pramipexole dihydrochloride monohydrate

5 mg

Y0001187 Pramipexole for system suitability

15 mg

Y0001267 Pramipexole impurity D

5 mg

Y0000215 Pravastatin sodium - reference spectrum

n/a

Y0000223 Pravastatin impurity A

0.1 mg

(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6R,8S,8aR)-6-hydroxy-2-methyl-8[[(2S)-2-methylbutanoyl]oxy]-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]
heptanoic acid (6'-epipravastatin)

2059

Y0000204 Pravastatin 1,1,3,3-tetramethylbutylamine

30 mg

76.4% CHO

2059

P2669000 Prazepam -* psy

50 mg

P2670000 Praziquantel

200 mg

Y0001533 Praziquantel for system suitability

10 mg

P2675000 Praziquantel impurity A

10 mg

P2680000 Prazosin hydrochloride

50 mg

P2698000 Prednicarbate

100 mg

Y0001443 Prednicarbate for system suitability

10 mg

10 mg

New Y0001630 Prednicarbate for system suitability A


Council of Europe, all rights reserved 2013

+5C

79

0685

+5C

79

1142

+5C

79

2416

+5C

79

+5C

79

+5C

79

79

-20C

79

-20C

79

+5C

79

2416
(6R)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine

Yes

Yes

2416
2059

Yes

1466
99.8% CHNO
(11bRS)-2-benzoyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]
isoquinolin-4-one

0855

Yes

+5C

79

0855

Yes

+5C

79

+5C

79

0855
0856

+5C

79

1467

Yes

+5C

79

1467

Yes

+5C

79

1467

Yes

+5C

79

99.1% CHO

65

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Code
P2700000 Prednisolone

Reference Standard

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
7
150 mg
1 99.2% CHO; Prednisolone CRS 6 is suitable for monographs
01/2011:0335, 01/2008:0353, 01/2008:0354 and 01/2008:0735 only.

Y0001359 Prednisolone for peak identification

Y0001355 Prednisolone for system suitability


P2800000 Prednisolone acetate

Monograph Leaflet
Yes

+5C

0353

Yes

+5C

79

0353

Yes

+5C

79

+5C

79

+5C

79

10 mg

120 mg

Y0000582 Prednisolone acetate for peak identification

10 mg

P2804000 Prednisolone hexanoate

10 mg

100 mg

P2810000 Prednisolone sodium phosphate

100 mg

P2900000 Prednisone

100 mg

P2920000 Pregnenolone isobutyrate

200 mg

Y0000263 Prekallikrein activator in albumin BRP

1 mL

P2939000 Prilocaine

150 mg

P2939060 Prilocaine hydrochloride

100 mg

Y0001408 Prilocaine impurity B

80 mg

2-methylbenzenamine hydrochloride

P2939025 Prilocaine impurity E

25 mg

(RS)-N-(methylphenyl)-2-(propylamino)propanamide

P2940000 Primaquine diphosphate

500 mg

Batch 2 is valid until 30 November 2013

P2950000 Primidone

150 mg

99.9% CHNO

0584

Y0000369 Primidone for peak identification

5 mg

0584

P3000000 Probenecid

100 mg

P3050000 Procainamide hydrochloride

100 mg

P3090000 Procaine benzylpenicillin

250 mg

P3100000 Procaine hydrochloride

100 mg

0050

P3200000 Prochlorperazine maleate

100 mg

P3300000 Progesterone

50 mg

Y0000148 Progesterone impurity C

10 mg

Y0000179 Proguanil hydrochloride - reference spectrum

n/a

Y0000181 Proguanil impurity C

10 mg

1,5-bis(4-chlorophenyl)biguanide

2002

Y0000182 Proguanil impurity D

10 mg

1,5-bis(1-methylethyl)biguanide

2002

P3350000 Proline

60 mg

Batch 2 is valid until 1 April 2013

P3390000 Promazine hydrochloride

100 mg

New P2805000 Prednisolone pivalate

Council of Europe, all rights reserved 2013

0734,0736,0
933,
0975,1467,0
334
0734

Batch 1 is valid until 30 April 2014

39.7% CHNO (procaine); 96.3% CHNOS

(20R)-20-hydroxypregn-4-en-3-one

Yes

1212

+5C

79

0734,0736

+5C

79

0549,0735,0
810

+5C

79

0354

+5C

79

0593,0993,2
397

-20C

79

-20C

90

1362

+5C

79

1363

+5C

79

1362,1363

+5C

79

1362,1363

+5C

79

0635

+5C

79

Yes

+5C

79

Yes

+5C

79

0243

+5C

79

0567

+5C

79

+5C

79

+5C

79

0244,20303

+5C

79

0429

+5C

79

0429

+5C

79

79

+5C

79

+5C

79

0785,0910,0
911, 1049

+5C

79

0475,1365,2
0303

+5C

79

See leaflet,
20615

30 IU per vial

0115

Yes

Yes

2002

66

Extra
Price
charges
79
a

0335,0353,0
354, 0735

10 mg

Batch 3 is valid until 1 April 2013

Storage

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
P3400000 Promethazine hydrochloride

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
2
50 mg
1

Information

Monograph Leaflet
0524

Storage
+5C

Extra
Price
charges
79
g

New Y0000769 Promethazine impurity D

15 mg

(2RS)-N,N-dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine S-oxide ;
Batch 1 is valid until 28 February 2014

0524

Yes

+5C

79

New Y0000797 Promethazine for peak identification

Batch 1 is valid until 31 March 2014

0524

Yes

+5C

79

79

5 mg

P3490000 Propacetamol hydrochloride - reference spectrum

n/a

Y0000455 Propafenone hydrochloride

10 mg

Y0000456 Propafenone impurity B

10 mg

Y0000278 Propanol - reference spectrum

n/a

Y0000016 Propofol

370 mg

Y0000017 Propofol for peak identification

0.1 ml

Y0000018 Propofol impurity J

20 mg

P3500000 Propranolol hydrochloride

30 mg

P3600000 Propranolol hydrochloride for performance test

20 mg

0568

Y0001547 Propylene glycol

150 mg

1403,1804,2
645

Y0000318 Propylene glycol dilaurate

100 mg

Y0000319 Propylene glycol monolaurate

100 mg

P3640000 Propyl gallate

50 mg

P3650000 Propyl parahydroxybenzoate

150 mg

P3700000 Propylthiouracil

100 mg

P3750000 Propyphenazone

200 mg

P3760000 Protirelin

5.03 mg

P3760020 D-His-Protirelin

0.1 mg

P3800000 Proxyphylline

100 mg

P3850000 Pseudoephedrine hydrochloride - * Drug Precursor

50 mg

Y0000387 Pseudoisoeugenyl 2-methylbutyrate for peak


identification

100 mg

Y0001537 Purified quillaia saponins

30 mg

P3900000 Purpureaglycoside A

25 mg

P4000000 Purpureaglycoside B

25 mg

Y0000402 Pyrantel embonate

10 mg

New Y0000403 Pyrantel impurity A

20 mg

P4050000 Pyrazinamide

30 mg

P4099900 Pyridostigmine bromide

30 mg

P4099910 Pyridostigmine impurity A

20 mg

Council of Europe, all rights reserved 2013

1366
(2E)-1-[2-[(2RS)-2-hydroxy-3-(propylamino)propoxy]phenyl]-3phenylprop-2-en-1-one

2103

+5C

79

2103

+5C

79

79

2036
1558

+5C

79

1558

+5C

79

1558

+5C

79

0568,0923

+5C

79

+5C

79

+5C

79

2087

+5C

79

1915

+5C

79

1039

+5C

79

+5C

79

0525

+5C

79

0636

+5C

79

5.03 mg per vial of pure protirelin peptide CHNO

1144

-20C

79

approx. 0.1 mg per vial

1144

-20C

79

0526

+5C

79

0487,1367

+5C

79

79

99.8% CHO ; Batch 4 is valid until 1 May 2013


2,6-bis (1-methylethyl)-1,4-benzoquinone

0431,0852,1
263

99.9% CHO

Yes

Yes

Yes

2108

Yes

+5C

1843

Yes

-20C

79

0117

+5C

79

0117

+5C

79

1680

+5C

79

1680

+5C

79

0859

+5C

79

1255

+5C

79

1255

+5C

79

Star anise oil

1-methyl-2-[(Z)-2-(thiophen-2-yl)ethenyl]-1,4,5,6-tetrahydropyrimidine ;
Batch 1 is valid until 30 April 2014

pyridin-3-yl-dimethylcarbamate
67

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0001486 Pyridostigmine impurity B

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
10 mg
1 3-hydroxy-1-methylpyridinium

Information

Monograph Leaflet

Storage

Extra
Price
charges
79
g

1255

+5C

0245

+5C

79

0245

+5C

79

P4100000 Pyridoxine hydrochloride

100 mg

Y0001226 Pyridoxine impurity A

5 mg

P4200000 Pyrimethamine

250 mg

0288

+5C

79

Y0000659 Pyrrolidone

20 mg

2180

+5C

79

Y0001009 Quercetin dihydrate

25 mg

90.5% CHO ; Batch 1 is valid until 31 August 2013

1827

Yes

+5C

79

Y0001564 Quillaia saponin assay

30 mg

64.9 % CHNO; monoammonium glycyrrhizate

1843

Yes

+5C

79

Y0001491 Quinapril hydrochloride

30 mg

1763

+5C

79

Y0001502 Quinapril for peak identification

5.075 mg

1763

Yes

+5C

79

Y0001503 Quinapril for system suitability

5.125 mg

1763

Yes

+5C

79

Q0100000 Quinidine sulfate

300 mg

0017,0018,0
019

+5C

79

Q0200000 Quinine sulfate

300 mg

0017,0018,0
019

+5C

79

R0100000 Rabies vaccine (inactivated) for veterinary use BRP

86 mg

11 IU per vial

Y0000896 Racecadotril

110 mg

Y0000897 Racecadotril impurity A

1.1 mL

Y0000898 Racecadotril impurity G

10 mg

Y0000902 Racecadotril for peak identification

5 mg

Y0001134 Raloxifene hydrochloride

110 mg

Y0001135 Raloxifene hydrochloride for peak identification

10 mg

2375

R0145000 Ramipril

20 mg

1368

R0145005 Ramipril impurity A

10 mg

(2S,3aS,6aS)-1-[(S)-2-[[(S)-1-(methoxycarbonyl)-3- phenylpropyl]amino]
propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (ramipril
methylester)

R0145010 Ramipril impurity B

10 mg

R0145015 Ramipril impurity C

10 mg

R0145020 Ramipril impurity D

R0150000 Ranitidine hydrochloride

6-methyl-1,3-dihydrofuro[3,4-c]pyridin-7-ol

See leaflet,
0451

Yes

-20C

90

99.9% CHNOS

2171

Yes

+5C

79

92,8% CHCOSH; ethanethioic acid ; Batch 1 is valid until 1 July 2013

2171

Yes

+5C

79

benzyl [[(2RS)-2-benzyl-3-sulfanylpropanoyl]amino]acetate

2171

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

1368

+5C

79

(2S,3aS,6aS)-1-[(S)-2-[[(S)-1-[(methylethoxy)carbonyl]-3- phenylpropyl]
amino]propanoyl]octahydrocyclopenta[b]pyrrole- 2-carboxylic acid (ramipril
isopropyl ester)

1368

+5C

79

(2S,3aS,6aS)-1-[(S)-2-[[(S)-1-(ethoxycarbonyl)-3-cyclohexylpropyl]amino]
propanoyl]octahydrocyclopenta[b]pyrrole-2- carboxylic acid
(hexahydroramipril)

1368

+5C

79

10 mg

1368

+5C

79

100 mg

ethyl (2S)-2-[(3S,5aS,8aS,9aS)-3-methyl-1,4-dioxodecahydro -1Hcyclopenta[e]pyrrolo[1,2a]pyrazin-2-yl]-4-phenylbutanoate (ramipril


diketopiperazine)

0946,1453

+5C

79

0.00025
mg

0946

-20C

79

Y0000411 Ranitidine for system suitability

20 mg

0946

+5C

79

Y0000457 Repaglinide

20 mg

2135

+5C

79

New Y0000416 Ranitidine impurity J

Council of Europe, all rights reserved 2013

2171

1,1'-N-[methylenebis(sulphanediylethylene)]bis(N'-methyl-2-nitroethene-1,1diamine) ; Batch 5 is valid until 30 April 2014

68

Yes

2375

99.7% CHClNOS

Yes

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000458 Repaglinide for system suitability

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
2
6 mg
1

Information

Monograph Leaflet
2135

Yes

Y0000459 Repaglinide impurity E

10 mg

2-ethoxy-4-[2-[[(1R)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]amino]-2oxoethyl]benzoic acid

R0200000 Reserpine

100 mg

99.8% CHNO

0528

1.4 mL

Batch 4 is valid until 30 April 2014

20424

Y0000767 Resorcinol

20 mg

benzene-1,3-diol

2348

Y0001194 Resveratrol

20 mg

99.6% CHO

2433,2480

Yes

R0300000 Retinol acetate

1000 mg

1 050 000 IU per g

0218,0219,0
220,
1192,1193

Yes

R0290000 Retinol esters

100 mg

R0500500 Reviparin sodium

250 mg

Y0000377 Ribavirin

150 mg

99.9% CHNO

R0600000 Riboflavin

130 mg

Vitamin B2 ; Batch 3 is valid until 31 August 2013

Y0000757 Riboflavin for peak identification

0.12 mg

0292

R0630000 Riboflavin sodium phosphate

250 mg

0786

Y0000662 Ribonucleic acid

100 mg

100.0 %

2090

Y0000149 Rifabutin

150 mg

95.5% CHNO

1657

Y0000184 Rifabutin impurity A

20 mg

1-(2-methylpropyl)piperidin-4-one

R0700000 Rifampicin

100 mg

R0800000 Rifampicin quinone

100 mg

R0900000 Rifamycin B

50 mg

Rifamycin impurity A

New R0950000 Rifamycin S

50 mg

Batch 2 is valid until 30 April 2014

300 mg

856 IU per mg
See leaflet ; Batch 1 is valid until 30 April 2014

New R0250000 Residual solvents solution class 1

R1000000 Rifamycin sodium


New Y0001074 Rifaximin

2135

Storage
+5C

Extra
Price
charges
79
a

+5C

79

Yes

+5C

79

Yes

+5C

79

+5C

79

+5C

79

-20C

79

0217,0218,0
219, 0220

+5C

79

0828

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

1657

+5C

79

0052

+5C

79

0052

+5C

79

0432

+5C

79

2109

Yes

0292,0786
Yes
Yes

+5C

79

0432,20702

0432
Yes

-20C

79

160 mg

2362

Yes

+5C

79

Y0001075 Rifaximin for system suitability

10 mg

2362

Yes

+5C

79

Y0000250 Rilmenidine dihydrogenophosphate - reference spectrum

n/a

2020

79

Y0000187 Rilmenidine for system suitability

30 mg

2020

+5C

79

Y0001541 Risedronate sodium 2.5-hydrate

15 mg

+5C

79

Y0001558 Risedronate impurity A

15 mg

78.4 %

2572

+5C

79

Y0001540 Risedronate impurity E

15 mg

2-(pyridin-3-yl)ethane-1,1-diyl]bis(phosphonic acid)

2572

+5C

79

R1000600 Risperidone

50 mg

1559

+5C

79

Y0000370 Risperidone for system suitability

20 mg

+5C

79

Y0001276 Risperidone impurity K

0.015 mg

3-[2-[4-(1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9tetrahydro-4Hpyrido[1,2-a]pyrimidin-4-one (desfluoro risperidone) ; Batch 1


is valid until 30 November 2013

1559

+5C

79

Y0000714 Ritonavir

80 mg

99.6% CHNOS

2136

+5C

79

Council of Europe, all rights reserved 2013

2572

1559

69

Yes

Yes

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000706 Ritonavir for peak identification

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
10 mg
1

Information

Monograph Leaflet

Storage

Extra
Price
charges
79
a

2136

Yes

+5C

2629,2630

Yes

+5C

79

2629,2630

Yes

+5C

79

2629,2630

Yes

+5C

79

2585

Yes

+5C

79

2585

Yes

+5C

79

Yes

Liquid nitrogen

100

79

Y0001516 Rivastigmine hydrogen tartrate

350 mg

Y0001485 Rivastigmine for system suitability

1.0114 mg

Y0001515 Rivastigmine impurity D

10 mg

3-[(1R)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate ((R)enantiomer)

Y0001302 Rizatriptan benzoate

200 mg

99.8% CHNO

Y0001303 Rizatriptan for system suitability

15 mg

R1300000 RK 13 cells

1 ml

Y0000594 Rocuronium bromide - reference spectrum

n/a

1764

Y0000527 Rocuronium for peak identification

10 mg

1764

-20C

g(c)

79

Y0000742 Ropivacaine hydrochloride monohydrate

10 mg

2335

+5C

79

Y0000743 Ropivacaine impurity G

5 mg

(+)-(2R)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide ((R)ropivacaine)

2335

+5C

79

Y0000786 Rosmarinic acid

50 mg

89.5% CHO ; Batch 1 is valid until 28 February 2013

R1500000 Roxithromycin

125 mg

96.7% CHNO

Y0000220 Roxithromycin for system suitability

5 mg

R2000000 Rubella vaccine (live) BRP

90 mg

3.6 log (ie 4000) infective viral units per vial

Y0000494 Ruscogenins

10 mg

38.2% ruscogenin
60.4% neoruscogenin

S0040000 Saccharin

30 mg

S0050000 Saccharin sodium

50 mg

S0100000 Salbutamol

50 mg

Y0000030 Salbutamol impurity B

10 mg

(1RS)-2-[(1,1-dimethylethyl)amino]-1-(4-hydroxyphenyl)ethanol
; Batch 4 is valid until 30 September 2013

Y0000071 Salbutamol impurity D

10 mg

5-[(1RS)-2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-2hydroxybenzaldehyde ; Batch 4 is valid until 31 January 2013

0529,0687

Y0000031 Salbutamol impurity F

10 mg

93.4% CHNO x HSO; 1,1'-[oxybis[methylene(4-hydroxy-1,3phenylene)]]bis[2-[(1,1- dimethylethyl)amino]ethanol]

0529,0687

Y0000034 Salbutamol impurity G

5 mg

2-[benzyl(1,1-dimethylethyl)amino]-1-[4-hydroxy-3-(hydroxy- methyl)phenyl]
ethanone

Y0000032 Salbutamol impurity I

0.006 mg

Y0001186 Salbutamol impurity J

S0150000 Salbutamol sulfate

50 mg

Y0001288 Salbutamol sulfate for system suitability

10 mg

Y0000669 Salicin

50 mg

S0200000 Salicylic acid

100 mg

10 mg

New Y0000405 Salicylic acid impurity B


Council of Europe, all rights reserved 2013

99.9% CHNO

cell lines (kidney, rabbit) titration of live measles, mumps and rubella vaccines 0162,1057

Yes

1447,2382,
2524

Yes

+5C

79

1146

Yes

+5C

79

+5C

79

1146
1057,0162

Yes

-80C

90

1847

Yes

+5C

79

0947

+5C

79

0787

+5C

79

0529,1033

+5C

79

0529

+5C

79

Yes

+5C

79

Yes

+5C

79

0529

+5C

79

(1RS)-2-[(1,1-dimethylethyl)amino]-1-[3-(hydroxymethyl)-4benzyloxyphenyl]ethanol

0529

+5C

79

Batch 1 is valid until 31 August 2013

0687

+5C

79

Batch 2 is valid until 30 November 2013

0687

+5C

79

0.00045 mg 1

99,6% CHO
4-hydroxyisophthalic acid ; Batch 1 is valid until 31 March 2014
70

0687

Yes

+5C

79

2312,1583

Yes

+5C

79

0366,1185

+5C

79

0366

+5C

79

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000422 Salmeterol xinafoate

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
2
50 mg
1 99.6% CHNO

Y0000423 Salmeterol xinafoate for system suitability

25 mg

Y0001559 Salvianolic acid B

15 mg

92.2 % CHO

Y0001052 Santonin

20 mg

99.8% CHO

15 mg

New Y0001625 Salmeterol xinafoate for peak identification

Information

Monograph Leaflet
Yes

+5C

1765

Yes

+5C

79

2663

Yes

+5C

79

1391,1809

Yes

+5C

79

1765

Yes

+5C

79

+5C

79

+5C

79

70 mg

Y0001056 Saquinavir for system suitability

0.3033 mg

Y0001483 Saw palmetto extract HRS

8000 mg

Y0000814 Selamectin

100 mg

Y0000815 Selamectin for system suitability

5 mg

2268

S0360000 Selegiline hydrochloride

50 mg

1260

S0360090 (RS)-Selegiline hydrochloride

25 mg

S0400000 Senna extract

50 mg

S0450000 Serine

50 mg

0788,1027

S0460000 Sertaconazole nitrate

125 mg

Y0000828 Sertraline hydrochloride

200 mg

99.9% CHClN

1705

Yes

Y0001285 Sertraline impurity E

15 mg

Mandelic acid CRS has been labelled as sertraline impurity E CRS in


anticipation of 01/2011:1705 corrected 7.1

1705

Y0000866 Sertraline for peak identification

5.4 mg

Batch 2 is valid until 30 September 2013

1705

Y0000867 Sertraline for system suitability

6.18 mg

New Y0000371 Sestamibi labelling kit

22 mg

Y0001046 Sevoflurane

1 ml

Y0001578 Sildenafil citrate

100 mg

Y0001579 Sildenafil impurity A

10 mg

S0500000 Silicone elastomer

2000 mg

New S0600000 Silicone oil

2267
2267

Yes

1848

Yes

79

+5C

79

+5C

79

+5C

79

1260

+5C

79

0206,0207,0
208, 1261

-20C

79

+5C

79

+5C

79

+5C

79

Yes

+5C

79

Yes

+5C

79

+5C

79

2268

97.6% CHNO

Yes

1148

1705
1926

Yes

+5C

79

2269

Yes

+5C

g(b)

79

98.8 % CHNOS

2270

Yes

+5C

79

5-[2-ethoxy-5[(4-methylpiperazin-1-yl)sulfonyl]phenyl]-1-methyl-3-(2methylpropyl)-6,7-dihydro-1H-pyrazol[4,3-d]pyrimidin-7-one

2270

+5C

79

30109

+5C

79

Batch 2 is valid until 31 March 2014

1 mL

S0650000 Simvastatin

100 mg

Y0001066 Simvastatin for peak identification

10 mg

Y0001208 Sinomenine

20 mg

81.8 % CHNO

S0660000 Sisomicin sulfate

60 mg

Y0000014 Sodium alendronate

150 mg

S0695000 Sodium amidotrizoate

125 mg

1150

Y0000300 Sodium aminosalicylate dihydrate - reference spectrum

n/a

1993

Y0000039 Sodium ascorbate

50 mg

1791

S0700000 Sodium calcium edetate

100 mg

0231

Council of Europe, all rights reserved 2013

Extra
Price
charges
79
a

1765

Y0001049 Saquinavir mesilate

99.5% CHNOS

Storage

+5C

79

1538,1563

30108
Yes

-20C

g(c)

79

1563

Yes

-20C

g(c)

79

2450

Yes

+5C

79

77.7% CHNOS

0331,1351

Yes

-20C

79

83.3% CHNNaOP

1564

Yes

+5C

79

+5C

79

79

+5C

79

+5C

79

99.4% CHO

71

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
S0710000 Sodium cetostearyl sulfate

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
100 mg
1

Information

Monograph Leaflet

Storage

0847

+5C

Extra
Price
charges
79
a

S0750000 Sodium cromoglicate

10 mg

0562

+5C

79

Y0001300 Sodium cromoglicate for system suitability

20 mg

0562

+5C

79

S0760000 Sodium cyclamate

100 mg

S0765000 Diclofenac sodium

100 mg

Y0001410 Sodium fusidate

10 mg

S0781000 Sodium hyaluronate - reference spectrum

n/a

S0780000 Sodium hyaluronate BRP

Y0001468 Sodium iodohippurate

Y0000620 Sodium laurilsulfate


Y0000808 Sodium phenylbutyrate
Y0000809 Sodium phenylbutyrate impurity C
S0785000 Sodium picosulfate

0774

+5C

79

1002,1281

+5C

79

0848

+5C

79

1472

79

300 mg

0912

+5C

79

15 mg

2352

+5C

79

40 mg

0802

+5C

79

5 mg

2183

+5C

79

10 mg

2183

+5C

79

100 mg

1031

+5C

79

Y0001104 Picosulfate for system suitability

0.5 mg

1031

+5C

79

Y0000210 Sodium polystyrene sulfonate - reference spectrum

n/a

1909

79

Y0000268 Sodium propionate - reference spectrum

n/a

2041

79

S0800000 Sodium salicylate

100 mg

0413

+5C

79

S0808000 Sodium stearyl fumarate

50 mg

1567

+5C

79

S0808060 Sodium stearyl maleate

10 mg

1567

+5C

79

S0900000 Sodium taurocholate BRP

10000 mg

0350

+5C

79

S0930000 Sodium valproate

150 mg

0678

+5C

79

S0945000 Somatostatin

2.32 mg

2.32mg somatostatin peptide per vial CHNOS

-20C

90

S0947000 Somatropin

55 mg

3.86 mg somatropin monomer per vial

See leaflet,
0950,
0951,0952

Yes

-20C

150

Y0000711 Somatropin/desamidosomatropin resolution mixture

33 mg

1.7 mg somatropin per vial

0950,0951,0
952

Yes

-20C

150

S0950000 Sorbic acid

10 mg

Y0000385 1,4-Sorbitan

50 mg

99,7% CHO ; Batch 1 is valid until 1 April 2013

S1000000 Sorbitol

1250 mg

98,7% CHO ; Batch 3 is valid until 31 December 2013

Y0000114 Sotalol hydrochloride

25 mg

Y0000115 Sotalol impurity B

20 mg

Y0001011 Spanish sage oil for peak identification

250 mg

Council of Europe, all rights reserved 2013

Batch 3 is valid until 31 October 2013

4-cyclohexylbutanoic acid

Yes

0949

0592

N-[4-[[(1-methylethyl)amino]acetyl]phenyl]methanesulphonamide

+5C

79

2048

Yes

+5C

79

0435,0436,0
437,
1235,1236,1
337,
1381,1531,2
048

Yes

+5C

79

2004

+5C

79

2004

+5C

79

+5C

79

1849
72

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000597 Spectinomycin hydrochloride

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
2
100 mg
1 81.3% CHClNO and CHClNO

Monograph Leaflet
1152

-20C

Y0000549 Spectinomycin for system suitability

20 mg

1152

Y0000655 Spectinomycin sulfate tetrahydrate

10 mg

1658

Y0001126 Spike lavender oil

400 l

S1100000 Spiramycin

200 mg

4500 IU per mg
Spiramycin I: 87.3%, Spiramycin II: 0.2%, Spiramycin III: 4.4%

Y0000381 Spirapril hydrochloride monohydrate

60 mg

95.9% CHClNOS

Y0000332 Spirapril for system suitability

15 mg

160 mg

See leaflet; Spironolactone CRS 2 is suitable for monograph 01/2008:0688


only. ; Batch 3 is valid until 30 April 2014

0688

Yes

Y0001295 Spironolactone for system suitability

2.057 mg

Batch 1 is valid until 28 February 2014

0688

Yes

Y0000185 Squalane

250 l

99.7% CH

1630

Y0001050 St. John's wort standardised dry extract

500 mg

0.050% of hypericin; St. John's wort standardised dry extract CRS has been
renamed as St. John's wort dry extract HRS in 01/2013:1874

1874

Y0001091 Artichoke leaf dry extract HRS

60 mg

2389

S1250000 Stanozolol

50 mg

S1250010 Stanozolol impurity A

10 mg

Y0001420 Stanozolol impurity B

10 mg

S1300000 Starch BRP

50000 mg

Y0000408 Stavudine

100 mg

Y0000421 Stavudine for system suitability

10 mg

S1340000 Stearic acid

100 mg

Plastic additive 19

S1350000 Stearyl alcohol

250 mg

99.5% CHO

Y0000868 Streptokinase for system suitability

30 l

S1400000 Streptomycin sulfate

100 mg

Y0001324 Sucralfate

10 mg

Y0001344 Sucralose

550 mg

100.0% CHClO

2368

Y0001342 Sucralose impurity B

0.5 mg

1,6-dichloro-1,6-dideoxy-?-D-fructofuranosyl 6-chloro-6-deoxy-?-Dglucopyranoside (1',6,6'-trichloro-1',6,6'-trideoxysucrose)

2368

New S1200000 Spironolactone

Council of Europe, all rights reserved 2013

Storage

Yes

Extra
Price
charges
79
a

-20C

79

-20C

79

2419

Yes

+5C

79

0179,0293,1
982,20702

Yes

-20C

79

+5C

79

+5C

79

+5C

79

+5C

79

Yes

+5C

79

Yes

-20C

79

Yes

-20C

79

1568

+5C

79

1568

+5C

79

1568

+5C

79

0350

+5C

79

+5C

79

+5C

79

+5C

79

1766
1766

(5,17)-17-hydroxy-17-methylandrostan-3-one

2130

99.6% CHNO

2130
0229,0882,1
474, 1663,
2058,
30105,
30106,3010
7,1663
0702,0753,0

Yes

+5C

79

0356

Yes

-20C

79

0032,0033,0
053,
0485,20702

Yes

-20C

79

+5C

79

+5C

79

+5C

79

801,
0802,0847,0
969,
1123,1340,1
411
77 000 IU per vial

Yes

1796

73

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Code
S1600000 Sucrose

Reference Standard

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
100 mg
1

S1608100 Sufentanil - reference spectrum

S1609000 Sufentanil citrate - reference spectrum


Y0000529 Sulbactam sodium

Information

Monograph Leaflet
0177,0178,0
187,
0188,0204,0
209,
1061,1570,2
318

Storage
+5C

n/a

1569

n/a

1269

10 mg

2209

Y0000528 Sulbactam

150 mg

2209

Yes

Y0000550 Sulbactam for peak identification

20 mg

2209

Yes

S1700000 Sulfacetamide sodium

50 mg

S1800000 Sulfadiazine

100 mg

Y0001480 Sulfadiazine for identification of impurity F

15 mg

Y0001469 Sulfadiazine impurity A

20 mg

S1900000 Sulfadimidine

100 mg

0295

Y0001495 Sulfadimidine for peak identification

50 mg

0295

S1950000 Sulfadoxine

50 mg

S1975000 Sulfafurazole

100 mg

S1975600 Sulfaguanidine

60 mg

S2000000 Sulfamerazine

100 mg

S2050000 Sulfamethizole

100 mg

S2100000 Sulfamethoxazole

50 mg

Y0000412 Sulfamethoxazole impurity A

5 mg

Y0000413 Sulfamethoxazole impurity F

5 mg

S2150000 Sulfamethoxypyridazine

Extra
Price
charges
79
a

79

79

79

-20C

79

+5C

79

0107,0295

+5C

79

0294

+5C

79

0294

+5C

79

0294

+5C

79

+5C

79

+5C

79

0740

+5C

79

0741

+5C

79

0295,1476

+5C

79

0358,1571

+5C

79

0637

+5C

79

0108

+5C

79

N-(4-(5-methyl)-isoxazol-3-ylsulphamoyl)phenylacetamide

0108

+5C

79

4-amino-N-(3-methylisoxazol-5-yl)benznesulphonamide

0108

+5C

79

0638

+5C

79

1571

+5C

79

+5C

79

+5C

79

0863

+5C

79

99.7% CHNOS

pyrimidin-2-amine

Batch 1 is valid until 31 August 2013

+5C

Yes

50 mg

New S2151000 Sulfanilamide

100 mg

S2159100 Sulfapyridine

20 mg

S2155000 Sulfasalazine

250 mg

98.1 % CHNOS ; Batch 3 is valid until 28 February 2013

S2155010 Sulfasalazine derivative for resolution

20 mg

2-hydroxy-5-[[4-[[(6-methylpyridin-2-yl)amino]-sulfonyl]phenyl]azo]benzoic
acid

S2158000 Sulfathiazole

100 mg

0742

+5C

79

S2159000 Sulfinpyrazone

30 mg

0790

+5C

79

Y0001238 Sulfinpyrazone for system suitability

0.5 mg

+5C

79

S2159010 Sulfinpyrazone impurity A

20 mg

1,2-diphenyl-4-[2-(phenylsulphonyl)ethyl]pyrazolidine-3,5-dione

0790

+5C

79

S2159015 Sulfinpyrazone impurity B

20 mg

1,2-diphenyl-4-(2-phenylthioethyl)pyrazolidine-3,5-dione

0790

+5C

79

S2180000 Sulindac

50 mg

Contains 0.3% m/m of E-isomer

0864

+5C

79

S2190000 Sulpiride

100 mg

Batch 3 is valid until 31 January 2013

1045,1348

+5C

79

Council of Europe, all rights reserved 2013

Batch 1 is valid until 30 April 2014

0863
0863,1457

0790

74

Yes

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
S2191000 Sulpiride impurity A
S2192000 Sulpiride impurity B

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
3
20 mg
1 [(2RS)-1-ethylpyrrolidin-2-yl]methanamine
2
20 mg
1 methyl 2-methoxy-5-sulphamoylbenzoate

Monograph Leaflet

+5C

1045

+5C

79

2211

+5C

79

10 mg

Y0000531 Sultamicillin tosilate

200 mg

Y0000532 Sultamicillin for peak identification

10 mg

Y0000022 Sumatriptan succinate

50 mg

Y0000026 Sumatriptan impurity mixture

3 mg

Y0000027 Sumatriptan for system suitability

2.02 mg

S2200000 Suxamethonium chloride

1000 mg

S2400000 Suxibuzone

50 mg

S2400004 Suxibuzone impurity B

10 mg

(4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methyl ethyl butanedioate

S2400006 Suxibuzone impurity C

10 mg

4-butyl-4-(hydroxymethyl)-1,2-diphenyl-1,2-dihydro-4H-pyrazole-3,5-dione

S5000001 Swine erysipelas bacteria, serotyp 1 (for vaccines - vet.


use) BRP

1 mg

6.5 x10 Cfu per vial

See leaflet,
0064

Yes

S5000002 Swine erysipelas bacteria, serotyp 2 (for vaccines - vet.


use) BRP

1 mg

2.6 x10 Cfu per vial

See leaflet,
0064

Y0001417 Tadalafil

200 mg

99.9% CHNO

2606

T0010000 Talampicillin hydrochloride

50 mg

T0014000 Tamoxifen citrate

80 mg

T0015000 Tamoxifen citrate for performance test

10 mg

1046

Y0000650 Tamsulosin hydrochloride

10 mg

2131

New Y0000653 Tamsulosin racemate

15 mg

Batch 1 is valid until 28 February 2014

Y0000651 Tamsulosin impurity D

10 mg

2-methoxy-5-[(2R)-2-[[2-(2-methoxyphenoxy)ethyl]amino]propyl]
benzenesulfonamide ; Batch 1 is valid until 1 June 2013

Y0000652 Tamsulosin impurity H

10 mg

Y0001102 Teicoplanin

52 mg

Y0001560 Tanshinone IIa

Y0001047 Teicoplanin for identification

Y0000648 Telmisartan
Y0000649 Telmisartan for peak identification

2211,2212

98.8% CHNOS

Extra
Price
charges
79
g

1045,1490

Y0000530 Sultamicillin

92.5% CHNOS

Storage

+5C

79

2211

Yes

+5C

79

1573

Yes

-20C

79

1573

Yes

-20C

79

1573

Yes

-20C

79

0248

+5C

79

1574

+5C

79

1574

+5C

79

+5C

79

+5C

e(b)

90

Yes

+5C

e(b)

90

Yes

+5C

79

0808,0852

+5C

79

1046

+5C

79

+5C

79

+5C

79

2131

+5C

79

2131

+5C

79

(2R)-N-[2-(2-ethoxyphenoxy)ethyl]-1-(4-methoxyphenyl)propan-2-amine ;
Batch 1 is valid until 1 June 2013

2131

+5C

79

51550 IU per ampoule

2358

Yes

-20C

79

15 mg

98.4 % CHO

2663

Yes

+5C

79

40 mg

2358

Yes

-20C

79

30 mg

+5C

79

10 mg

Batch 1 is valid until 31 January 2013

2154

Yes

+5C

79

Y0001003 Telmisartan for system suitability

0.26 mg

Batch 2 is valid until 1 April 2013

2154

Yes

T0040000 Temazepam - * psy

50 mg

Y0000344 Temazepam impurity C

5 mg

Y0000345 Temazepam impurity D

5 mg

Council of Europe, all rights reserved 2013

Batch 4 is valid until 31 August 2013

1574

Yes

2154

+5C

79

0954

+5C

79

(3RS)-7-chloro-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4benzodiazepin-3-yl acetate

0954

+5C

79

(3RS)-7-chloro-3-methoxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4benzodiazepin-2-one

0954

+5C

79

75

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000346 Temazepam impurity F

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
1
5 mg
1 (5RS)-7-chloro-1-methyl-5-phenyl-4,5-dihydro-1H-1,4-benzodiazepine-2,3dione

Monograph Leaflet

Storage

Extra
Price
charges
79
a

0954

+5C

0954

+5C

79

1156

+5C

79

+5C

79

+5C

79

Y0000347 Temazepam impurity G

5 mg

T0040800 Tenoxicam

100 mg

Y0001114 Tenoxicam impurity mixture

0.0042 mg

1156

Y0000621 Terazosin hydrochloride dihydrate

40 mg

2021

Y0000666 Terazosin for system suitability

0.5 mg

+5C

79

Y0000622 Terazosin impurity A

10 mg

2-chloro-6,7-dimethoxyquinazolin-4-amine

2021

+5C

79

Y0000665 Terazosin impurity E

10 mg

2,2'-(piperazine-1,4-diyl)bis(6,7-dimethoxyquinazolin-4-amine)

2021

+5C

79

Y0000623 Terazosin impurity L

10 mg

1-(furan-2-ylcarbonyl)piperazine

2021

+5C

79

Y0000624 Terazosin impurity N

10 mg

93.1% CHNO; 1-[[(2RS)-tetrahydrofuran-2-yl]carbonyl]piperazine

2021

+5C

79

Y0000535 Terbinafine hydrochloride

10 mg

+5C

79

Y0001143 Terbinafine for system suitability

10 mg

+5C

79

100 mg

Batch 1 is valid until 30 April 2014

0690

+5C

79

1-(3,5-dihydroxyphenyl)-2-[(1,1-dimethylethyl)amino]-ethanone

0690

+5C

79

1270

+5C

79

New T0050000 Terbutaline sulfate

(5RS)-7-chloro-1,4-dimethyl-5-phenyl-4,5-dihydro-1H-1,4benzodiazepine-2,3-dione

2021

Yes
Yes

Yes

1734
1734

Yes

T0050015 Terbutaline impurity C

15 mg

T0060000 Terconazole

250 mg

T0071000 Terfenadine

100 mg

0955

+5C

79

T0080000 Terfenadine impurity A

20 mg

1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(hydroxydiphenylmethyl) piperidin-1-yl]
butan-1-one

0955

+5C

79

T0100000 Testosterone

30 mg

Batch 2 is valid until 31 August 2013

1373

+5C

79

T0210000 Testosterone caproate

50 mg

T0240000 Testosterone decanoate

50 mg

Y0000696 Testosterone decanoate for system suitability

0.4 mg

1736

T0250000 Testosterone enantate

100 mg

1048

Y0001317 Testosterone enantate for system suitability

2 mg

1048

Y0001312 Testosterone enantate for peak identification

10 mg

1048

Y0001313 Testosterone enantate impurity H

10 mg

Y0000342 Testosterone for impurity D identification

20 mg

Y0000343 Testosterone for system suitability

20 mg

T0260000 Testosterone isocaproate

50 mg

Y0000716 Testosterone isocaproate for system suitability

5 mg

T0300000 Testosterone propionate

60 mg

Y0001409 Testosterone propionate for system suitability

5 mg

T0400000 Tetanus vaccine (adsorbed)

30 mg

490 IU per ampoule for challenge assays in guinea-pigs


260 IU per ampoule for challenge assays in mice

Y0001087 Tetra-O-acetyl-mannose triflate


Council of Europe, all rights reserved 2013

60 mg

100.0% CHFOS
76

99.8% CHO

delta-5-testosterone-3,17-dienantate

99.9% CHO
99.8% CHO; Testosterone propionate CRS 1 is suitable for 01/2008:1048
only

1048

+5C

79

1048, 1736

-20C

g(c)

79

-20C

g(c)

79

-20C

g(c)

79

Yes

-20C

g(c)

79

Yes

-20C

g(c)

79

1048

-20C

g(c)

79

1373

+5C

79

1373

+5C

79

1048,1737

+5C

79

Yes

1737

Yes

+5C

79

0297

Yes

+5C

79

0297

Yes

+5C

79

See leaflet,
20708

Yes

-20C

90

79
2294
Yes
-20C
c
For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
T0500000 Tetracaine hydrochloride

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
100 mg
1

Information

Monograph Leaflet
0057

Y0001002 Tetracaine for system suitability

2 mg

T0550000 Tetracosactide

0.366 mg

366 g per vial of CHNOS

T0600000 Tetracycline hydrochloride

100 mg

97.1% CHClNO ; Batch 2 is valid until 31 December 2013

Y0001165 Tetrandrine

20 mg

99.7% CHNO

Y0000015 Tetrazepam - reference spectrum

n/a

Y0000008 Tetrazepam impurity C

20 mg

Y0000460 Tetryzoline hydrochloride

10 mg

Y0000723 Thebaine - * narc

15 mg

T0700000 Theobromine

100 mg

0298

Storage
+5C

0057

Yes

+5C

79

0644

Yes

-20C

79

0173,0198,0
199,
0210,0211,1
654

Yes

+5C

79

+5C

79

79

2478
1738

7-chloro-5-cyclohexyl-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one

1738

+5C

79

2101

+5C

79

+5C

79

+5C

79

+5C

79

79

1839,1841

99.5% CHNO

Extra
Price
charges
79
g

Yes

T0800000 Theophylline

100 mg

0300,0301

Y0000294 Theophylline - reference spectrum

n/a

0299,0302

Y0000336 Thiamazole

125 mg

0884,1706

+5C

79

Y0000372 Thiamazole impurity A

15 mg

2,2-dimethoxy-N-methylethanamine

1706

+5C

79

Y0000373 Thiamazole impurity C

20 mg

1-methyl-2-(methylsulphanyl)-1H-imidazole ; Batch 1 is valid until 31 August


2013

1706

+5C

79

Y0000467 Thiamine hydrochloride

10 mg

Y0000059 Thiamine impurity E

10 mg

Y0000060 Thiamine nitrate

n/a

3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4methylthiazol-2(3H)-thione

Yes

0303

+5C

79

0303,0531

+5C

79

0531

+5C

79

+5C

79

+5C

79

T1100000 Thiamphenicol

125 mg

Y0000546 Thioctic acid

110 mg

0109

Y0000592 Thioctic acid for system suitability

10 mg

1648

+5C

79

Y0000545 Thioctic acid containing impurity B

30 mg

1648

+5C

79

Y0000109 Thiomersal

30 mg

1625

+5C

79

T1200000 Thiopental

500 mg

0212

+5C

79

Y0001478 Thiopental for system suitability

10 mg

0212

+5C

79

Y0000704 Thioridazine

10 mg

2005

+5C

79

+5C

79

+5C

79

99.8% CHOS

1648

Yes

Yes

T1300000 Thioridazine hydrochloride

100 mg

0586

Y0000541 Thioridazine for system suitability

0.21 mg

0586, 2005

T1305100 Thioxanthene

20 mg

1347

+5C

79

T1305000 Thioxanthone

10 mg

1347

+5C

79

T1340000 Threonine

50 mg

0785,1049

+5C

79

T1350000 Thymol

50 mg

0791

+5C

79

50 mg

T1410000 Tiabendazole
Council of Europe, all rights reserved 2013

77

Yes

79
0866
+5C
g
For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0000414 Tiamulin for peak identification
Y0000333 Tiamulin hydrogen fumarate

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
2
10 mg
1 Batch 1 is valid until 30 November 2013
2
500 mg
1 98.6% CHNOS

Y0000379 Tiamulin - reference spectrum

Y0000151 Tianeptine sodium - reference spectrum


Y0000152 Tianeptine for system suitability

Monograph Leaflet

Storage

1659

Yes

+5C

1659,1660

Yes

+5C

Extra
Price
charges
79
g
g

79

79

79

79

n/a

1660

n/a

2022

30 mg

2022

+5C

Y0000153 Tianeptine impurity A

20 mg

2022

+5C

79

T1405000 Tiapride hydrochloride

60 mg

1575

+5C

79

T1405050 Tiapride N-oxide

20 mg

1575

+5C

79

T1410900 Tiaprofenic acid

50 mg

1157

+5C

79

1157

+5C

79

79

ethyl 7-bromoheptanoate

T1410910 Tiaprofenic acid impurity C

20 mg

Y0000748 Tibolone - reference spectrum

n/a

Y0000668 Tibolone for system suitability

10 mg

1739

Yes

+5C

79

Y0000465 Ticarcillin monosodium

250 mg

93.2% CHNNaOS
Correction factor 1.054

0956

Yes

+5C

79

T1420010 Ticarcillin impurity A

50 mg

89.8% CHNOS; (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(thiophen-3-yl)


acetyl]-amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(decarboxyticarcillin)

0956

+5C

79

T1423000 Ticlopidine hydrochloride

50 mg

1050

+5C

79

T1423025 Ticlopidine impurity F

10 mg

1050

+5C

79

Y0000325 Tilidine hydrochloride hemihydrate - reference spectrum

n/a

1767

79

T1450000 Timolol maleate

100 mg

0572

+5C

79

Y0000644 (R)-timolol

20 mg

+5C

79

Y0001270 Timolol for system suitability

5.045 mg

+5C

79

(2RS)-2-(5-benzoylthiophen-3-yl)propanoic acid

1739

6-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine

Batch 1 is valid until 30 November 2013

0572
0572

Yes

T1470000 Tinidazole

100 mg

1051

+5C

79

Y0000899 Tinidazole impurity A

15 mg

2-methyl-5-nitro-1H-imidazole

1051

+5C

79

T1471000 Tinidazole impurity B

20 mg

1-[2-(ethylsulphonyl)ethyl]-2-methyl-4-nitro-1H-imidazole

1051

+5C

79

T1490000 Tinzaparin sodium

250 mg

0828

+5C

79

Y0000292 Tioconazole - reference spectrum

n/a

2074

79

Y0000282 Tioconazole for system suitability

50 mg

2074

+5C

79

Y0001188 Tiotropium bromide monohydrate

10 mg

2420

+5C

79

Y0001189 Tiotropium for system suitability

10 mg

2420

+5C

79

Y0001179 Tiotropium impurity mixture

0.08 mg

2420

+5C

79

Y0001216 Tiotropium impurity F

10 mg

dithiophen-2-ylmethanone

2420

+5C

79

Yes
Yes

T1500000 Tobramycin

49 mg

49 mg per vial of CHNO; Suitable for LC assay only

0645

Yes

+5C

79

Y0000383 All-rac-alpha-tocopherol for peak identification

50 mg

Batch 1 is valid until 31 August 2013

0692

Yes

+5C

79

Y0000384 All-rac-alpha-tocopheryl acetate for peak identification

30 mg

0439

Yes

+5C

79

Council of Europe, all rights reserved 2013

78

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
T1550000 alpha-Tocopherol
New T1600000 alpha-Tocopheryl acetate

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
7
500 mg
1 97,7% CHO ; Vitamin E ; Batch 6 is valid until 31 December 2013

Monograph Leaflet

Storage

Extra
Price
charges
79
a

0692,1256,2
0432

Yes

+5C

0439,0691,1
257

Yes

+5C

79

+5C

79

500 mg

98.8% CHO ; Batch 8 is valid until 28 February 2014

Y0001210 Tobramycin for identification

250 mg

Suitable for identification tests only

T1610000 RRR-alpha-Tocopheryl hydrogen succinate

150 mg

98.6% CHO

+5C

79

T1700000 Tolbutamide

100 mg

0304

+5C

79

Y0000154 Tolfenamic acid

100 mg

2039

+5C

79

T1707000 Tolnaftate

60 mg

1158

+5C

79

Y0001123 Tolnaftate for system suitability

10 mg

1158

+5C

79

Y0000461 Torasemide anhydrous

10 mg

2132

+5C

79

Y0001366 Torasemide impurity E

0.0006 mg

+5C

79

Y0000462 Torasemide for system suitability

5 mg

+5C

79

Y0000155 Tramadol hydrochloride

75 mg

1681

+5C

79

Y0000156 Tramadol impurity A

25 mg

(1RS,2SR)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-cyclohexanol ;
Batch 3 is valid until 31 January 2013

1681

+5C

79

Y0000157 Tramadol impurity E

15 mg

(2RS)-2-[(dimethylamino)methyl]cyclohexanone

1681

+5C

79

Y0000072 Tramazoline hydrochloride monohydrate

20 mg

+5C

79

Y0000065 Tramazoline impurity A

15 mg

N-(naphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine ; Batch 1 is valid until


31 August 2013

1597

+5C

79

Y0000066 Tramazoline impurity B

10 mg

75% CHNO; Mixture of 1-acetyl-N-(5,6,7,8-tetrahydronaphthalen-1yl)-4,5-dihydro-1H-imidazol-2-amine and 1-[(EZ)-1-[(5,6,7,8tetrahydronaphthalen-1-yl)imino]ethyl]imidazolidin-2-one

1597

+5C

79

Y0000501 Trandolapril

10 mg

2245

+5C

79

Y0000495 Trandolapril impurity C

10 mg

(2S,3aR,7aS)-1-[(2S)-2-[[(1S)-3-cyclohexyl-1-(ethoxycarbonyl)propyl]amino]
propanoyl]octahydro-1H-indole-2-carboxylic acid (hexahydrotrandolapril)

2245

+5C

79

Y0000496 Trandolapril impurity D

10 mg

ethyl (2S)-2-[(3S,5aS,9aR,10aS)-3-methyl-1,4-dioxodecahydro
pyrazino[1,2-a]indol-2(1H)-yl]-4-phenylbutanoate (trandolapril
diketopiperazine)

2245

+5C

79

T1810000 Tranexamic acid

50 mg

0875

+5C

79

T1820000 Trapidil

50 mg

1576

+5C

79

T1820002 Trapidil impurity A

20 mg

5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol

1576

+5C

79

T1820004 Trapidil impurity B

20 mg

1,2,4-triazol-3-amine

1576

+5C

79

Y0001172 Trehalose dihydrate

250 mg

89.8% CHO,2HO

+5C

79

T1850000 Tretinoin

50 mg

0693,1019,1
385

+5C

g(b)

79

T1899000 3,4,6-Tri-O-acetyl-D-glucal - reference spectrum

n/a

1325

79

G0400010 Triacetin - reference spectrum

n/a

1106

79

T1899990 Triamcinolone

150 mg

1376

79

Council of Europe, all rights reserved 2013

0645
1258,1259

ethyl [[4-[(3-methylphenyl)amino]pyridin-3-yl]sulfonyl]carbamate

Yes

2132
2132

Yes

1597

79

2297

Yes

Yes

Yes

+5C

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
T1900000 Triamcinolone acetonide

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
5
150 mg
1 98.6% CHFO

Y0001459 Triamcinolone acetonide for system suitability

10 mg

T1950000 Triamcinolone hexacetonide

100 mg

Y0000050 Triamcinolone impurity C

10 mg

Y0000837 Triamterene

10 mg

Y0000870 Triamterene impurity B

0.5 mg

Information

Monograph Leaflet

9-fluoro-11,16alpha,17,21-tetrahydroxypregn-4-ene-3,20-dione

Extra
Price
charges
79
a

0533,0867,1
075

Yes

+5C

0533

Yes

+5C

79

0533,0867

+5C

79

1376

+5C

79

+5C

79

+5C

79

0058
0058

2,7-diamino-6-phenylpteridin-4-ol

Storage

Yes

T1975000 Triazolam - * psy

10 mg

+5C

79

Y0000165 Tribenoside

150 mg

98.3% CHO ; Batch 1 is valid until 31 August 2013

1065
1740

Yes

+5C

79

Y0000166 Tribenoside impurity A

70 mg

90.3% CHO; 3,5,6-tri-O-benzyl-1,2-O-(1-methylethylidene)-alpha-Dglucofuranose ; Batch 3 is valid until 1 May 2013

1740

Yes

-20C

g(c)

79

New Y0001628 Tribenoside impurity D

Benzyl ether

35 mg

1740

+5C

79

Y0001055 Tributyl acetylcitrate

1 mL

1770

+5C

79

Y0000279 Tri-n-butyl phosphate

300 l

1682

+5C

79

Y0000799 Tributyl acetylcitrate for peak identification

25 mg

1770

+5C

79

T1977990 Tricaprin

150 mg

1410

-20C

79

T1977995 Tricaproin

40 mg

1410

-20C

79

-20C

79

79

79

79

Yes

T1978000 Tricaprylin

225 mg

1410

Y0000111 Trichloroacetic acid - reference spectrum

n/a

1967

T1985000 Trichlorotrifluoroethane

2.5 ml

0393

T1986000 Triethyl citrate - reference spectrum

n/a

1479

T2000000 Trifluoperazine hydrochloride

100 mg

0059,20303

+5C

79

T2005000 Triflusal

50 mg

1377

+5C

79

1377

+5C

79

2032

+5C

79

1626

+5C

79

1626

+5C

79

T2005010 Triflusal impurity B

25 mg

Y0000720 Triglycerol diisostearate

200 mg

Y0000108 Trihexyphenidyl hydrochloride

100 mg

Y0000068 Trihexyphenidyl impurity A

20 mg

2-hydroxy-4-(trifluoromethyl)benzoic acid

1-phenyl-3-(piperidin-1-yl)propan-1-one

Yes

+5C

T2009000 Trilaurin

1250 mg

1410

-20C

79

Y0001319 Trimebutine maleate

10 mg

2182

+5C

79

Y0001260 Trimebutine for system suitability

1.017 mg

2181,2182

+5C

79

Y0000092 Trimetazidine dihydrochloride - reference spectrum

n/a

1741

79

Y0000093 Trimetazidine for system suitability

50 mg

T2100000 Trimethadione

250 mg

100% CHNO

Y0001497 3-Trimethylsilyl-1-propanesulfonic acid sodium salt

120 mg

91.8 % CHOSSi,Na

T2200000 Trimethoprim

50 mg

Y0000684 Trimethoprim for system suitability

T2200010 Trimethoprim impurity B

Council of Europe, all rights reserved 2013

0.00075 mg 1
15 mg

Yes

1741

+5C

79

0440

+5C

79

+5C

79

0060

+5C

79

Batch 2 is valid until 31 January 2013

0060

+5C

79

(2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone

0060

+5C

79

80

2645, 2165

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
T2450000 Trimethyltetradecylammonium bromide

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
2
200 mg
1

Information

Monograph Leaflet
0378

T2500000 Trimipramine maleate

100 mg

0534

Y0000759 Trimipramine for peak identification

0.51 mg

0534

T2500100 Trimyristin

500 mg

T2501200 Tristearin

100 mg

Storage
+5C

Extra
Price
charges
79
g

+5C

79

+5C

79

1410

-20C

79

1410

-20C

79

Yes

T2545000 Trolamine

2250 mg

Batch 2 is valid until 31 August 2013

1577

+5C

79

Y0001184 Trolamine impurity A

250 mg

Ethanolamine

1577

+5C

79

Y0001183 Trolamine impurity B

1 ml

Diethanolamine

1577

+5C

79

T2550000 Trometamol

100 mg

1053

+5C

79

New T2580000 Tropicamide

50 mg

Batch 1 is valid until 28 February 2014

1159,1197

+5C

79

Y0001247 Tropicamide impurity C

10 mg

(2RS)-3-hydroxy-2-phenylpropanoic acid (tropic acid)

1159

+5C

79

Y0001248 Tropicamide impurity D

10 mg

Phenylacetic acid

1159

+5C

79

Y0001316 Tropicamide for peak identification

10 mg

1159

+5C

79

Y0000616 Tropisetron hydrochloride

40 mg

2102

+5C

79

Y0000618 Tropisetron impurity B

10 mg

2102

+5C

79

1H-indole-3-carboxylic acid

T2580300 Tropine

50 mg

1308

+5C

79

Y0000429 Trospium chloride

10 mg

1798

+5C

79

Y0000432 Trospium impurity A

20 mg

hydroxydiphenylacetic acid (benzilic acid)

1798

+5C

79

Y0000431 Trospium impurity B

20 mg

(1R,3r,5S)-8-azabicyclo[3.2.1]oct-3-yl hydroxydiphenylacetate

1798

+5C

79

Y0000430 Trospium impurity C

5 mg

(1R,3r,5S)-3-hydroxyspiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium]

1798

+5C

79

Y0000497 Troxerutin

30 mg

2133

+5C

79

T2600000 Trypsin BRP

100 mg

+5C

79

T2610000 Tryptophan

100 mg

+5C

79

T2880000 Tylosin

150 mg

+5C

79

T2880100 Tylosin D

5 mg

1273,1274,1
661

+5C

79

Y0000498 Tylosin phosphate for peak identification

10 mg

1273,1274,1
661

+5C

79

T2880200 Tylosin tartrate - reference spectrum

n/a

1274

79

T2900000 Tyrosine

50 mg

+5C

79

T3000000 Tyrothricin

20 mg

+5C

79

U0020000 Ubidecarenone

50 mg

1578

+5C

79

U0020001 Ubidecarenone for system suitability

1 mg

1578

+5C

79

Council of Europe, all rights reserved 2013

0.707 microkatal per mg

0476,0579,0
580, 0694

1025 IU per mg ; Batch 1 is valid until 31 August 2013

1273,1274,1
661, 20702

Yes

1272

Batch 1 is valid until 30 November 2013

81

Yes

0782,0895,1
161,
1272,1384
0907,1662

Batch 1 is valid until 1 June 2013

Yes

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
U0020008 Ubidecarenone impurity D

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
2
5 mg
1 5,6-dimethoxy-3-methyl-2-[(all-E)-3,7,11,15,19,23,27,31,35nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyl]benzene-1,4dione

Monograph Leaflet

Storage

1578

+5C

Extra
Price
charges
79
a

U0100000 Uracil arabinoside

60 mg

0760

+5C

79

U0600000 Urea

100 mg

0743

+5C

79

U0800000 Ursodeoxycholic acid

100 mg

+5C

79

Y0001163 Ursodeoxycholic acid for system suitability

1.26 mg

Batch 1 is valid until 1 May 2013

1275

Yes

+5C

79

Y0000834 Valaciclovir hydrochloride (anhydrous)

100 mg

96.5% CHNOCl

1768

Yes

+5C

79

Y0001225 Valaciclovir for system suitability

10 mg

1768

Yes

+5C

79

Y0001096 Valaciclovir impurity D

10 mg

2-[(2-amino-6-oxo-1,6dihydro-9H-purin-9-yl)methoxy]ethyl N-ethyl-L-valinate

1768

+5C

79

Y0001097 Valaciclovir impurity E

10 mg

2-[(2-amino-6-oxo-1,6dihydro-9H-purin-9-yl)methoxy]ethyl N-[(benzyloxy)
carbonyl]-L-valinate

1768

+5C

79

Y0001098 Valaciclovir impurity F para-toluenesulfonate

12 mg

2-hydroxyethyl L-valinate

1768

+5C

79

Y0001099 Valaciclovir impurity G

10 mg

N,N-dimethylpyridin-4-amine

Y0000583 Valerian standardised dry extract

400 mg

0.43 % of CHO

V0030000 Valine

50 mg

0453,1898,1
899,2400,25
26
0770,0771,0

Y0000584 Valnemulin hydrochloride

10 mg

2137

Y0000533 Valnemulin hydrogen tartrate

120 mg

Y0000585 Valnemulin for peak identification

10.25 mg

Y0000586 Valnemulin impurity E

10 mg

V0033000 Valproic acid

100 mg

Y0001422 Valproic acid for system suitability

Y0001132 Valsartan

Y0001131 Valsartan for peak identification


Y0001145 Valsartan for system suitability

1189,1275

+5C

79

-20C

79

+5C

79

+5C

79

+5C

79

+5C

79

2137

+5C

79

1378

+5C

79

10 mg

0678,1378

+5C

79

10 mg

2423

+5C

79

10 mg

0.202 mg

Batch 1 is valid until 31 August 2013

V0045000 Vancomycin hydrochloride

100 mg

102000 IU per vial

V0050000 Vanillin

100 mg

0747

Y0001198 Varicella vaccine ( live)

420 mg

0648

Y0000561 Vecuronium bromide

10 mg

1769

Y0000625 Vecuronium for peak identification

10 mg

1769

Y0001093 Vedaprofen

5 mg

2248

Y0001118 Vedaprofen impurity mixture

0.006 mg

2248

Y0000587 Venlafaxine hydrochloride

50 mg

2119

Y0000588 Venlafaxine for system suitability

1.002 mg

2119

Council of Europe, all rights reserved 2013

1768
Yes

796

2137

98.7% CHNOS

2137
(3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyl-5-hydroxy-4,6,9,10-tetramethyl-1oxodecahydro-3a,9-propano-3aH-cyclopenta[8]annulen-8-yl 2-hydroxyacetate
(pleuromulin)

Batch 2 is valid until 31 December 2012


82

Yes

Yes

2423

Yes

+5C

79

2423

Yes

+5C

79

1058,20702

Yes

-20C

79

+5C

79

-80C

90

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

+5C

79

Yes
Yes
Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
V0100000 Verapamil hydrochloride

Effective from 2013/11/12


Batch n Quantity Sale
per vial Unit
1
100 mg
1

Information

Monograph Leaflet

Storage

0573

+5C

Extra
Price
charges
79
g

V0100018 Verapamil impurity I

5 mg

(2RS)-2-(3,4-dimethoxyphenyl)-2-[2-[[2-(3,4-dimethoxy-phenyl)ethyl]
(methyl)amino]ethyl]-3-methylbutanenitrile hydrochloride

0573

+5C

79

V0100026 Verapamil impurity M

10 mg

5,5'-[[2-(3,4-dimethoxyphenyl)ethyl]imino]bis[2-(3,4-dimethoxyphenyl)-2-(1methylethyl)pentanenitrile]

0573

+5C

79

Y0000661 Verbenalin

11 mg

0.97 mg per vial of CHO

V0180000 VERO cells

1 ml

Cell lines (kidney, african green monkey, Cercopithecus aethiops) titration of


live measles, mumps and rubella vaccines

Y0001400 Vigabatrin

10 mg

Y0001401 Vigabatrin impurity A

25 mg

94.7% CHNO; (5RS)-5-ethenylpyrrolidin-2-one

2305

Y0001402 Vigabatrin impurity B

20 mg

(2E)-2-(2-aminoethyl)but-2-enoic acid

2305

Y0001404 Vigabatrin impurity D

50 mg

4-aminobutanoic acid

Y0001403 Vigabatrin impurity E

10 mg

2-[(2RS)-2-aminobut-3-enyl]propanedioic acid

V0300000 Vinblastine sulfate

5.01 mg

5.01 mg per vial of CHNOS

V0305000 Vinblastine sulfate - reference spectrum

n/a

V0400000 Vincristine sulfate

4.96 mg

V0405000 Vincristine sulfate - reference spectrum

n/a

V0500000 Vindesine sulfate

5 mg

V0500010 Vindesine sulfate - reference spectrum

n/a

Y0000463 Vinorelbine tartrate

50 mg

Y0000464 Vinorelbine impurity B

7 mg

Y0000589 Vinpocetine

10 mg

Y0000590 Vinpocetine impurity A

10 mg

(12RS,13aSR,13bSR)-13a-ethyl-12-hydroxy-2,3,5,6, 12,13,13a,13boctahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12carboxylate (ethyl vincaminate)

Y0000591 Vinpocetine impurity B

10 mg

Y0000790 Vinpocetine impurity C

10 mg

Y0000760 Vinpocetine impurity D

Y0000793 Vinyl acetate


Y0001395 Voriconazole

1854

Yes

+5C

79

0213,0538,1
057

Yes

Liquid nitrogen

100

+5C

79

-20C

79

+5C

79

2305

+5C

79

2305

+5C

79

-80C

g(d)

79

79

79

79

g(d)

79

79

2305

0748,0749

Yes

Yes

0748
0748,0749

4.98 mg per vial of CHNOS

Yes

-80C

0749
5.19 mg per vial of CHNOS ; Batch 2 is valid until 24 April 2013

1276

Yes

-80C

1276
2107

-80C

g(d)

79

2107

-80C

g(d)

79

2139

+5C

79

2139

+5C

79

(13aS,13bS)-13a-ethyl-2,3,5,6,13a,13b-hexahydro-1H-indolo[3,2,1-de]pyrido
[3,2,1-ij][1,5]naphthyridine-12-carboxylate (apovincamine)

2139

+5C

79

ethyl (13aS,13bS)-13a-ethyl-9-methoxy-2,3,5,6,13a,13b-hexahydro-1Hindolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate
(methoxyvinpocetine)

2139

+5C

79

10 mg

(12RS,13aRS,13bRS)-13a-ethyl-2,3,5,6,12,13,13a,13b-octahydro-1H-indolo
[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate
(dihydrovinpocetine)

2139

+5C

79

200 mg

+5C

79

120 mg

100% CHFNO

2576

+5C

79

Y0001396 Voriconazole impurity B

10 mg

(2RS,3SR)-2-(2,4-difluorophenyl)-3-pyrimidin-4-yl-1-(1H-1,2,4-triazol-1-yl)
butan-2-ol

2576

+5C

79

Y0001398 Voriconazole impurity D

10 mg

(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4triazol-1-yl)butan-2-ol (epi-voriconazole)

2576

+5C

79

Council of Europe, all rights reserved 2013

4-O-deacetylvinorelbine

Yes

2152,2523

83

Yes

For extra charges, please see supply terms and conditions.

List of European Pharmacopoeia Reference Standards


Order
Reference Standard
Code
Y0001397 Voriconazole impurity E

Effective from 2013/11/12


Batch n Quantity Sale
Information
per vial Unit
1
50 mg
1 [(1R,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonic acid
((+-)-camphorsulfonic acid)

W0100000 Warfarin sodium

Y0000778 Warfarin sodium clathrate


X0075000 Xylazine hydrochloride

Monograph Leaflet

Storage

2576

+5C

Extra
Price
charges
79
g

10 mg

0698,0699

+5C

79

10 mg

0699

+5C

79

125 mg

1481

+5C

79

Y0000158 Xylazine impurity C

50 mg

2,6-dimethylphenyl isothiocyanate

1481

+5C

79

Y0000159 Xylazine impurity E

15 mg

87.5% CHNS ; methyl (2,6-dimethylphenyl)carbamodithioate

1481

Yes

+5C

79

Y0001224 Xylazine impurity mixture

0.02 mg

1481

Yes

+5C

79

500 mg

1381

Yes

+5C

79

X0100000 Xylometazoline hydrochloride

100 mg

0972,1162

+5C

79

X0101000 Xylometazoline impurity A

10 mg

1162

+5C

79

X0200000 Xylose

100 mg

+5C

79

Y0000656 Yohimbine hydrochloride

20 mg

99.1% CHClNO

2172

+5C

79

Z1900000 Zidovudine

60 mg

99.5% CHNO

1059

+5C

79

Z1902000 Zidovudine impurity A

10 mg

1-[(2,5)-5-hydroxymethyl-2,5-dihydro-2-furyl]-5-methyl pyrimidine-2,4
(1,3)-dione

1059

+5C

79

Z1904000 Zidovudine impurity B

15 mg

1-(3-chloro-2,3-dideoxy--D-ribofuranosyl)-5-methylpyrimidine-2,4(1,3)dione

1059

+5C

79

Z2000000 Zinc acexamate

50 mg

1279

+5C

79

Z2000010 Zinc acexamate impurity A

50 mg

6-[[6-(acetylamino)hexanoyl]amino]hexanoic acid

1279

+5C

79

Y0001286 Ziprasidone hydrochloride monohydrate

100 mg

95.6% CHClNOS

2421

Yes

+5C

79

Y0001272 Ziprasidone for system suitability 1

10 mg

2421

Yes

+5C

79

Y0001241 Ziprasidone for system suitability 2

0.465 mg

2421

Yes

+5C

79

Z2500000 Zolpidem tartrate - * psy

200 mg

1280

+5C

79

Z2500010 Zolpidem impurity A

10 mg

N,N'-dimethyl-2-[7-methyl-2-(4-methylphenyl)imidazol[1,2-a] pyridin-3-yl]
acetamide

1280

+5C

79

Z3000000 Zopiclone -* psy

40 mg

Batch 1 is valid until 31 January 2013

1060

+5C

79

Z3001000 Zopiclone oxide

20 mg

Batch 2 is valid until 1 April 2013

1060

+5C

79

Y0000062 Zuclopenthixol decanoate - reference spectrum

n/a

79

Y0000534 Zuclopenthixol for system suitability

0.26 mg

+5C

79

Y0000083 Zuclopenthixol impurity B

10 mg

+5C

79

New X0080000 Xylitol

Council of Europe, all rights reserved 2013

See leaflet ; Batch 1 is valid until 30 April 2014


N-(2-aminoethyl)-2-(4-1,1-dimethylethyl-2,6-dimethylphenyl) acetamide

1278
Yes

1707
1707
2-chloro-9H-thioxanthen-9-one

84

1707

Yes

For extra charges, please see supply terms and conditions.

Related Interests